Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,12738349,half-life,The addition of naloxone does not affect the efficacy of buprenorphine for two reasons: (1) naloxone is poorly absorbed sublingually relative to buprenorphine and (2) the half-life for buprenorphine is much longer than for naloxone (32 vs. 1 h for naloxone).,Pharmacokinetics of the combination tablet of buprenorphine and naloxone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12738349/),h,32,2170,DB00921,Buprenorphine
,12738349,half-life,The addition of naloxone does not affect the efficacy of buprenorphine for two reasons: (1) naloxone is poorly absorbed sublingually relative to buprenorphine and (2) the half-life for buprenorphine is much longer than for naloxone (32 vs. 1 h for naloxone).,Pharmacokinetics of the combination tablet of buprenorphine and naloxone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12738349/),h,1,2171,DB00921,Buprenorphine
,7250147,peak plasma concentrations,The mean peak plasma concentrations (+/-standard deviation) were 2290 +/- 357ng ml-1 and 805 +/- 416ng ml-1 respectively and the corresponding times to the peak levels were 4.0 +/- 1.5 minutes and 30.3 +/- 24.6 minutes suggesting the rapid release of the drug from intramuscular sites.,Plasma concentration and disposition of buprenorphine after intravenous and intramuscular doses to baboons. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7250147/),[ng] / [ml],2290,2684,DB00921,Buprenorphine
,7250147,peak plasma concentrations,The mean peak plasma concentrations (+/-standard deviation) were 2290 +/- 357ng ml-1 and 805 +/- 416ng ml-1 respectively and the corresponding times to the peak levels were 4.0 +/- 1.5 minutes and 30.3 +/- 24.6 minutes suggesting the rapid release of the drug from intramuscular sites.,Plasma concentration and disposition of buprenorphine after intravenous and intramuscular doses to baboons. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7250147/),[ng] / [ml],805,2685,DB00921,Buprenorphine
,7250147,times to the peak levels,The mean peak plasma concentrations (+/-standard deviation) were 2290 +/- 357ng ml-1 and 805 +/- 416ng ml-1 respectively and the corresponding times to the peak levels were 4.0 +/- 1.5 minutes and 30.3 +/- 24.6 minutes suggesting the rapid release of the drug from intramuscular sites.,Plasma concentration and disposition of buprenorphine after intravenous and intramuscular doses to baboons. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7250147/),min,4.0,2686,DB00921,Buprenorphine
,7250147,times to the peak levels,The mean peak plasma concentrations (+/-standard deviation) were 2290 +/- 357ng ml-1 and 805 +/- 416ng ml-1 respectively and the corresponding times to the peak levels were 4.0 +/- 1.5 minutes and 30.3 +/- 24.6 minutes suggesting the rapid release of the drug from intramuscular sites.,Plasma concentration and disposition of buprenorphine after intravenous and intramuscular doses to baboons. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7250147/),min,30.3,2687,DB00921,Buprenorphine
,7250147,bioavailability,Comparison of areas under the plasma concentration versus time curves to 24 hours after dosing showed the mean bioavailability of buprenorphine from the intramuscular doses was 70% of that from the reference intravenous doses.,Plasma concentration and disposition of buprenorphine after intravenous and intramuscular doses to baboons. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7250147/),%,70,2688,DB00921,Buprenorphine
,16950210,micro,"Relative to heroin-dependent volunteers maintained on BUP placebo, whole-brain microOR availability was 30%, 54%, 67%, and 82% at 4, 28, 52, and 76 hours after BUP.",Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16950210/),%,30,3433,DB00921,Buprenorphine
,16950210,micro,"Relative to heroin-dependent volunteers maintained on BUP placebo, whole-brain microOR availability was 30%, 54%, 67%, and 82% at 4, 28, 52, and 76 hours after BUP.",Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16950210/),%,54,3434,DB00921,Buprenorphine
,16950210,micro,"Relative to heroin-dependent volunteers maintained on BUP placebo, whole-brain microOR availability was 30%, 54%, 67%, and 82% at 4, 28, 52, and 76 hours after BUP.",Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16950210/),%,67,3435,DB00921,Buprenorphine
,16950210,micro,"Relative to heroin-dependent volunteers maintained on BUP placebo, whole-brain microOR availability was 30%, 54%, 67%, and 82% at 4, 28, 52, and 76 hours after BUP.",Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16950210/),%,82,3436,DB00921,Buprenorphine
,15966752,time to maximum plasma concentration,"The mean time to maximum plasma concentration following sublingual administration is variable, ranging from 40 minutes to 3.5 hours.",Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966752/),min,40,3559,DB00921,Buprenorphine
,15966752,time to maximum plasma concentration,"The mean time to maximum plasma concentration following sublingual administration is variable, ranging from 40 minutes to 3.5 hours.",Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966752/),h,3.5,3560,DB00921,Buprenorphine
,15966752,terminal elimination half-life,The terminal elimination half-life of buprenorphine is long and there is considerable variation in reported values (mean values ranging from 3 to 44 hours).,Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966752/),h,3 to 44,3561,DB00921,Buprenorphine
,23246635,Maximum buprenorphine concentrations,"Maximum buprenorphine concentrations (mean ± SE) were detected 10 min after 2, 4, 8, 12, 16 mg IV: 19.3 ± 1.0, 44.5 ± 4.8, 85.2 ± 7.7, 124.6 ± 16.6, and 137.7 ± 18.8 μg/L, respectively.",Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23246635/),[μg] / [l],19.3,8966,DB00921,Buprenorphine
,23246635,Maximum buprenorphine concentrations,"Maximum buprenorphine concentrations (mean ± SE) were detected 10 min after 2, 4, 8, 12, 16 mg IV: 19.3 ± 1.0, 44.5 ± 4.8, 85.2 ± 7.7, 124.6 ± 16.6, and 137.7 ± 18.8 μg/L, respectively.",Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23246635/),[μg] / [l],44.5,8967,DB00921,Buprenorphine
,23246635,Maximum buprenorphine concentrations,"Maximum buprenorphine concentrations (mean ± SE) were detected 10 min after 2, 4, 8, 12, 16 mg IV: 19.3 ± 1.0, 44.5 ± 4.8, 85.2 ± 7.7, 124.6 ± 16.6, and 137.7 ± 18.8 μg/L, respectively.",Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23246635/),[μg] / [l],85.2,8968,DB00921,Buprenorphine
,23246635,Maximum buprenorphine concentrations,"Maximum buprenorphine concentrations (mean ± SE) were detected 10 min after 2, 4, 8, 12, 16 mg IV: 19.3 ± 1.0, 44.5 ± 4.8, 85.2 ± 7.7, 124.6 ± 16.6, and 137.7 ± 18.8 μg/L, respectively.",Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23246635/),[μg] / [l],124.6,8969,DB00921,Buprenorphine
,23246635,Maximum buprenorphine concentrations,"Maximum buprenorphine concentrations (mean ± SE) were detected 10 min after 2, 4, 8, 12, 16 mg IV: 19.3 ± 1.0, 44.5 ± 4.8, 85.2 ± 7.7, 124.6 ± 16.6, and 137.7 ± 18.8 μg/L, respectively.",Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23246635/),[μg] / [l],137.7,8970,DB00921,Buprenorphine
,23246635,Maximum norbuprenorphine concentrations,Maximum norbuprenorphine concentrations occurred 10-15 min (3.7 ± 0.7 μg/L) after 16 mg IV administration.,Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23246635/),[μg] / [l],3.7,8971,DB00921,Buprenorphine
,20672450,AUC0-24h,"Compared to baseline values, BUP AUC0-24h (46.8 vs. 46.2 ng*hr/mL) and Cmax (6.54 vs. 5.88 ng/mL) did not differ significantly after achieving steady-state LPV/r.",Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20672450/),[h·ng] / [ml],46.8,15377,DB00921,Buprenorphine
,20672450,AUC0-24h,"Compared to baseline values, BUP AUC0-24h (46.8 vs. 46.2 ng*hr/mL) and Cmax (6.54 vs. 5.88 ng/mL) did not differ significantly after achieving steady-state LPV/r.",Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20672450/),[h·ng] / [ml],46.2,15378,DB00921,Buprenorphine
,20672450,Cmax,"Compared to baseline values, BUP AUC0-24h (46.8 vs. 46.2 ng*hr/mL) and Cmax (6.54 vs. 5.88 ng/mL) did not differ significantly after achieving steady-state LPV/r.",Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20672450/),[ng] / [ml],6.54,15379,DB00921,Buprenorphine
,20672450,Cmax,"Compared to baseline values, BUP AUC0-24h (46.8 vs. 46.2 ng*hr/mL) and Cmax (6.54 vs. 5.88 ng/mL) did not differ significantly after achieving steady-state LPV/r.",Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20672450/),[ng] / [ml],5.88,15380,DB00921,Buprenorphine
,20672450,AUC0-24 hours,"Similar analyses of norBUP, the primary metabolite of BUP, demonstrated no significant difference in norBUP AUC0-24 hours (73.7 vs. 52.7 ng x h/mL); however, Cmax (5.29 vs. 3.11 ng/mL) levels were statistically different (P < 0.05) after LPV/r administration.",Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20672450/),[h·ng] / [ml],73.7,15381,DB00921,Buprenorphine
,20672450,AUC0-24 hours,"Similar analyses of norBUP, the primary metabolite of BUP, demonstrated no significant difference in norBUP AUC0-24 hours (73.7 vs. 52.7 ng x h/mL); however, Cmax (5.29 vs. 3.11 ng/mL) levels were statistically different (P < 0.05) after LPV/r administration.",Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20672450/),[h·ng] / [ml],52.7,15382,DB00921,Buprenorphine
,20672450,Cmax,"Similar analyses of norBUP, the primary metabolite of BUP, demonstrated no significant difference in norBUP AUC0-24 hours (73.7 vs. 52.7 ng x h/mL); however, Cmax (5.29 vs. 3.11 ng/mL) levels were statistically different (P < 0.05) after LPV/r administration.",Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20672450/),[ng] / [ml],5.29,15383,DB00921,Buprenorphine
,20672450,Cmax,"Similar analyses of norBUP, the primary metabolite of BUP, demonstrated no significant difference in norBUP AUC0-24 hours (73.7 vs. 52.7 ng x h/mL); however, Cmax (5.29 vs. 3.11 ng/mL) levels were statistically different (P < 0.05) after LPV/r administration.",Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20672450/),[ng] / [ml],3.11,15384,DB00921,Buprenorphine
,20672450,AUC0-24 hours,Naloxone concentrations were similarly unchanged for AUC0-24 hours (0.421 vs. 0.374 ng x hr/mL) and Cmax (0.186 vs. 0.186 ng/mL).,Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20672450/),[h·ng] / [ml],0.421,15385,DB00921,Buprenorphine
,20672450,AUC0-24 hours,Naloxone concentrations were similarly unchanged for AUC0-24 hours (0.421 vs. 0.374 ng x hr/mL) and Cmax (0.186 vs. 0.186 ng/mL).,Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20672450/),[h·ng] / [ml],0.374,15386,DB00921,Buprenorphine
,20672450,Cmax,Naloxone concentrations were similarly unchanged for AUC0-24 hours (0.421 vs. 0.374 ng x hr/mL) and Cmax (0.186 vs. 0.186 ng/mL).,Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20672450/),[ng] / [ml],0.186,15387,DB00921,Buprenorphine
,20672450,AUC0-24 hours,The AUC0-24 hours and Cmin of LPV in this study did not significantly differ from historical controls (159.6 vs. 171.3 microg x hr/mL) and (2.3 vs. 1.3 microg/mL).,Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20672450/),[h·μg] / [ml],159.6,15388,DB00921,Buprenorphine
,20672450,AUC0-24 hours,The AUC0-24 hours and Cmin of LPV in this study did not significantly differ from historical controls (159.6 vs. 171.3 microg x hr/mL) and (2.3 vs. 1.3 microg/mL).,Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20672450/),[h·μg] / [ml],171.3,15389,DB00921,Buprenorphine
,20672450,Cmin,The AUC0-24 hours and Cmin of LPV in this study did not significantly differ from historical controls (159.6 vs. 171.3 microg x hr/mL) and (2.3 vs. 1.3 microg/mL).,Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20672450/),[μg] / [ml],2.3,15390,DB00921,Buprenorphine
,20672450,Cmin,The AUC0-24 hours and Cmin of LPV in this study did not significantly differ from historical controls (159.6 vs. 171.3 microg x hr/mL) and (2.3 vs. 1.3 microg/mL).,Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20672450/),[μg] / [ml],1.3,15391,DB00921,Buprenorphine
,20940093,Limits,"Limits of detection and quantification for BPN and nor-BPN were 0.02 and 0.05 μg/L, respectively.",Development and validation of a highly sensitive GC/MS method for the determination of buprenorphine and nor-buprenorphine in blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20940093/),[μg] / [l],0.02,16310,DB00921,Buprenorphine
,20940093,Limits,"Limits of detection and quantification for BPN and nor-BPN were 0.02 and 0.05 μg/L, respectively.",Development and validation of a highly sensitive GC/MS method for the determination of buprenorphine and nor-buprenorphine in blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20940093/),[μg] / [l],0.05,16311,DB00921,Buprenorphine
,20940093,Absolute recovery,Absolute recovery ranged from 90.2 to 97.6% for both analytes and their internal standard.,Development and validation of a highly sensitive GC/MS method for the determination of buprenorphine and nor-buprenorphine in blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20940093/),%,90.2 to 97.6,16312,DB00921,Buprenorphine
,17472657,terminal half-life,"After intravenous injection at a dosage of 0.02 mg/kg bw, the terminal half-life was 73.8+/-19.9 min (mean+/-SD), the apparent volume of distribution 5.22+/-1.01 L/kg, and total body clearance 79.1+/-18.5 mL/min/kg.","Clinical pharmacology of buprenorphine in healthy, lactating goats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472657/),min,73.8,19613,DB00921,Buprenorphine
,17472657,apparent volume of distribution,"After intravenous injection at a dosage of 0.02 mg/kg bw, the terminal half-life was 73.8+/-19.9 min (mean+/-SD), the apparent volume of distribution 5.22+/-1.01 L/kg, and total body clearance 79.1+/-18.5 mL/min/kg.","Clinical pharmacology of buprenorphine in healthy, lactating goats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472657/),[l] / [kg],5.22,19614,DB00921,Buprenorphine
,17472657,total body clearance,"After intravenous injection at a dosage of 0.02 mg/kg bw, the terminal half-life was 73.8+/-19.9 min (mean+/-SD), the apparent volume of distribution 5.22+/-1.01 L/kg, and total body clearance 79.1+/-18.5 mL/min/kg.","Clinical pharmacology of buprenorphine in healthy, lactating goats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472657/),[ml] / [kg·min],79.1,19615,DB00921,Buprenorphine
,17472657,clearance,"After intramuscular administration of buprenorphine at the same dosage, bioavailability was complete and clearance was 54.7+/-16.6 mL/min/kg.","Clinical pharmacology of buprenorphine in healthy, lactating goats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472657/),[ml] / [kg·min],54.7,19616,DB00921,Buprenorphine
,16207308,bioavailability,Peak plasma buprenorphine concentration was lower and occurred later in the OTM group but median bioavailability was 116.3%.,PK-PD modeling of buprenorphine in cats: intravenous and oral transmucosal administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207308/),%,116.3,22033,DB00921,Buprenorphine
,16207308,Peak effect,Peak effect was at 90 min and there was no difference at any time between the two groups.,PK-PD modeling of buprenorphine in cats: intravenous and oral transmucosal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207308/),min,90,22034,DB00921,Buprenorphine
,28895776,maximum buprenorphine plasma concentration,The maximum buprenorphine plasma concentration (14.8 ng/ml) was observed 30 mins after administration and there was low inter-individual variability.,Evaluation of analgesic effect and absorption of buprenorphine after buccal administration in cats with oral disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28895776/),[ng] / [ml],14.8,22442,DB00921,Buprenorphine
,21395892,bioavailability,Buprenorphine bioavailability was 38-44% and T(max) was 35-40 minutes after all intranasal doses.,The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395892/),%,38-44,25521,DB00921,Buprenorphine
,21395892,T(max),Buprenorphine bioavailability was 38-44% and T(max) was 35-40 minutes after all intranasal doses.,The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395892/),min,35-40,25522,DB00921,Buprenorphine
,21395892,bioavailability,"Naloxone bioavailability was 24% and 30% following 2/0.5 and 8/2 mg, respectively.",The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395892/),%,24,25523,DB00921,Buprenorphine
,21395892,bioavailability,"Naloxone bioavailability was 24% and 30% following 2/0.5 and 8/2 mg, respectively.",The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395892/),%,30,25524,DB00921,Buprenorphine
,15701707,k(eo),"The k(eo) was 0.024 min(-1) [95% confidence interval (CI): 0.018-0.030 min(-1)] and 0.123 min(-1) (95% CI: 0.095-0.151 min(-1)) for buprenorphine and fentanyl, respectively.",Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15701707/),1/[min],0.024,25962,DB00921,Buprenorphine
,15701707,k(eo),"The k(eo) was 0.024 min(-1) [95% confidence interval (CI): 0.018-0.030 min(-1)] and 0.123 min(-1) (95% CI: 0.095-0.151 min(-1)) for buprenorphine and fentanyl, respectively.",Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15701707/),1/[min],0.123,25963,DB00921,Buprenorphine
,15701707,k(off),The k(off) was 0.073 min(-1) (95% CI: 0.042-0.104 min(-1)) and k(on) was 0.023 ml/ng/min (95% CI: 0.013-0.033 ml/ng/min).,Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15701707/),1/[min],0.073,25964,DB00921,Buprenorphine
,15701707,k(on),The k(off) was 0.073 min(-1) (95% CI: 0.042-0.104 min(-1)) and k(on) was 0.023 ml/ng/min (95% CI: 0.013-0.033 ml/ng/min).,Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15701707/),[ml] / [min·ng],0.023,25965,DB00921,Buprenorphine
,33467733,recovery,"Fragment ions 468.6→396.2 and 468.6→414.2 were monitored, and the method resulted in a high repeatability and reproducibility and a limit of quantification of 0.25 µg/L with a recovery of 98.7-109.0%.",High-Performance Liquid Chromatography-Tandem Mass Spectrometry for Buprenorphine Evaluation in Plasma-Application to Pharmacokinetic Studies in Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33467733/),%,98.7-109.0,26958,DB00921,Buprenorphine
,15203048,limit of quantification,The limit of quantification was 0.025 ng/microl plasma for 7-AFNZ and 0.125 ng/microl for the four other compounds.,"Development and validation of a gas chromatography-mass spectrometry method for the simultaneous determination of buprenorphine, flunitrazepam and their metabolites in rat plasma: application to the pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15203048/),[ng] / [plasma·μl],0.025,27615,DB00921,Buprenorphine
,15203048,limit of quantification,The limit of quantification was 0.025 ng/microl plasma for 7-AFNZ and 0.125 ng/microl for the four other compounds.,"Development and validation of a gas chromatography-mass spectrometry method for the simultaneous determination of buprenorphine, flunitrazepam and their metabolites in rat plasma: application to the pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15203048/),[ng] / [μl],0.125,27616,DB00921,Buprenorphine
,15203048,Recoveries,"Recoveries were 71, 67 and 81%, for BUP, FNZ and N-DMFNZ, respectively, and 51% for NBUP and 7-AFNZ, with CV ranging from 5.4 to 13.9%, and were concentration-independent.","Development and validation of a gas chromatography-mass spectrometry method for the simultaneous determination of buprenorphine, flunitrazepam and their metabolites in rat plasma: application to the pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15203048/),%,71,27617,DB00921,Buprenorphine
,15203048,Recoveries,"Recoveries were 71, 67 and 81%, for BUP, FNZ and N-DMFNZ, respectively, and 51% for NBUP and 7-AFNZ, with CV ranging from 5.4 to 13.9%, and were concentration-independent.","Development and validation of a gas chromatography-mass spectrometry method for the simultaneous determination of buprenorphine, flunitrazepam and their metabolites in rat plasma: application to the pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15203048/),%,67,27618,DB00921,Buprenorphine
,15203048,Recoveries,"Recoveries were 71, 67 and 81%, for BUP, FNZ and N-DMFNZ, respectively, and 51% for NBUP and 7-AFNZ, with CV ranging from 5.4 to 13.9%, and were concentration-independent.","Development and validation of a gas chromatography-mass spectrometry method for the simultaneous determination of buprenorphine, flunitrazepam and their metabolites in rat plasma: application to the pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15203048/),%,81,27619,DB00921,Buprenorphine
,15203048,Recoveries,"Recoveries were 71, 67 and 81%, for BUP, FNZ and N-DMFNZ, respectively, and 51% for NBUP and 7-AFNZ, with CV ranging from 5.4 to 13.9%, and were concentration-independent.","Development and validation of a gas chromatography-mass spectrometry method for the simultaneous determination of buprenorphine, flunitrazepam and their metabolites in rat plasma: application to the pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15203048/),%,51,27620,DB00921,Buprenorphine
,32650192,time for,"The mean (SD) time for fentanyl and norfentanyl clearance was 7.3 (4.9) and 13.3 (6.9) days, respectively.",Protracted renal clearance of fentanyl in persons with opioid use disorder. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32650192/),d,7.3,35406,DB00921,Buprenorphine
,32650192,time for,"The mean (SD) time for fentanyl and norfentanyl clearance was 7.3 (4.9) and 13.3 (6.9) days, respectively.",Protracted renal clearance of fentanyl in persons with opioid use disorder. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32650192/),d,13.3,35407,DB00921,Buprenorphine
,32650192,clearance,"The mean (SD) time for fentanyl and norfentanyl clearance was 7.3 (4.9) and 13.3 (6.9) days, respectively.",Protracted renal clearance of fentanyl in persons with opioid use disorder. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32650192/),d,7.3,35408,DB00921,Buprenorphine
,32650192,clearance,"The mean (SD) time for fentanyl and norfentanyl clearance was 7.3 (4.9) and 13.3 (6.9) days, respectively.",Protracted renal clearance of fentanyl in persons with opioid use disorder. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32650192/),d,13.3,35409,DB00921,Buprenorphine
,34059460,compartment volumes,"Typical values (% interindividual variability) for the three compartment volumes were 900 (33), 2425 (not estimated) and 6360 (28) mL kg-1.",Pharmacokinetics of a high-concentration formulation of buprenorphine (Simbadol) in male dogs. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34059460/),[ml] / [kg],900,36052,DB00921,Buprenorphine
,34059460,compartment volumes,"Typical values (% interindividual variability) for the three compartment volumes were 900 (33), 2425 (not estimated) and 6360 (28) mL kg-1.",Pharmacokinetics of a high-concentration formulation of buprenorphine (Simbadol) in male dogs. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34059460/),[ml] / [kg],2425,36053,DB00921,Buprenorphine
,34059460,compartment volumes,"Typical values (% interindividual variability) for the three compartment volumes were 900 (33), 2425 (not estimated) and 6360 (28) mL kg-1.",Pharmacokinetics of a high-concentration formulation of buprenorphine (Simbadol) in male dogs. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34059460/),[ml] / [kg],6360,36054,DB00921,Buprenorphine
,34059460,metabolic,"The metabolic and two distribution clearances were 25.7 (21), 107.5 (74) and 5.7 (61) mL minute-1 kg-1.",Pharmacokinetics of a high-concentration formulation of buprenorphine (Simbadol) in male dogs. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34059460/),[ml] / [kg·min],25.7,36055,DB00921,Buprenorphine
,34059460,distribution clearances,"The metabolic and two distribution clearances were 25.7 (21), 107.5 (74) and 5.7 (61) mL minute-1 kg-1.",Pharmacokinetics of a high-concentration formulation of buprenorphine (Simbadol) in male dogs. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34059460/),[ml] / [kg·min],107.5,36056,DB00921,Buprenorphine
,34059460,distribution clearances,"The metabolic and two distribution clearances were 25.7 (21), 107.5 (74) and 5.7 (61) mL minute-1 kg-1.",Pharmacokinetics of a high-concentration formulation of buprenorphine (Simbadol) in male dogs. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34059460/),[ml] / [kg·min],5.7,36057,DB00921,Buprenorphine
,34059460,absorption half-life,The absorption half-life for the fast absorption phase was 8.9 minutes with a 0.7 (103) minute delay.,Pharmacokinetics of a high-concentration formulation of buprenorphine (Simbadol) in male dogs. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34059460/),min,8.9,36058,DB00921,Buprenorphine
,34059460,absorption half-life,The absorption half-life for the slow absorption phase was 347 minutes with a 226 (42) minute delay.,Pharmacokinetics of a high-concentration formulation of buprenorphine (Simbadol) in male dogs. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34059460/),min,347,36059,DB00921,Buprenorphine
,34059460,bioavailability,Median (range) bioavailability calculated from noncompartmental analysis was 143 (80-239)%.,Pharmacokinetics of a high-concentration formulation of buprenorphine (Simbadol) in male dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34059460/),%,143,36060,DB00921,Buprenorphine
,34059460,terminal half-life,Calculated terminal half-life was 963 minutes.,Pharmacokinetics of a high-concentration formulation of buprenorphine (Simbadol) in male dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34059460/),min,963,36061,DB00921,Buprenorphine
,33375952,peak plasma concentrations,"Equal numbers of each sex were randomly assigned to receive BUP (0.02 mg/kg IM) or BSR (0.2 mg/kg SC), resulting in peak plasma concentrations (mean ± 1 SD) of 15.2 ± 8.1 and 2.8 ± 1.2 ng/mL, terminal phase t1/2 of 2.2 ± 1.0 and 32.6 ± 9.6 h, and AUC0-last of 16.1 ± 3.7 and 98.6 ± 42.7 ng × h/mL.",Pharmacokinetics of Buprenorphine and Sustained-release Buprenorphine in Common Marmosets (Callithrix jacchus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33375952/),[ng] / [ml],15.2,36158,DB00921,Buprenorphine
,33375952,peak plasma concentrations,"Equal numbers of each sex were randomly assigned to receive BUP (0.02 mg/kg IM) or BSR (0.2 mg/kg SC), resulting in peak plasma concentrations (mean ± 1 SD) of 15.2 ± 8.1 and 2.8 ± 1.2 ng/mL, terminal phase t1/2 of 2.2 ± 1.0 and 32.6 ± 9.6 h, and AUC0-last of 16.1 ± 3.7 and 98.6 ± 42.7 ng × h/mL.",Pharmacokinetics of Buprenorphine and Sustained-release Buprenorphine in Common Marmosets (Callithrix jacchus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33375952/),[ng] / [ml],2.8,36159,DB00921,Buprenorphine
,33375952,terminal phase t1/2,"Equal numbers of each sex were randomly assigned to receive BUP (0.02 mg/kg IM) or BSR (0.2 mg/kg SC), resulting in peak plasma concentrations (mean ± 1 SD) of 15.2 ± 8.1 and 2.8 ± 1.2 ng/mL, terminal phase t1/2 of 2.2 ± 1.0 and 32.6 ± 9.6 h, and AUC0-last of 16.1 ± 3.7 and 98.6 ± 42.7 ng × h/mL.",Pharmacokinetics of Buprenorphine and Sustained-release Buprenorphine in Common Marmosets (Callithrix jacchus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33375952/),h,2.2,36160,DB00921,Buprenorphine
,33375952,terminal phase t1/2,"Equal numbers of each sex were randomly assigned to receive BUP (0.02 mg/kg IM) or BSR (0.2 mg/kg SC), resulting in peak plasma concentrations (mean ± 1 SD) of 15.2 ± 8.1 and 2.8 ± 1.2 ng/mL, terminal phase t1/2 of 2.2 ± 1.0 and 32.6 ± 9.6 h, and AUC0-last of 16.1 ± 3.7 and 98.6 ± 42.7 ng × h/mL.",Pharmacokinetics of Buprenorphine and Sustained-release Buprenorphine in Common Marmosets (Callithrix jacchus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33375952/),h,32.6,36161,DB00921,Buprenorphine
,33375952,AUC0-last,"Equal numbers of each sex were randomly assigned to receive BUP (0.02 mg/kg IM) or BSR (0.2 mg/kg SC), resulting in peak plasma concentrations (mean ± 1 SD) of 15.2 ± 8.1 and 2.8 ± 1.2 ng/mL, terminal phase t1/2 of 2.2 ± 1.0 and 32.6 ± 9.6 h, and AUC0-last of 16.1 ± 3.7 and 98.6 ± 42.7 ng × h/mL.",Pharmacokinetics of Buprenorphine and Sustained-release Buprenorphine in Common Marmosets (Callithrix jacchus). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33375952/),[h·ng] / [ml],16.1,36162,DB00921,Buprenorphine
,33375952,AUC0-last,"Equal numbers of each sex were randomly assigned to receive BUP (0.02 mg/kg IM) or BSR (0.2 mg/kg SC), resulting in peak plasma concentrations (mean ± 1 SD) of 15.2 ± 8.1 and 2.8 ± 1.2 ng/mL, terminal phase t1/2 of 2.2 ± 1.0 and 32.6 ± 9.6 h, and AUC0-last of 16.1 ± 3.7 and 98.6 ± 42.7 ng × h/mL.",Pharmacokinetics of Buprenorphine and Sustained-release Buprenorphine in Common Marmosets (Callithrix jacchus). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33375952/),[h·ng] / [ml],98.6,36163,DB00921,Buprenorphine
,24862514,clearance,"Following i.v. administration, mean ± SD volume of distribution at steady-state (L/kg), clearance (mL·min/kg), and terminal half-life (h) were 11.6 ± 8.5, 23.8 ± 3.5, and 9.8 ± 3.5.","Pharmacokinetics of buprenorphine following intravenous and buccal administration in cats, and effects on thermal threshold. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24862514/),h,11.6,37572,DB00921,Buprenorphine
,24862514,clearance,"Following i.v. administration, mean ± SD volume of distribution at steady-state (L/kg), clearance (mL·min/kg), and terminal half-life (h) were 11.6 ± 8.5, 23.8 ± 3.5, and 9.8 ± 3.5.","Pharmacokinetics of buprenorphine following intravenous and buccal administration in cats, and effects on thermal threshold. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24862514/),h,23.8,37573,DB00921,Buprenorphine
,24862514,terminal half-life (,"Following i.v. administration, mean ± SD volume of distribution at steady-state (L/kg), clearance (mL·min/kg), and terminal half-life (h) were 11.6 ± 8.5, 23.8 ± 3.5, and 9.8 ± 3.5.","Pharmacokinetics of buprenorphine following intravenous and buccal administration in cats, and effects on thermal threshold. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24862514/),h,23.8,37574,DB00921,Buprenorphine
,24862514,terminal half-life (,"Following i.v. administration, mean ± SD volume of distribution at steady-state (L/kg), clearance (mL·min/kg), and terminal half-life (h) were 11.6 ± 8.5, 23.8 ± 3.5, and 9.8 ± 3.5.","Pharmacokinetics of buprenorphine following intravenous and buccal administration in cats, and effects on thermal threshold. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24862514/),h,9.8,37575,DB00921,Buprenorphine
,24862514,absorption half-life,"Following buccal administration, absorption half-life was 23.7 ± 9.1 min, and terminal half-life was 8.9 ± 4.9 h.","Pharmacokinetics of buprenorphine following intravenous and buccal administration in cats, and effects on thermal threshold. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24862514/),min,23.7,37576,DB00921,Buprenorphine
,24862514,terminal half-life,"Following buccal administration, absorption half-life was 23.7 ± 9.1 min, and terminal half-life was 8.9 ± 4.9 h.","Pharmacokinetics of buprenorphine following intravenous and buccal administration in cats, and effects on thermal threshold. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24862514/),h,8.9,37577,DB00921,Buprenorphine
,24862514,ke0,"Median (range) ke0 and EC50 were 0.003 (0.002-0.018)/min and 0.599 (0.073-1.628) ng/mL (i.v.), and 0.017 (0.002-0.023)/min and 0.429 (0.144-0.556) ng/mL (buccal).","Pharmacokinetics of buprenorphine following intravenous and buccal administration in cats, and effects on thermal threshold. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24862514/),1/[min],0.003,37578,DB00921,Buprenorphine
,24862514,ke0,"Median (range) ke0 and EC50 were 0.003 (0.002-0.018)/min and 0.599 (0.073-1.628) ng/mL (i.v.), and 0.017 (0.002-0.023)/min and 0.429 (0.144-0.556) ng/mL (buccal).","Pharmacokinetics of buprenorphine following intravenous and buccal administration in cats, and effects on thermal threshold. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24862514/),1/[min],0.017,37579,DB00921,Buprenorphine
,24862514,EC50,"Median (range) ke0 and EC50 were 0.003 (0.002-0.018)/min and 0.599 (0.073-1.628) ng/mL (i.v.), and 0.017 (0.002-0.023)/min and 0.429 (0.144-0.556) ng/mL (buccal).","Pharmacokinetics of buprenorphine following intravenous and buccal administration in cats, and effects on thermal threshold. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24862514/),[ng] / [ml],0.599,37580,DB00921,Buprenorphine
,24862514,EC50,"Median (range) ke0 and EC50 were 0.003 (0.002-0.018)/min and 0.599 (0.073-1.628) ng/mL (i.v.), and 0.017 (0.002-0.023)/min and 0.429 (0.144-0.556) ng/mL (buccal).","Pharmacokinetics of buprenorphine following intravenous and buccal administration in cats, and effects on thermal threshold. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24862514/),[ng] / [ml],0.429,37581,DB00921,Buprenorphine
,16154698,apparent bioavailability,The apparent bioavailability of buprenorphine s.l. as compared to buprenorphine i.v. was 58% with a 15.8 min later onset of antinociceptive effects.,Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16154698/),%,58,37913,DB00921,Buprenorphine
,16154698,half-life,"The half-life of buprenorphine-induced analgesic and antihyperalgesic effects were 171 and 288 min, respectively.",Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16154698/),min,171,37914,DB00921,Buprenorphine
,16154698,half-life,"The half-life of buprenorphine-induced analgesic and antihyperalgesic effects were 171 and 288 min, respectively.",Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16154698/),min,288,37915,DB00921,Buprenorphine
,17365275,apparent elimination half-life,[3H]BNP was eliminated with an apparent elimination half-life of 27.5 min after microinjection into the parietal cortex area 2 regions of the rat brain.,P-glycoprotein mediates brain-to-blood efflux transport of buprenorphine across the blood-brain barrier. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17365275/),min,27.5,39422,DB00921,Buprenorphine
,17365275,apparent efflux clearance,"The apparent efflux clearance of [3H]BNP across the BBB was 0.154 ml/min/g brain, which was calculated from the elimination rate constant (2.52 x 10- 2 min- 1) and the distribution volume in the brain (6.11 ml/g brain).",P-glycoprotein mediates brain-to-blood efflux transport of buprenorphine across the blood-brain barrier. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17365275/),[ml] / [brain·g·min],0.154,39423,DB00921,Buprenorphine
,17365275,elimination rate constant,"The apparent efflux clearance of [3H]BNP across the BBB was 0.154 ml/min/g brain, which was calculated from the elimination rate constant (2.52 x 10- 2 min- 1) and the distribution volume in the brain (6.11 ml/g brain).",P-glycoprotein mediates brain-to-blood efflux transport of buprenorphine across the blood-brain barrier. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17365275/),1·min-,2.52 x 10- 2,39424,DB00921,Buprenorphine
,17365275,distribution volume,"The apparent efflux clearance of [3H]BNP across the BBB was 0.154 ml/min/g brain, which was calculated from the elimination rate constant (2.52 x 10- 2 min- 1) and the distribution volume in the brain (6.11 ml/g brain).",P-glycoprotein mediates brain-to-blood efflux transport of buprenorphine across the blood-brain barrier. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17365275/),[ml] / [g],6.11,39425,DB00921,Buprenorphine
,17933594,flow rate,"Analytes were separated on Finnigan BetaBasic-18 column (150 mm x 2.1mm i.d., 5 microm) using methanol: water: formic acid (56:44:0.1, v/v/v) as mobile phase at a flow rate of 0.2 ml/min.",Simultaneous determination of thienorphine and its active metabolite thienorphine glucuronide in rat plasma by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17933594/),[ml] / [min],0.2,39465,DB00921,Buprenorphine
,17933594,LOQ,"LOQ of thienorphine and thienorphine glucuronide conjugate was 0.1 and 2 ng/ml, respectively.",Simultaneous determination of thienorphine and its active metabolite thienorphine glucuronide in rat plasma by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17933594/),[ng] / [ml],0.1,39466,DB00921,Buprenorphine
,17933594,LOQ,"LOQ of thienorphine and thienorphine glucuronide conjugate was 0.1 and 2 ng/ml, respectively.",Simultaneous determination of thienorphine and its active metabolite thienorphine glucuronide in rat plasma by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17933594/),[ng] / [ml],2,39467,DB00921,Buprenorphine
,6115924,bioavailabilities,"Relative to the 100% bioavailability from the intraarterial route the mean bioavailabilities were intravenous, 98%; intrarectal, 54%; intrahepatoportal, 49%; sublingual, 13%; and intraduodenal, 9.7%.",The systemic bioavailability of buprenorphine by various routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6115924/),%,98,40265,DB00921,Buprenorphine
,6115924,bioavailabilities,"Relative to the 100% bioavailability from the intraarterial route the mean bioavailabilities were intravenous, 98%; intrarectal, 54%; intrahepatoportal, 49%; sublingual, 13%; and intraduodenal, 9.7%.",The systemic bioavailability of buprenorphine by various routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6115924/),%,54,40266,DB00921,Buprenorphine
,6115924,bioavailabilities,"Relative to the 100% bioavailability from the intraarterial route the mean bioavailabilities were intravenous, 98%; intrarectal, 54%; intrahepatoportal, 49%; sublingual, 13%; and intraduodenal, 9.7%.",The systemic bioavailability of buprenorphine by various routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6115924/),%,49,40267,DB00921,Buprenorphine
,6115924,bioavailabilities,"Relative to the 100% bioavailability from the intraarterial route the mean bioavailabilities were intravenous, 98%; intrarectal, 54%; intrahepatoportal, 49%; sublingual, 13%; and intraduodenal, 9.7%.",The systemic bioavailability of buprenorphine by various routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6115924/),%,13,40268,DB00921,Buprenorphine
,6115924,bioavailabilities,"Relative to the 100% bioavailability from the intraarterial route the mean bioavailabilities were intravenous, 98%; intrarectal, 54%; intrahepatoportal, 49%; sublingual, 13%; and intraduodenal, 9.7%.",The systemic bioavailability of buprenorphine by various routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6115924/),%,9.7,40269,DB00921,Buprenorphine
,27227503,Maximum bupivacaine plasma concentration,"Maximum bupivacaine plasma concentration was 1,030 ± 497.5 ng/mL at a mean ± SD value of 30 ± 24 minutes after administration.",Pharmacokinetics of bupivacaine after intraperitoneal administration to cats undergoing ovariohysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27227503/),[ng] / [ml],"1,030",40903,DB00921,Buprenorphine
,27227503,elimination half-life,Mean elimination half-life was 4.79 ± 2.7 hours.,Pharmacokinetics of bupivacaine after intraperitoneal administration to cats undergoing ovariohysterectomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27227503/),h,4.79,40904,DB00921,Buprenorphine
,27227503,clearance,"Mean clearance indexed by bioavailability and volume of distribution indexed by bioavailability were 0.35 ± 0.18 L•h/kg and 2.10 ± 0.84 L/kg, respectively.",Pharmacokinetics of bupivacaine after intraperitoneal administration to cats undergoing ovariohysterectomy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27227503/),[h·l] / [kg],0.35,40905,DB00921,Buprenorphine
,27227503,volume of distribution,"Mean clearance indexed by bioavailability and volume of distribution indexed by bioavailability were 0.35 ± 0.18 L•h/kg and 2.10 ± 0.84 L/kg, respectively.",Pharmacokinetics of bupivacaine after intraperitoneal administration to cats undergoing ovariohysterectomy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27227503/),[h·l] / [kg],0.35,40906,DB00921,Buprenorphine
,27227503,volume of distribution,"Mean clearance indexed by bioavailability and volume of distribution indexed by bioavailability were 0.35 ± 0.18 L•h/kg and 2.10 ± 0.84 L/kg, respectively.",Pharmacokinetics of bupivacaine after intraperitoneal administration to cats undergoing ovariohysterectomy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27227503/),[l] / [kg],2.10,40907,DB00921,Buprenorphine
,31010456,AUC0-inf,"The AUC0-inf for fentanyl and the low and high dose buprenorphine patches were 115 ± 14, 462 ± 74, and 778 ± 344 ng× h/mL, and the plasma half-lifes were 22 ± 4, 77 ± 27, and 42 ± 11 h, respectively.",Evaluation of Analgesic Patches in Cynomolgus Macaques (Macaca fascicularis). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31010456/),[h·ng] / [ml],115,41289,DB00921,Buprenorphine
,31010456,AUC0-inf,"The AUC0-inf for fentanyl and the low and high dose buprenorphine patches were 115 ± 14, 462 ± 74, and 778 ± 344 ng× h/mL, and the plasma half-lifes were 22 ± 4, 77 ± 27, and 42 ± 11 h, respectively.",Evaluation of Analgesic Patches in Cynomolgus Macaques (Macaca fascicularis). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31010456/),[h·ng] / [ml],462,41290,DB00921,Buprenorphine
,31010456,AUC0-inf,"The AUC0-inf for fentanyl and the low and high dose buprenorphine patches were 115 ± 14, 462 ± 74, and 778 ± 344 ng× h/mL, and the plasma half-lifes were 22 ± 4, 77 ± 27, and 42 ± 11 h, respectively.",Evaluation of Analgesic Patches in Cynomolgus Macaques (Macaca fascicularis). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31010456/),[h·ng] / [ml],778,41291,DB00921,Buprenorphine
,31010456,plasma half-lifes,"The AUC0-inf for fentanyl and the low and high dose buprenorphine patches were 115 ± 14, 462 ± 74, and 778 ± 344 ng× h/mL, and the plasma half-lifes were 22 ± 4, 77 ± 27, and 42 ± 11 h, respectively.",Evaluation of Analgesic Patches in Cynomolgus Macaques (Macaca fascicularis). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31010456/),h,22,41292,DB00921,Buprenorphine
,31010456,plasma half-lifes,"The AUC0-inf for fentanyl and the low and high dose buprenorphine patches were 115 ± 14, 462 ± 74, and 778 ± 344 ng× h/mL, and the plasma half-lifes were 22 ± 4, 77 ± 27, and 42 ± 11 h, respectively.",Evaluation of Analgesic Patches in Cynomolgus Macaques (Macaca fascicularis). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31010456/),h,77,41293,DB00921,Buprenorphine
,31010456,plasma half-lifes,"The AUC0-inf for fentanyl and the low and high dose buprenorphine patches were 115 ± 14, 462 ± 74, and 778 ± 344 ng× h/mL, and the plasma half-lifes were 22 ± 4, 77 ± 27, and 42 ± 11 h, respectively.",Evaluation of Analgesic Patches in Cynomolgus Macaques (Macaca fascicularis). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31010456/),h,42,41294,DB00921,Buprenorphine
,31010456,Minimal therapeutic concentrations,Minimal therapeutic concentrations for fentanyl (0.2 ng/mL) and buprenorphine (0.1 ng/mL) were achieved in all macaques within 8 h of fentanyl and 24 h of buprenorphine TDP application.,Evaluation of Analgesic Patches in Cynomolgus Macaques (Macaca fascicularis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31010456/),[ng] / [ml],0.2,41295,DB00921,Buprenorphine
,31010456,Minimal therapeutic concentrations,Minimal therapeutic concentrations for fentanyl (0.2 ng/mL) and buprenorphine (0.1 ng/mL) were achieved in all macaques within 8 h of fentanyl and 24 h of buprenorphine TDP application.,Evaluation of Analgesic Patches in Cynomolgus Macaques (Macaca fascicularis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31010456/),[ng] / [ml],0.1,41296,DB00921,Buprenorphine
,28242230,TT,Baseline TT was 45.4 ± 1.4 °C for all treatments.,Thermal antinociception following oral administration of tapentadol in conscious cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28242230/),°c,45.4,44226,DB00921,Buprenorphine
,28242230,Maximum TT,"Maximum TT values were 48.8 ± 4.8 °C at 1 hour in LowTAP, 48.5 ± 3.0 °C at 2 hours in HighTAP and 50.2 ± 5.3 °C at 1 hour in BUP.",Thermal antinociception following oral administration of tapentadol in conscious cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28242230/),°c,48.8,44227,DB00921,Buprenorphine
,28242230,Maximum TT,"Maximum TT values were 48.8 ± 4.8 °C at 1 hour in LowTAP, 48.5 ± 3.0 °C at 2 hours in HighTAP and 50.2 ± 5.3 °C at 1 hour in BUP.",Thermal antinociception following oral administration of tapentadol in conscious cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28242230/),°c,48.5,44228,DB00921,Buprenorphine
,28242230,Maximum TT,"Maximum TT values were 48.8 ± 4.8 °C at 1 hour in LowTAP, 48.5 ± 3.0 °C at 2 hours in HighTAP and 50.2 ± 5.3 °C at 1 hour in BUP.",Thermal antinociception following oral administration of tapentadol in conscious cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28242230/),°c,50.2,44229,DB00921,Buprenorphine
,27647259,terminal half-life,"The time-course of intravenous STD-BUP was biphasic, with a 4.39 h average terminal half-life.",Pharmacokinetics of liposomal encapsulated buprenorphine suspension following subcutaneous administration to cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27647259/),h,4.39,47796,DB00921,Buprenorphine
,29755192,plasma concentrations (Cmax),"Maximum bupivacaine plasma concentrations (Cmax) for BE and BD were 1155 ± 168 ng/mL and 1678 ± 364 ng/mL (P = 0.29) at 67 ± 13 min (Tmax) and 123 ± 59 min (P = 0.17), respectively.",Efficacy and pharmacokinetics of bupivacaine with epinephrine or dexmedetomidine after intraperitoneal administration in cats undergoing ovariohysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29755192/),[ng] / [ml],1155,48784,DB00921,Buprenorphine
,29755192,plasma concentrations (Cmax),"Maximum bupivacaine plasma concentrations (Cmax) for BE and BD were 1155 ± 168 ng/mL and 1678 ± 364 ng/mL (P = 0.29) at 67 ± 13 min (Tmax) and 123 ± 59 min (P = 0.17), respectively.",Efficacy and pharmacokinetics of bupivacaine with epinephrine or dexmedetomidine after intraperitoneal administration in cats undergoing ovariohysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29755192/),[ng] / [ml],1678,48785,DB00921,Buprenorphine
,29755192,Tmax,"Maximum bupivacaine plasma concentrations (Cmax) for BE and BD were 1155 ± 168 ng/mL and 1678 ± 364 ng/mL (P = 0.29) at 67 ± 13 min (Tmax) and 123 ± 59 min (P = 0.17), respectively.",Efficacy and pharmacokinetics of bupivacaine with epinephrine or dexmedetomidine after intraperitoneal administration in cats undergoing ovariohysterectomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29755192/),min,67,48786,DB00921,Buprenorphine
,31028107,blood concentrations,"Steady-state maternal blood concentrations of NorBUP in dams infused with 1 or 3 mg/kg per day were comparable to values reported in pregnant humans treated with buprenorphine (1.0 and 9.6 ng/ml, respectively), suggesting a clinically relevant dosing regimen.","In Utero Exposure to Norbuprenorphine, a Major Metabolite of Buprenorphine, Induces Fetal Opioid Dependence and Leads to Neonatal Opioid Withdrawal Syndrome. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31028107/),[ng] / [ml],1.0,49281,DB00921,Buprenorphine
,31028107,blood concentrations,"Steady-state maternal blood concentrations of NorBUP in dams infused with 1 or 3 mg/kg per day were comparable to values reported in pregnant humans treated with buprenorphine (1.0 and 9.6 ng/ml, respectively), suggesting a clinically relevant dosing regimen.","In Utero Exposure to Norbuprenorphine, a Major Metabolite of Buprenorphine, Induces Fetal Opioid Dependence and Leads to Neonatal Opioid Withdrawal Syndrome. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31028107/),[ng] / [ml],9.6,49282,DB00921,Buprenorphine
,16536895,Steady-state release,Steady-state release in-vitro was 0.5 mg/implant/day.,In-vitro and in-vivo characterization of a buprenorphine delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16536895/),-1·mg,0.5,49365,DB00921,Buprenorphine
,16536895,release rate,"Steady-state plasma levels were attained between 3 and 8 weeks, and were maintained for study duration, with a calculated mean release rate of 0.14+/-0.04 mg/implant/day.",In-vitro and in-vivo characterization of a buprenorphine delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16536895/),[mg] / [d·implant],0.14,49366,DB00921,Buprenorphine
,33619904,Cmax,"The pharmacokinetic parameters, median (minimum-maximum), were Cmax 4.31 µg/L (1.93-15.5), AUCinf 2.89 h*µg/L (1.72-40.2), CL 3.39 L/h/kg (0.25-6.02), terminal t½ 1.75 h (1.07-31.0), Vss 8.04 L/kg (1.05-49.3).",Pharmacokinetics of buprenorphine in pregnant sheep after intravenous injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33619904/),[μg] / [l],4.31,50432,DB00921,Buprenorphine
,33619904,AUCinf,"The pharmacokinetic parameters, median (minimum-maximum), were Cmax 4.31 µg/L (1.93-15.5), AUCinf 2.89 h*µg/L (1.72-40.2), CL 3.39 L/h/kg (0.25-6.02), terminal t½ 1.75 h (1.07-31.0), Vss 8.04 L/kg (1.05-49.3).",Pharmacokinetics of buprenorphine in pregnant sheep after intravenous injection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33619904/),[h·μg] / [l],2.89,50433,DB00921,Buprenorphine
,33619904,CL,"The pharmacokinetic parameters, median (minimum-maximum), were Cmax 4.31 µg/L (1.93-15.5), AUCinf 2.89 h*µg/L (1.72-40.2), CL 3.39 L/h/kg (0.25-6.02), terminal t½ 1.75 h (1.07-31.0), Vss 8.04 L/kg (1.05-49.3).",Pharmacokinetics of buprenorphine in pregnant sheep after intravenous injection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33619904/),[l] / [h·kg],3.39,50434,DB00921,Buprenorphine
,33619904,terminal t½,"The pharmacokinetic parameters, median (minimum-maximum), were Cmax 4.31 µg/L (1.93-15.5), AUCinf 2.89 h*µg/L (1.72-40.2), CL 3.39 L/h/kg (0.25-6.02), terminal t½ 1.75 h (1.07-31.0), Vss 8.04 L/kg (1.05-49.3).",Pharmacokinetics of buprenorphine in pregnant sheep after intravenous injection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33619904/),h,1.75,50435,DB00921,Buprenorphine
,33619904,Vss,"The pharmacokinetic parameters, median (minimum-maximum), were Cmax 4.31 µg/L (1.93-15.5), AUCinf 2.89 h*µg/L (1.72-40.2), CL 3.39 L/h/kg (0.25-6.02), terminal t½ 1.75 h (1.07-31.0), Vss 8.04 L/kg (1.05-49.3).",Pharmacokinetics of buprenorphine in pregnant sheep after intravenous injection. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33619904/),[l] / [kg],8.04,50436,DB00921,Buprenorphine
,15917146,distribution half-life,"Plasma buprenorphine kinetics was well described by a three-compartment linear model, with a distribution half-life of 7.4+/-2.7 min and an elimination half-life of 463.9+/-152.3 min.",Flunitrazepam does not alter cerebral distribution of buprenorphine in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917146/),min,7.4,50703,DB00921,Buprenorphine
,15917146,elimination half-life,"Plasma buprenorphine kinetics was well described by a three-compartment linear model, with a distribution half-life of 7.4+/-2.7 min and an elimination half-life of 463.9+/-152.3 min.",Flunitrazepam does not alter cerebral distribution of buprenorphine in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917146/),min,463.9,50704,DB00921,Buprenorphine
,25831576,maximum concentration,An average maximum concentration of 1.21 ng/ml (0.3-2.9 ng/ml) was detected 12 hr postadministration.,Pharmacokinetics of a single subcutaneous dose of sustained release buprenorphine in northern elephant seals (Mirounga angustirostris). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25831576/),[ng] / [ml],1.21,52697,DB00921,Buprenorphine
,11000552,bioavailability,"The bioavailability for PEG 300 was 70% (S.D.+/-27%, n=6), whereas the bioavailability for 5% dextrose was 89% (S.D.+/-23%, n=6).",Intranasal absorption of buprenorphine--in vivo bioavailability study in sheep. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11000552/),%,70,53360,DB00921,Buprenorphine
,11000552,bioavailability,"The bioavailability for PEG 300 was 70% (S.D.+/-27%, n=6), whereas the bioavailability for 5% dextrose was 89% (S.D.+/-23%, n=6).",Intranasal absorption of buprenorphine--in vivo bioavailability study in sheep. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11000552/),%,89,53361,DB00921,Buprenorphine
,11000552,initial,"A two-compartment model with initial and terminal serum half-lives of 10 and 23 min, respectively, may describe the pharmacokinetics.",Intranasal absorption of buprenorphine--in vivo bioavailability study in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11000552/),min,10,53362,DB00921,Buprenorphine
,11000552,terminal serum half-lives,"A two-compartment model with initial and terminal serum half-lives of 10 and 23 min, respectively, may describe the pharmacokinetics.",Intranasal absorption of buprenorphine--in vivo bioavailability study in sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11000552/),min,23,53363,DB00921,Buprenorphine
,11000552,t(max),The rate of absorption for both nasal formulations was very fast (t(max)=10 min).,Intranasal absorption of buprenorphine--in vivo bioavailability study in sheep. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11000552/),min,10,53364,DB00921,Buprenorphine
,11000552,C(max),"The C(max) was 37 ng/ml (S.D.+/-17) and 48 (S.D.+/-10) for PEG 300 and dextrose, respectively.",Intranasal absorption of buprenorphine--in vivo bioavailability study in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11000552/),[ng] / [ml],37,53365,DB00921,Buprenorphine
,11000552,C(max),"The C(max) was 37 ng/ml (S.D.+/-17) and 48 (S.D.+/-10) for PEG 300 and dextrose, respectively.",Intranasal absorption of buprenorphine--in vivo bioavailability study in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11000552/),,48,53366,DB00921,Buprenorphine
,28445495,clearance,"The absolute buprenorphine clearance was 0.98 L kg-1 hour-1, volume of distribution at steady state was 7.9 L kg-1 and the elimination-half-life was 12.3 hours.","Pharmacokinetic and pharmacodynamic modelling after subcutaneous, intravenous and buccal administration of a high-concentration formulation of buprenorphine in conscious cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28445495/),[l] / [h·kg],0.98,53744,DB00921,Buprenorphine
,28445495,volume of distribution at steady state,"The absolute buprenorphine clearance was 0.98 L kg-1 hour-1, volume of distribution at steady state was 7.9 L kg-1 and the elimination-half-life was 12.3 hours.","Pharmacokinetic and pharmacodynamic modelling after subcutaneous, intravenous and buccal administration of a high-concentration formulation of buprenorphine in conscious cats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28445495/),[l] / [kg],7.9,53745,DB00921,Buprenorphine
,28445495,elimination-half-life,"The absolute buprenorphine clearance was 0.98 L kg-1 hour-1, volume of distribution at steady state was 7.9 L kg-1 and the elimination-half-life was 12.3 hours.","Pharmacokinetic and pharmacodynamic modelling after subcutaneous, intravenous and buccal administration of a high-concentration formulation of buprenorphine in conscious cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28445495/),h,12.3,53746,DB00921,Buprenorphine
,28445495,Bioavailability,"Bioavailability for SC and OTM was 94% and 24%, respectively.","Pharmacokinetic and pharmacodynamic modelling after subcutaneous, intravenous and buccal administration of a high-concentration formulation of buprenorphine in conscious cats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28445495/),%,94,53747,DB00921,Buprenorphine
,28445495,Bioavailability,"Bioavailability for SC and OTM was 94% and 24%, respectively.","Pharmacokinetic and pharmacodynamic modelling after subcutaneous, intravenous and buccal administration of a high-concentration formulation of buprenorphine in conscious cats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28445495/),%,24,53748,DB00921,Buprenorphine
,28445495,half-life,An initial peak (0.08 hours) was followed by a slow (half-life 11.2 hours) and progressive (peak acceleration at 2.8 hours) uptake.,"Pharmacokinetic and pharmacodynamic modelling after subcutaneous, intravenous and buccal administration of a high-concentration formulation of buprenorphine in conscious cats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28445495/),h,11.2,53749,DB00921,Buprenorphine
,21970858,F(a)F(g),"F(a)F(g) was calculated from pharmacokinetic parameters after intravenous and oral administration or using the portal-systemic concentration difference method, with values ranging from 0.027 (ezetimibe) to 1 (tolcapone).",Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21970858/),,0.027,53866,DB00921,Buprenorphine
,21970858,F(a)F(g),"F(a)F(g) was calculated from pharmacokinetic parameters after intravenous and oral administration or using the portal-systemic concentration difference method, with values ranging from 0.027 (ezetimibe) to 1 (tolcapone).",Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21970858/),,1,53867,DB00921,Buprenorphine
,21970858,"CL(int, UGT)","Glucuronides of model compounds were observed in the portal plasma after oral administration, with CL(int, UGT) values ranging from 57.8 (tolcapone) to 19,200 µL/min/mg (resveratrol).",Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21970858/),[μl] / [mg·min],57.8,53868,DB00921,Buprenorphine
,21970858,"CL(int, UGT)","Glucuronides of model compounds were observed in the portal plasma after oral administration, with CL(int, UGT) values ranging from 57.8 (tolcapone) to 19,200 µL/min/mg (resveratrol).",Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21970858/),[μl] / [mg·min],"19,200",53869,DB00921,Buprenorphine
,28644085,elimination half-life,"The elimination half-life was 13.5 and 11.1 hours for IM and SC administration, respectively.",Pharmacokinetics of a Sustained Release Formulation of Buprenorphine After Intramuscular and Subcutaneous Administration to American Kestrels ( Falco sparverius ). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28644085/),h,13.5,54408,DB00921,Buprenorphine
,28644085,elimination half-life,"The elimination half-life was 13.5 and 11.1 hours for IM and SC administration, respectively.",Pharmacokinetics of a Sustained Release Formulation of Buprenorphine After Intramuscular and Subcutaneous Administration to American Kestrels ( Falco sparverius ). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28644085/),h,11.1,54409,DB00921,Buprenorphine
,8889672,biovailability,"Buprenorphine biovailability by the sublingual and buccal routes was estimated as 51.4% and 27.8%, respectively, although there was considerable interindividual variability by both routes of administration.","Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8889672/),%,51.4,58240,DB00921,Buprenorphine
,8889672,biovailability,"Buprenorphine biovailability by the sublingual and buccal routes was estimated as 51.4% and 27.8%, respectively, although there was considerable interindividual variability by both routes of administration.","Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8889672/),%,27.8,58241,DB00921,Buprenorphine
less,8889672,peak plasma concentrations,Norbuprenorphine mean peak plasma concentrations were less than 1 ng/mL and were highly variable among different routes of administration and individuals.,"Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8889672/),[ng] / [ml],1,58242,DB00921,Buprenorphine
,2340348,sensitivities,Specific and sensitive reverse-phase HPLC assays of buprenorphine and its metabolite in biological fluids were developed with sensitivities of 2-6 ng ml-1 using fluorimetric detection.,Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),[ng] / [ml],2-6,58734,DB00921,Buprenorphine
,2340348,terminal rate constants,The terminal rate constants of the IV infusion studies from the triexponential fits of plasma concentration-time data averaged 41.6 +/- 7.5 h with an averaged total body clearance of 191 +/- 19 ml min-1.,Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,km-Q51,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),h,41.6,58735,DB00921,Buprenorphine
,2340348,total body clearance,The terminal rate constants of the IV infusion studies from the triexponential fits of plasma concentration-time data averaged 41.6 +/- 7.5 h with an averaged total body clearance of 191 +/- 19 ml min-1.,Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),[ml] / [min],191,58736,DB00921,Buprenorphine
less,2340348,half-life,"This terminal rate constant was in contrast to the less than 100 min half-life of the second exponential fitting of the less lipophilic morphine, naloxone, and naltrexone.",Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),min,100,58737,DB00921,Buprenorphine
,2340348,apparent volumes of distribution,"The apparent volumes of distribution of buprenorphine, referenced to the total plasma concentration, were 33 +/- 61 (Vc, central compartment volume) and 663 +/- 891 (Vd, total body volume), indicative of a highly bound, sequestered or lipophilic drug.",Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),,33,58738,DB00921,Buprenorphine
,2340348,Vc,"The apparent volumes of distribution of buprenorphine, referenced to the total plasma concentration, were 33 +/- 61 (Vc, central compartment volume) and 663 +/- 891 (Vd, total body volume), indicative of a highly bound, sequestered or lipophilic drug.",Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),,33,58739,DB00921,Buprenorphine
,2340348,Vd,"The apparent volumes of distribution of buprenorphine, referenced to the total plasma concentration, were 33 +/- 61 (Vc, central compartment volume) and 663 +/- 891 (Vd, total body volume), indicative of a highly bound, sequestered or lipophilic drug.",Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),,663,58740,DB00921,Buprenorphine
,2340348,terminal half-life,"Direct IV administration of the metabolite, buprenorphine glucuronide, gave a terminal half-life of 6 h and more than 90 per cent of the systemically circulating metabolite was excreted in bile; only 10 per cent in urine.",Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),h,6,58741,DB00921,Buprenorphine
,2340348,oral bioavailability,"The oral bioavailability, estimated from the areas under the buprenorphine plasma concentration-time curve following IV and oral administration of buprenorphine in the dogs, was 3-6 per cent.",Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),%,3-6,58742,DB00921,Buprenorphine
,27781278,Cmax,"The adjuvants increased Cmax (21 ± 16 ng/ml vs 75 ± 33 ng/ml; 3.6-fold) and AUC(0-22 h) (10.6 ± 8.11 μg min/ml vs 22.9 ± 11.7 μg min/ml; 2.2-fold) values of buprenorphine (control vs adjuvant-treated, respectively).",Improving the oral bioavailability of buprenorphine: an in-vivo proof of concept. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27781278/),[ng] / [ml],21,60072,DB00921,Buprenorphine
,27781278,Cmax,"The adjuvants increased Cmax (21 ± 16 ng/ml vs 75 ± 33 ng/ml; 3.6-fold) and AUC(0-22 h) (10.6 ± 8.11 μg min/ml vs 22.9 ± 11.7 μg min/ml; 2.2-fold) values of buprenorphine (control vs adjuvant-treated, respectively).",Improving the oral bioavailability of buprenorphine: an in-vivo proof of concept. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27781278/),[ng] / [ml],75,60073,DB00921,Buprenorphine
,27781278,AUC(0-22 h),"The adjuvants increased Cmax (21 ± 16 ng/ml vs 75 ± 33 ng/ml; 3.6-fold) and AUC(0-22 h) (10.6 ± 8.11 μg min/ml vs 22.9 ± 11.7 μg min/ml; 2.2-fold) values of buprenorphine (control vs adjuvant-treated, respectively).",Improving the oral bioavailability of buprenorphine: an in-vivo proof of concept. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27781278/),[min·μg] / [ml],10.6,60074,DB00921,Buprenorphine
,27781278,AUC(0-22 h),"The adjuvants increased Cmax (21 ± 16 ng/ml vs 75 ± 33 ng/ml; 3.6-fold) and AUC(0-22 h) (10.6 ± 8.11 μg min/ml vs 22.9 ± 11.7 μg min/ml; 2.2-fold) values of buprenorphine (control vs adjuvant-treated, respectively).",Improving the oral bioavailability of buprenorphine: an in-vivo proof of concept. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27781278/),[min·μg] / [ml],22.9,60075,DB00921,Buprenorphine
,27781278,absolute oral bioavailability,The absolute oral bioavailability of buprenorphine doubled (from 1.24% to 2.68%) in the presence of the adjuvants.,Improving the oral bioavailability of buprenorphine: an in-vivo proof of concept. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27781278/),%,1.24,60076,DB00921,Buprenorphine
,27781278,absolute oral bioavailability,The absolute oral bioavailability of buprenorphine doubled (from 1.24% to 2.68%) in the presence of the adjuvants.,Improving the oral bioavailability of buprenorphine: an in-vivo proof of concept. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27781278/),%,2.68,60077,DB00921,Buprenorphine
,8149883,elimination half-life (t1/2),"The elimination half-life (t1/2), total body clearance (CLtot), and steady-state volume of distribution (Vdss) of BN (0.6 mg/kg iv dose) in the intact rat were 2.8 hr, 23.3 ml/min/kg, and 4.2 liters/kg, respectively, and those of NBN (0.6 mg/kg iv dose) were 0.9 hr, 35.0 ml/min/kg, and 2.0 liters/kg.","Pharmacokinetic analysis of enterohepatic circulation of buprenorphine and its active metabolite, norbuprenorphine, in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149883/),h,2.8,63854,DB00921,Buprenorphine
,8149883,total body clearance (CLtot),"The elimination half-life (t1/2), total body clearance (CLtot), and steady-state volume of distribution (Vdss) of BN (0.6 mg/kg iv dose) in the intact rat were 2.8 hr, 23.3 ml/min/kg, and 4.2 liters/kg, respectively, and those of NBN (0.6 mg/kg iv dose) were 0.9 hr, 35.0 ml/min/kg, and 2.0 liters/kg.","Pharmacokinetic analysis of enterohepatic circulation of buprenorphine and its active metabolite, norbuprenorphine, in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149883/),[ml] / [kg·min],23.3,63855,DB00921,Buprenorphine
,8149883,total body clearance (CLtot),"The elimination half-life (t1/2), total body clearance (CLtot), and steady-state volume of distribution (Vdss) of BN (0.6 mg/kg iv dose) in the intact rat were 2.8 hr, 23.3 ml/min/kg, and 4.2 liters/kg, respectively, and those of NBN (0.6 mg/kg iv dose) were 0.9 hr, 35.0 ml/min/kg, and 2.0 liters/kg.","Pharmacokinetic analysis of enterohepatic circulation of buprenorphine and its active metabolite, norbuprenorphine, in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149883/),h,0.9,63856,DB00921,Buprenorphine
,8149883,total body clearance (CLtot),"The elimination half-life (t1/2), total body clearance (CLtot), and steady-state volume of distribution (Vdss) of BN (0.6 mg/kg iv dose) in the intact rat were 2.8 hr, 23.3 ml/min/kg, and 4.2 liters/kg, respectively, and those of NBN (0.6 mg/kg iv dose) were 0.9 hr, 35.0 ml/min/kg, and 2.0 liters/kg.","Pharmacokinetic analysis of enterohepatic circulation of buprenorphine and its active metabolite, norbuprenorphine, in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149883/),[ml] / [kg·min],35.0,63857,DB00921,Buprenorphine
,8149883,steady-state volume of distribution (Vdss),"The elimination half-life (t1/2), total body clearance (CLtot), and steady-state volume of distribution (Vdss) of BN (0.6 mg/kg iv dose) in the intact rat were 2.8 hr, 23.3 ml/min/kg, and 4.2 liters/kg, respectively, and those of NBN (0.6 mg/kg iv dose) were 0.9 hr, 35.0 ml/min/kg, and 2.0 liters/kg.","Pharmacokinetic analysis of enterohepatic circulation of buprenorphine and its active metabolite, norbuprenorphine, in rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149883/),[l] / [kg],4.2,63858,DB00921,Buprenorphine
,8149883,steady-state volume of distribution (Vdss),"The elimination half-life (t1/2), total body clearance (CLtot), and steady-state volume of distribution (Vdss) of BN (0.6 mg/kg iv dose) in the intact rat were 2.8 hr, 23.3 ml/min/kg, and 4.2 liters/kg, respectively, and those of NBN (0.6 mg/kg iv dose) were 0.9 hr, 35.0 ml/min/kg, and 2.0 liters/kg.","Pharmacokinetic analysis of enterohepatic circulation of buprenorphine and its active metabolite, norbuprenorphine, in rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149883/),h,0.9,63859,DB00921,Buprenorphine
,8149883,steady-state volume of distribution (Vdss),"The elimination half-life (t1/2), total body clearance (CLtot), and steady-state volume of distribution (Vdss) of BN (0.6 mg/kg iv dose) in the intact rat were 2.8 hr, 23.3 ml/min/kg, and 4.2 liters/kg, respectively, and those of NBN (0.6 mg/kg iv dose) were 0.9 hr, 35.0 ml/min/kg, and 2.0 liters/kg.","Pharmacokinetic analysis of enterohepatic circulation of buprenorphine and its active metabolite, norbuprenorphine, in rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149883/),[ml] / [kg·min],35.0,63860,DB00921,Buprenorphine
,8149883,steady-state volume of distribution (Vdss),"The elimination half-life (t1/2), total body clearance (CLtot), and steady-state volume of distribution (Vdss) of BN (0.6 mg/kg iv dose) in the intact rat were 2.8 hr, 23.3 ml/min/kg, and 4.2 liters/kg, respectively, and those of NBN (0.6 mg/kg iv dose) were 0.9 hr, 35.0 ml/min/kg, and 2.0 liters/kg.","Pharmacokinetic analysis of enterohepatic circulation of buprenorphine and its active metabolite, norbuprenorphine, in rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149883/),[l] / [kg],2.0,63861,DB00921,Buprenorphine
,31227029,peak plasma concentration,"The low dose (0.24 mg/kg SC) achieved a peak plasma concentration of 19.1 ± 5.68 ng/mL at 0.308 ± 0.077 h, with an AUC of 236.4 ± 22.5 h/ng/mL and terminal elimination half-life of 19.6 ± 4.02 h; for the high dose (0.72 mg/kg SC), these parameters were 65.2 ± 14.7 ng/mL, 0.034 ± 0.004 h, 641.3 ± 79.4 h/ng/mL, and 20.6 ± 2.30 h, respectively.","Pharmacokinetics of a Long-lasting, Highly Concentrated Buprenorphine Solution after Subcutaneous Administration in Rhesus Macaques (Macaca mulatta). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31227029/),[ng] / [ml],19.1,69334,DB00921,Buprenorphine
,31227029,AUC,"The low dose (0.24 mg/kg SC) achieved a peak plasma concentration of 19.1 ± 5.68 ng/mL at 0.308 ± 0.077 h, with an AUC of 236.4 ± 22.5 h/ng/mL and terminal elimination half-life of 19.6 ± 4.02 h; for the high dose (0.72 mg/kg SC), these parameters were 65.2 ± 14.7 ng/mL, 0.034 ± 0.004 h, 641.3 ± 79.4 h/ng/mL, and 20.6 ± 2.30 h, respectively.","Pharmacokinetics of a Long-lasting, Highly Concentrated Buprenorphine Solution after Subcutaneous Administration in Rhesus Macaques (Macaca mulatta). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31227029/),[h] / [ml·ng],236.4,69335,DB00921,Buprenorphine
,31227029,terminal elimination half-life,"The low dose (0.24 mg/kg SC) achieved a peak plasma concentration of 19.1 ± 5.68 ng/mL at 0.308 ± 0.077 h, with an AUC of 236.4 ± 22.5 h/ng/mL and terminal elimination half-life of 19.6 ± 4.02 h; for the high dose (0.72 mg/kg SC), these parameters were 65.2 ± 14.7 ng/mL, 0.034 ± 0.004 h, 641.3 ± 79.4 h/ng/mL, and 20.6 ± 2.30 h, respectively.","Pharmacokinetics of a Long-lasting, Highly Concentrated Buprenorphine Solution after Subcutaneous Administration in Rhesus Macaques (Macaca mulatta). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31227029/),h,19.6,69336,DB00921,Buprenorphine
,31227029,terminal elimination half-life,"The low dose (0.24 mg/kg SC) achieved a peak plasma concentration of 19.1 ± 5.68 ng/mL at 0.308 ± 0.077 h, with an AUC of 236.4 ± 22.5 h/ng/mL and terminal elimination half-life of 19.6 ± 4.02 h; for the high dose (0.72 mg/kg SC), these parameters were 65.2 ± 14.7 ng/mL, 0.034 ± 0.004 h, 641.3 ± 79.4 h/ng/mL, and 20.6 ± 2.30 h, respectively.","Pharmacokinetics of a Long-lasting, Highly Concentrated Buprenorphine Solution after Subcutaneous Administration in Rhesus Macaques (Macaca mulatta). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31227029/),[ng] / [ml],65.2,69337,DB00921,Buprenorphine
,31227029,terminal elimination half-life,"The low dose (0.24 mg/kg SC) achieved a peak plasma concentration of 19.1 ± 5.68 ng/mL at 0.308 ± 0.077 h, with an AUC of 236.4 ± 22.5 h/ng/mL and terminal elimination half-life of 19.6 ± 4.02 h; for the high dose (0.72 mg/kg SC), these parameters were 65.2 ± 14.7 ng/mL, 0.034 ± 0.004 h, 641.3 ± 79.4 h/ng/mL, and 20.6 ± 2.30 h, respectively.","Pharmacokinetics of a Long-lasting, Highly Concentrated Buprenorphine Solution after Subcutaneous Administration in Rhesus Macaques (Macaca mulatta). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31227029/),h,0.034,69338,DB00921,Buprenorphine
,31227029,terminal elimination half-life,"The low dose (0.24 mg/kg SC) achieved a peak plasma concentration of 19.1 ± 5.68 ng/mL at 0.308 ± 0.077 h, with an AUC of 236.4 ± 22.5 h/ng/mL and terminal elimination half-life of 19.6 ± 4.02 h; for the high dose (0.72 mg/kg SC), these parameters were 65.2 ± 14.7 ng/mL, 0.034 ± 0.004 h, 641.3 ± 79.4 h/ng/mL, and 20.6 ± 2.30 h, respectively.","Pharmacokinetics of a Long-lasting, Highly Concentrated Buprenorphine Solution after Subcutaneous Administration in Rhesus Macaques (Macaca mulatta). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31227029/),[h] / [ml·ng],641.3,69339,DB00921,Buprenorphine
,31227029,terminal elimination half-life,"The low dose (0.24 mg/kg SC) achieved a peak plasma concentration of 19.1 ± 5.68 ng/mL at 0.308 ± 0.077 h, with an AUC of 236.4 ± 22.5 h/ng/mL and terminal elimination half-life of 19.6 ± 4.02 h; for the high dose (0.72 mg/kg SC), these parameters were 65.2 ± 14.7 ng/mL, 0.034 ± 0.004 h, 641.3 ± 79.4 h/ng/mL, and 20.6 ± 2.30 h, respectively.","Pharmacokinetics of a Long-lasting, Highly Concentrated Buprenorphine Solution after Subcutaneous Administration in Rhesus Macaques (Macaca mulatta). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31227029/),h,20.6,69340,DB00921,Buprenorphine
,14563545,Cmax,Mean Cmax values ranged from 1.6 to 6.4 ng/ml and tmax from 0.5 to 3 h.,Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naïve healthy male volunteers under a naltrexone block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14563545/),[ng] / [ml],1.6 to 6.4,74743,DB00921,Buprenorphine
,14563545,tmax,Mean Cmax values ranged from 1.6 to 6.4 ng/ml and tmax from 0.5 to 3 h.,Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naïve healthy male volunteers under a naltrexone block. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14563545/),h,0.5 to 3,74744,DB00921,Buprenorphine
,14563545,terminal half-life,The terminal half-life was approximately 26 h (range 9-69).,Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naïve healthy male volunteers under a naltrexone block. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14563545/),h,26,74745,DB00921,Buprenorphine
,14563545,times of disintegration,Median times of disintegration were similar for all doses and formulations (range 6-12 min).,Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naïve healthy male volunteers under a naltrexone block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14563545/),min,6-12,74746,DB00921,Buprenorphine
,20709341,Background concentration,Background concentration (before injection) was 1.27 ± 0.27 ng/mL (mean ± SD).,Plasma concentrations of buprenorphine after epidural administration in conscious cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20709341/),[ng] / [ml],1.27,76200,DB00921,Buprenorphine
,20709341,peak plasma concentration,"Including background concentration, the mean peak plasma concentration was obtained 15 min after injection (5.82 ± 3.75 ng/mL), and ranged from 3.79 to 2.20 ng/mL (30 min-3 h), remaining between 1.93 and 1.77 ng/mL (4-12 h), and declined to 1.40 ± 0.62 ng/mL at 24h.",Plasma concentrations of buprenorphine after epidural administration in conscious cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20709341/),[ng] / [ml],5.82,76201,DB00921,Buprenorphine
,20709341,peak plasma concentration,"Including background concentration, the mean peak plasma concentration was obtained 15 min after injection (5.82 ± 3.75 ng/mL), and ranged from 3.79 to 2.20 ng/mL (30 min-3 h), remaining between 1.93 and 1.77 ng/mL (4-12 h), and declined to 1.40 ± 0.62 ng/mL at 24h.",Plasma concentrations of buprenorphine after epidural administration in conscious cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20709341/),[ng] / [ml],3.79 to 2.20,76202,DB00921,Buprenorphine
,20709341,peak plasma concentration,"Including background concentration, the mean peak plasma concentration was obtained 15 min after injection (5.82 ± 3.75 ng/mL), and ranged from 3.79 to 2.20 ng/mL (30 min-3 h), remaining between 1.93 and 1.77 ng/mL (4-12 h), and declined to 1.40 ± 0.62 ng/mL at 24h.",Plasma concentrations of buprenorphine after epidural administration in conscious cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20709341/),[ng] / [ml],1.93 and 1.77,76203,DB00921,Buprenorphine
,20709341,peak plasma concentration,"Including background concentration, the mean peak plasma concentration was obtained 15 min after injection (5.82 ± 3.75 ng/mL), and ranged from 3.79 to 2.20 ng/mL (30 min-3 h), remaining between 1.93 and 1.77 ng/mL (4-12 h), and declined to 1.40 ± 0.62 ng/mL at 24h.",Plasma concentrations of buprenorphine after epidural administration in conscious cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20709341/),[ng] / [ml],1.40,76204,DB00921,Buprenorphine
,20709341,Elimination half-life,Elimination half-life was 58.8 ± 40.2 min and clearance 56.7 ± 21.5 mL/min.,Plasma concentrations of buprenorphine after epidural administration in conscious cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20709341/),min,58.8,76205,DB00921,Buprenorphine
,20709341,clearance,Elimination half-life was 58.8 ± 40.2 min and clearance 56.7 ± 21.5 mL/min.,Plasma concentrations of buprenorphine after epidural administration in conscious cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20709341/),[ml] / [min],56.7,76206,DB00921,Buprenorphine
,10235658,distribution half-life,"The plasma concentration time curves were biexponential and the pharmacokinetic parameters obtained were : distribution half-life 37.24+/-6.57 min, elimination half-life 482.69+/-79 min, clearance 1221.97+/-209.42 ml/min, and volume of distribution 736.46+/-71.25 L.",Buprenorphine pharmacokinetic parameters during coronary artery bypass graft surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235658/),min,37.24,80580,DB00921,Buprenorphine
,10235658,elimination half-life,"The plasma concentration time curves were biexponential and the pharmacokinetic parameters obtained were : distribution half-life 37.24+/-6.57 min, elimination half-life 482.69+/-79 min, clearance 1221.97+/-209.42 ml/min, and volume of distribution 736.46+/-71.25 L.",Buprenorphine pharmacokinetic parameters during coronary artery bypass graft surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235658/),min,482.69,80581,DB00921,Buprenorphine
,10235658,clearance,"The plasma concentration time curves were biexponential and the pharmacokinetic parameters obtained were : distribution half-life 37.24+/-6.57 min, elimination half-life 482.69+/-79 min, clearance 1221.97+/-209.42 ml/min, and volume of distribution 736.46+/-71.25 L.",Buprenorphine pharmacokinetic parameters during coronary artery bypass graft surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235658/),[ml] / [min],1221.97,80582,DB00921,Buprenorphine
,10235658,volume of distribution,"The plasma concentration time curves were biexponential and the pharmacokinetic parameters obtained were : distribution half-life 37.24+/-6.57 min, elimination half-life 482.69+/-79 min, clearance 1221.97+/-209.42 ml/min, and volume of distribution 736.46+/-71.25 L.",Buprenorphine pharmacokinetic parameters during coronary artery bypass graft surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235658/),l,736.46,80583,DB00921,Buprenorphine
,10235658,plasma BN concentration,"The mean +/- SEM plasma BN concentration during CPB was 0.51+/-0.03 ng/ml which was adequate for the maintenance of analgesia and anaesthesia, as none of our patients expressed the signs and symptoms of awareness during surgery.",Buprenorphine pharmacokinetic parameters during coronary artery bypass graft surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235658/),[ng] / [ml],0.51,80584,DB00921,Buprenorphine
,26865472,area under the curve,"Following BTDS administration, mean area under the curve of buprenorphine increased proportionally (12.6, 24.3, and 51.1 ng/[mL · h]), maximum mean plasma concentration rose with increasing dose (176, 191, and 471 pg/mL), and absolute bioavailability was 14% to 16%.",Dose-Dependent Flux of Buprenorphine Following Transdermal Administration in Healthy Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26865472/),[ng] / [h·ml],12.6,81982,DB00921,Buprenorphine
,26865472,area under the curve,"Following BTDS administration, mean area under the curve of buprenorphine increased proportionally (12.6, 24.3, and 51.1 ng/[mL · h]), maximum mean plasma concentration rose with increasing dose (176, 191, and 471 pg/mL), and absolute bioavailability was 14% to 16%.",Dose-Dependent Flux of Buprenorphine Following Transdermal Administration in Healthy Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26865472/),[ng] / [h·ml],24.3,81983,DB00921,Buprenorphine
,26865472,area under the curve,"Following BTDS administration, mean area under the curve of buprenorphine increased proportionally (12.6, 24.3, and 51.1 ng/[mL · h]), maximum mean plasma concentration rose with increasing dose (176, 191, and 471 pg/mL), and absolute bioavailability was 14% to 16%.",Dose-Dependent Flux of Buprenorphine Following Transdermal Administration in Healthy Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26865472/),[ng] / [h·ml],51.1,81984,DB00921,Buprenorphine
,26865472,maximum mean plasma concentration,"Following BTDS administration, mean area under the curve of buprenorphine increased proportionally (12.6, 24.3, and 51.1 ng/[mL · h]), maximum mean plasma concentration rose with increasing dose (176, 191, and 471 pg/mL), and absolute bioavailability was 14% to 16%.",Dose-Dependent Flux of Buprenorphine Following Transdermal Administration in Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26865472/),p,176,81985,DB00921,Buprenorphine
,26865472,maximum mean plasma concentration,"Following BTDS administration, mean area under the curve of buprenorphine increased proportionally (12.6, 24.3, and 51.1 ng/[mL · h]), maximum mean plasma concentration rose with increasing dose (176, 191, and 471 pg/mL), and absolute bioavailability was 14% to 16%.",Dose-Dependent Flux of Buprenorphine Following Transdermal Administration in Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26865472/),p,191,81986,DB00921,Buprenorphine
,26865472,maximum mean plasma concentration,"Following BTDS administration, mean area under the curve of buprenorphine increased proportionally (12.6, 24.3, and 51.1 ng/[mL · h]), maximum mean plasma concentration rose with increasing dose (176, 191, and 471 pg/mL), and absolute bioavailability was 14% to 16%.",Dose-Dependent Flux of Buprenorphine Following Transdermal Administration in Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26865472/),p,471,81987,DB00921,Buprenorphine
,26865472,absolute bioavailability,"Following BTDS administration, mean area under the curve of buprenorphine increased proportionally (12.6, 24.3, and 51.1 ng/[mL · h]), maximum mean plasma concentration rose with increasing dose (176, 191, and 471 pg/mL), and absolute bioavailability was 14% to 16%.",Dose-Dependent Flux of Buprenorphine Following Transdermal Administration in Healthy Subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26865472/),%,14,81988,DB00921,Buprenorphine
,26865472,absolute bioavailability,"Following BTDS administration, mean area under the curve of buprenorphine increased proportionally (12.6, 24.3, and 51.1 ng/[mL · h]), maximum mean plasma concentration rose with increasing dose (176, 191, and 471 pg/mL), and absolute bioavailability was 14% to 16%.",Dose-Dependent Flux of Buprenorphine Following Transdermal Administration in Healthy Subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26865472/),%,16,81989,DB00921,Buprenorphine
,26865472,residual amount,"Mean residual amount of buprenorphine in the BTDS after 7-day application was 4.50, 8.57, and 17.1 mg.",Dose-Dependent Flux of Buprenorphine Following Transdermal Administration in Healthy Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26865472/),mg,4.50,81990,DB00921,Buprenorphine
,26865472,residual amount,"Mean residual amount of buprenorphine in the BTDS after 7-day application was 4.50, 8.57, and 17.1 mg.",Dose-Dependent Flux of Buprenorphine Following Transdermal Administration in Healthy Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26865472/),mg,8.57,81991,DB00921,Buprenorphine
,26865472,residual amount,"Mean residual amount of buprenorphine in the BTDS after 7-day application was 4.50, 8.57, and 17.1 mg.",Dose-Dependent Flux of Buprenorphine Following Transdermal Administration in Healthy Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26865472/),mg,17.1,81992,DB00921,Buprenorphine
,26865472,Flux,"Flux of buprenorphine was approximately 5, 10, and 20 μg/h for BTDS containing 5, 10, and 20 mg buprenorphine, respectively.",Dose-Dependent Flux of Buprenorphine Following Transdermal Administration in Healthy Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26865472/),[μg] / [h],5,81993,DB00921,Buprenorphine
,26865472,Flux,"Flux of buprenorphine was approximately 5, 10, and 20 μg/h for BTDS containing 5, 10, and 20 mg buprenorphine, respectively.",Dose-Dependent Flux of Buprenorphine Following Transdermal Administration in Healthy Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26865472/),[μg] / [h],10,81994,DB00921,Buprenorphine
,26865472,Flux,"Flux of buprenorphine was approximately 5, 10, and 20 μg/h for BTDS containing 5, 10, and 20 mg buprenorphine, respectively.",Dose-Dependent Flux of Buprenorphine Following Transdermal Administration in Healthy Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26865472/),[μg] / [h],20,81995,DB00921,Buprenorphine
,21501371,half-life,"Following IV administration, buprenorphine mean ± SD half-life was 5.79 ± 1.09 hours.",Intravenous and sublingual buprenorphine in horses: pharmacokinetics and influence of sampling site. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21501371/),h,5.79,87375,DB00921,Buprenorphine
,21501371,Systemic clearance (Cl),Systemic clearance (Cl) following IV administration was 6.13 ± 0.86 mL kg(-1) minute(-1) and volume of distribution at steady-state was 3.16 ± 0.65 L kg(-1).,Intravenous and sublingual buprenorphine in horses: pharmacokinetics and influence of sampling site. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21501371/),[ml] / [kg·minute],6.13,87376,DB00921,Buprenorphine
,21501371,volume of distribution at steady-state,Systemic clearance (Cl) following IV administration was 6.13 ± 0.86 mL kg(-1) minute(-1) and volume of distribution at steady-state was 3.16 ± 0.65 L kg(-1).,Intravenous and sublingual buprenorphine in horses: pharmacokinetics and influence of sampling site. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21501371/),[l] / [kg],3.16,87377,DB00921,Buprenorphine
,25944578,TT,"Baseline TT was 47.6 ± 4.1°C, which increased in all groups treated with all buprenorphine dosages and formulations.",Pharmacokinetic and pharmacodynamic evaluation of high doses of buprenorphine delivered via high-concentration formulations in cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25944578/),°c,47.6,88576,DB00921,Buprenorphine
,25944578,time to maximum effect (Tmax),"The time to maximum effect (Tmax) ranged between 0.25 and 2.00 h; and plasma concentrations associated with maximum antinociceptive effect (Cmax) were 1.01-1.72 ng/ml after the 0.02 mg/kg dose, 1.4-4.9 ng/ml after the 0.06 mg/kg dose, 4.6-51.4 ng/ml after the 0.12 mg/kg dose and 5.3-22.3 ng/ml after the 0.24 mg/kg dose.",Pharmacokinetic and pharmacodynamic evaluation of high doses of buprenorphine delivered via high-concentration formulations in cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25944578/),h,0.25 and 2.00,88577,DB00921,Buprenorphine
,25944578,maximum antinociceptive effect (Cmax),"The time to maximum effect (Tmax) ranged between 0.25 and 2.00 h; and plasma concentrations associated with maximum antinociceptive effect (Cmax) were 1.01-1.72 ng/ml after the 0.02 mg/kg dose, 1.4-4.9 ng/ml after the 0.06 mg/kg dose, 4.6-51.4 ng/ml after the 0.12 mg/kg dose and 5.3-22.3 ng/ml after the 0.24 mg/kg dose.",Pharmacokinetic and pharmacodynamic evaluation of high doses of buprenorphine delivered via high-concentration formulations in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25944578/),[ng] / [ml],1.01-1.72,88578,DB00921,Buprenorphine
,25944578,maximum antinociceptive effect (Cmax),"The time to maximum effect (Tmax) ranged between 0.25 and 2.00 h; and plasma concentrations associated with maximum antinociceptive effect (Cmax) were 1.01-1.72 ng/ml after the 0.02 mg/kg dose, 1.4-4.9 ng/ml after the 0.06 mg/kg dose, 4.6-51.4 ng/ml after the 0.12 mg/kg dose and 5.3-22.3 ng/ml after the 0.24 mg/kg dose.",Pharmacokinetic and pharmacodynamic evaluation of high doses of buprenorphine delivered via high-concentration formulations in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25944578/),[ng] / [ml],1.4-4.9,88579,DB00921,Buprenorphine
,25944578,maximum antinociceptive effect (Cmax),"The time to maximum effect (Tmax) ranged between 0.25 and 2.00 h; and plasma concentrations associated with maximum antinociceptive effect (Cmax) were 1.01-1.72 ng/ml after the 0.02 mg/kg dose, 1.4-4.9 ng/ml after the 0.06 mg/kg dose, 4.6-51.4 ng/ml after the 0.12 mg/kg dose and 5.3-22.3 ng/ml after the 0.24 mg/kg dose.",Pharmacokinetic and pharmacodynamic evaluation of high doses of buprenorphine delivered via high-concentration formulations in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25944578/),[ng] / [ml],4.6-51.4,88580,DB00921,Buprenorphine
,25944578,maximum antinociceptive effect (Cmax),"The time to maximum effect (Tmax) ranged between 0.25 and 2.00 h; and plasma concentrations associated with maximum antinociceptive effect (Cmax) were 1.01-1.72 ng/ml after the 0.02 mg/kg dose, 1.4-4.9 ng/ml after the 0.06 mg/kg dose, 4.6-51.4 ng/ml after the 0.12 mg/kg dose and 5.3-22.3 ng/ml after the 0.24 mg/kg dose.",Pharmacokinetic and pharmacodynamic evaluation of high doses of buprenorphine delivered via high-concentration formulations in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25944578/),[ng] / [ml],5.3-22.3,88581,DB00921,Buprenorphine
,25944578,elimination half-life,The range of estimates for the buprenorphine elimination half-life were as follows: 0.02 mg/kg = 1.35-5.33 h; 0.06 mg/kg = 16.1-31.2 h; 0.12 mg/kg = 10.1-34.0 h; and 0.24 = mg/kg 16.1-31.6 h.,Pharmacokinetic and pharmacodynamic evaluation of high doses of buprenorphine delivered via high-concentration formulations in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25944578/),h,1.35-5.33,88582,DB00921,Buprenorphine
,25944578,elimination half-life,The range of estimates for the buprenorphine elimination half-life were as follows: 0.02 mg/kg = 1.35-5.33 h; 0.06 mg/kg = 16.1-31.2 h; 0.12 mg/kg = 10.1-34.0 h; and 0.24 = mg/kg 16.1-31.6 h.,Pharmacokinetic and pharmacodynamic evaluation of high doses of buprenorphine delivered via high-concentration formulations in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25944578/),h,16.1-31.2,88583,DB00921,Buprenorphine
,25944578,elimination half-life,The range of estimates for the buprenorphine elimination half-life were as follows: 0.02 mg/kg = 1.35-5.33 h; 0.06 mg/kg = 16.1-31.2 h; 0.12 mg/kg = 10.1-34.0 h; and 0.24 = mg/kg 16.1-31.6 h.,Pharmacokinetic and pharmacodynamic evaluation of high doses of buprenorphine delivered via high-concentration formulations in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25944578/),h,10.1-34.0,88584,DB00921,Buprenorphine
,25944578,elimination half-life,The range of estimates for the buprenorphine elimination half-life were as follows: 0.02 mg/kg = 1.35-5.33 h; 0.06 mg/kg = 16.1-31.2 h; 0.12 mg/kg = 10.1-34.0 h; and 0.24 = mg/kg 16.1-31.6 h.,Pharmacokinetic and pharmacodynamic evaluation of high doses of buprenorphine delivered via high-concentration formulations in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25944578/),h,16.1-31.6,88585,DB00921,Buprenorphine
,25944578,'plasma concentration,The mean 'plasma concentration for the offset of analgesia' was 2.3 ± 2.0 ng/ml.,Pharmacokinetic and pharmacodynamic evaluation of high doses of buprenorphine delivered via high-concentration formulations in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25944578/),[ng] / [ml],2.3,88586,DB00921,Buprenorphine
greater,1797849,recoveries,The recoveries of buprenorphine and nalbuphine (internal standard) were greater than 90%.,Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),%,90,95107,DB00921,Buprenorphine
,1797849,limit of detection,The limit of detection was 1.0 ng/ml of plasma based on a signal-to-noise ratio of 3.,Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),[ng] / [ml],1.0,95108,DB00921,Buprenorphine
,1797849,signal-to-noise ratio,The limit of detection was 1.0 ng/ml of plasma based on a signal-to-noise ratio of 3.,Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),,3,95109,DB00921,Buprenorphine
,1797849,distribution,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),min,1.32,95110,DB00921,Buprenorphine
,1797849,distribution,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),min,24.8,95111,DB00921,Buprenorphine
,1797849,distribution,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),min,230,95112,DB00921,Buprenorphine
,1797849,distribution,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),min,0.94,95113,DB00921,Buprenorphine
,1797849,elimination half-lives,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),min,1.32,95114,DB00921,Buprenorphine
,1797849,elimination half-lives,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),min,24.8,95115,DB00921,Buprenorphine
,1797849,elimination half-lives,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),min,230,95116,DB00921,Buprenorphine
,1797849,elimination half-lives,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),[ml] / [min],224,95117,DB00921,Buprenorphine
,1797849,elimination half-lives,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),min,0.94,95118,DB00921,Buprenorphine
,1797849,elimination half-lives,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),min,12.5,95119,DB00921,Buprenorphine
,1797849,elimination half-lives,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),min,232,95120,DB00921,Buprenorphine
,1797849,elimination half-lives,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),[ml] / [min],30,95121,DB00921,Buprenorphine
,1797849,clearance,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),min,24.8,95122,DB00921,Buprenorphine
,1797849,clearance,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),min,230,95123,DB00921,Buprenorphine
,1797849,clearance,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),[ml] / [min],224,95124,DB00921,Buprenorphine
,1797849,clearance,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),min,232,95125,DB00921,Buprenorphine
,1797849,clearance,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),[ml] / [min],30,95126,DB00921,Buprenorphine
,32000269,Precision,Precision ranged from 15-20%.,Therapeutic Drug Monitoring in Buprenorphine/Naloxone Treatment for Opioid Use Disorder: Clinical Feasibility and Optimizing Assay Precision. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32000269/),%,15-20,98138,DB00921,Buprenorphine
,32000269,limit of detection (LoD),"The estimated limit of detection (LoD) and limit of quantitation (LoQ) were 0.02 and 0.069 ng/mL, respectively.",Therapeutic Drug Monitoring in Buprenorphine/Naloxone Treatment for Opioid Use Disorder: Clinical Feasibility and Optimizing Assay Precision. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32000269/),[ng] / [ml],0.02,98139,DB00921,Buprenorphine
,32000269,limit of quantitation (LoQ),"The estimated limit of detection (LoD) and limit of quantitation (LoQ) were 0.02 and 0.069 ng/mL, respectively.",Therapeutic Drug Monitoring in Buprenorphine/Naloxone Treatment for Opioid Use Disorder: Clinical Feasibility and Optimizing Assay Precision. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32000269/),[ng] / [ml],0.069,98140,DB00921,Buprenorphine
<,30248201,clearance,Drugs with low clearance (<1 mL/[kg·min]) are likely to cause an infant exposure level greater than 10% of the weight-adjusted maternal dose even if the milk-to-plasma concentration ratio is 1.,Opioids in Breast Milk: Pharmacokinetic Principles and Clinical Implications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30248201/),[ml] / [kg·min],1,99196,DB00921,Buprenorphine
,30248201,milk-to-plasma concentration ratio,Drugs with low clearance (<1 mL/[kg·min]) are likely to cause an infant exposure level greater than 10% of the weight-adjusted maternal dose even if the milk-to-plasma concentration ratio is 1.,Opioids in Breast Milk: Pharmacokinetic Principles and Clinical Implications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30248201/),,1,99197,DB00921,Buprenorphine
,29256372,maximal plasma concentration (Cmax),"Within the first h after administration, the maximal plasma concentration (Cmax) of the drug was 64.3 ± 9.2 ng/mL (males) and 71.3 ± 3.7 ng/mL (females) in the SRBHigh group; 11.5 ± 3.2 ng/mL (males) and 6.9 ± 0.9 ng/mL (females) in the SRBMedium group; and 2.3 ± 0.8 ng/mL (males) and 2.0 ± 0.5 ng/mL (females) in the SRBLow group.",Pharmacokinetics and Adverse Effects of 3 Sustained-release Buprenorphine Dosages in Healthy Guinea Pigs (Cavia porcellus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29256372/),[ng] / [ml],64.3,100604,DB00921,Buprenorphine
,29256372,maximal plasma concentration (Cmax),"Within the first h after administration, the maximal plasma concentration (Cmax) of the drug was 64.3 ± 9.2 ng/mL (males) and 71.3 ± 3.7 ng/mL (females) in the SRBHigh group; 11.5 ± 3.2 ng/mL (males) and 6.9 ± 0.9 ng/mL (females) in the SRBMedium group; and 2.3 ± 0.8 ng/mL (males) and 2.0 ± 0.5 ng/mL (females) in the SRBLow group.",Pharmacokinetics and Adverse Effects of 3 Sustained-release Buprenorphine Dosages in Healthy Guinea Pigs (Cavia porcellus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29256372/),[ng] / [ml],71.3,100605,DB00921,Buprenorphine
,29256372,maximal plasma concentration (Cmax),"Within the first h after administration, the maximal plasma concentration (Cmax) of the drug was 64.3 ± 9.2 ng/mL (males) and 71.3 ± 3.7 ng/mL (females) in the SRBHigh group; 11.5 ± 3.2 ng/mL (males) and 6.9 ± 0.9 ng/mL (females) in the SRBMedium group; and 2.3 ± 0.8 ng/mL (males) and 2.0 ± 0.5 ng/mL (females) in the SRBLow group.",Pharmacokinetics and Adverse Effects of 3 Sustained-release Buprenorphine Dosages in Healthy Guinea Pigs (Cavia porcellus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29256372/),[ng] / [ml],11.5,100606,DB00921,Buprenorphine
,29256372,maximal plasma concentration (Cmax),"Within the first h after administration, the maximal plasma concentration (Cmax) of the drug was 64.3 ± 9.2 ng/mL (males) and 71.3 ± 3.7 ng/mL (females) in the SRBHigh group; 11.5 ± 3.2 ng/mL (males) and 6.9 ± 0.9 ng/mL (females) in the SRBMedium group; and 2.3 ± 0.8 ng/mL (males) and 2.0 ± 0.5 ng/mL (females) in the SRBLow group.",Pharmacokinetics and Adverse Effects of 3 Sustained-release Buprenorphine Dosages in Healthy Guinea Pigs (Cavia porcellus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29256372/),[ng] / [ml],6.9,100607,DB00921,Buprenorphine
,29256372,maximal plasma concentration (Cmax),"Within the first h after administration, the maximal plasma concentration (Cmax) of the drug was 64.3 ± 9.2 ng/mL (males) and 71.3 ± 3.7 ng/mL (females) in the SRBHigh group; 11.5 ± 3.2 ng/mL (males) and 6.9 ± 0.9 ng/mL (females) in the SRBMedium group; and 2.3 ± 0.8 ng/mL (males) and 2.0 ± 0.5 ng/mL (females) in the SRBLow group.",Pharmacokinetics and Adverse Effects of 3 Sustained-release Buprenorphine Dosages in Healthy Guinea Pigs (Cavia porcellus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29256372/),[ng] / [ml],2.3,100608,DB00921,Buprenorphine
,29256372,maximal plasma concentration (Cmax),"Within the first h after administration, the maximal plasma concentration (Cmax) of the drug was 64.3 ± 9.2 ng/mL (males) and 71.3 ± 3.7 ng/mL (females) in the SRBHigh group; 11.5 ± 3.2 ng/mL (males) and 6.9 ± 0.9 ng/mL (females) in the SRBMedium group; and 2.3 ± 0.8 ng/mL (males) and 2.0 ± 0.5 ng/mL (females) in the SRBLow group.",Pharmacokinetics and Adverse Effects of 3 Sustained-release Buprenorphine Dosages in Healthy Guinea Pigs (Cavia porcellus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29256372/),[ng] / [ml],2.0,100609,DB00921,Buprenorphine
,12803393,peak plasma concentration,Its median peak plasma concentration was 7.5 ng/ml and was reached after 15 minutes.,Systemic uptake of buprenorphine by cats after oral mucosal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12803393/),[ng] / [ml],7.5,101789,DB00921,Buprenorphine
,29309700,absolute bioavailability,The absolute bioavailability of SL buprenorphine was 45.4% (95% confidence interval = 37.8-54.3%).,The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29309700/),%,45.4,103472,DB00921,Buprenorphine
,29309700,times to peak plasma concentration,"The median times to peak plasma concentration were 10 minutes and 60 minutes after IV and SL administration, respectively.",The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29309700/),min,10,103473,DB00921,Buprenorphine
,29309700,times to peak plasma concentration,"The median times to peak plasma concentration were 10 minutes and 60 minutes after IV and SL administration, respectively.",The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29309700/),min,60,103474,DB00921,Buprenorphine
,29309700,peak plasma concentration,"The peak plasma concentration was 2.65 ng/mL and 0.74 ng/mL after IV and SL administration, respectively.",The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29309700/),[ng] / [ml],2.65,103475,DB00921,Buprenorphine
,29309700,peak plasma concentration,"The peak plasma concentration was 2.65 ng/mL and 0.74 ng/mL after IV and SL administration, respectively.",The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29309700/),[ng] / [ml],0.74,103476,DB00921,Buprenorphine
,29309700,half-lives,"The half-lives were 9.1 hours and 11.2 hours after IV and SL administration, respectively.",The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29309700/),h,9.1,103477,DB00921,Buprenorphine
,29309700,half-lives,"The half-lives were 9.1 hours and 11.2 hours after IV and SL administration, respectively.",The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29309700/),h,11.2,103478,DB00921,Buprenorphine
,9048270,bioavailability,The 3- and 5-minute sublingual exposures each allowed 29 +/- 10% bioavailability (area under the plasma concentration-time curve unextrapolated) and were bioequivalent.,Bioavailability of sublingual buprenorphine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9048270/),%,29,104069,DB00921,Buprenorphine
,9048270,bioavailability,Study results indicate that bioavailability of sublingual buprenorphine is approximately 30%.,Bioavailability of sublingual buprenorphine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9048270/),%,30,104070,DB00921,Buprenorphine
,29466036,peak plasma buprenorphine concentrations,"RESULTS Mean peak plasma buprenorphine concentrations were 46.7 and 2.4 ng/mL after IV and OTM administration, respectively.",Pharmacokinetics of buprenorphine after intravenous and oral transmucosal administration in guinea pigs (Cavia porcellus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29466036/),[ng] / [ml],46.7,108045,DB00921,Buprenorphine
,29466036,peak plasma buprenorphine concentrations,"RESULTS Mean peak plasma buprenorphine concentrations were 46.7 and 2.4 ng/mL after IV and OTM administration, respectively.",Pharmacokinetics of buprenorphine after intravenous and oral transmucosal administration in guinea pigs (Cavia porcellus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29466036/),[ng] / [ml],2.4,108046,DB00921,Buprenorphine
,29466036,time to maximum plasma buprenorphine concentration,"Mean time to maximum plasma buprenorphine concentration was 1.5 and 71.2 minutes, and mean terminal half-life was 184.9 and 173.0 minutes for IV and OTM administration, respectively.",Pharmacokinetics of buprenorphine after intravenous and oral transmucosal administration in guinea pigs (Cavia porcellus). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29466036/),min,1.5,108047,DB00921,Buprenorphine
,29466036,time to maximum plasma buprenorphine concentration,"Mean time to maximum plasma buprenorphine concentration was 1.5 and 71.2 minutes, and mean terminal half-life was 184.9 and 173.0 minutes for IV and OTM administration, respectively.",Pharmacokinetics of buprenorphine after intravenous and oral transmucosal administration in guinea pigs (Cavia porcellus). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29466036/),min,71.2,108048,DB00921,Buprenorphine
,29466036,terminal half-life,"Mean time to maximum plasma buprenorphine concentration was 1.5 and 71.2 minutes, and mean terminal half-life was 184.9 and 173.0 minutes for IV and OTM administration, respectively.",Pharmacokinetics of buprenorphine after intravenous and oral transmucosal administration in guinea pigs (Cavia porcellus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29466036/),min,184.9,108049,DB00921,Buprenorphine
,29466036,terminal half-life,"Mean time to maximum plasma buprenorphine concentration was 1.5 and 71.2 minutes, and mean terminal half-life was 184.9 and 173.0 minutes for IV and OTM administration, respectively.",Pharmacokinetics of buprenorphine after intravenous and oral transmucosal administration in guinea pigs (Cavia porcellus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29466036/),min,173.0,108050,DB00921,Buprenorphine
,29466036,target plasma concentration,"On the basis of pharmacokinetic parameters for this study, buprenorphine at 0.2 mg/kg may be administered IV every 7 hours or OTM every 4 hours to maintain a target plasma concentration of 1 ng/mL.",Pharmacokinetics of buprenorphine after intravenous and oral transmucosal administration in guinea pigs (Cavia porcellus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29466036/),[ng] / [ml],1,108051,DB00921,Buprenorphine
,14991469,time to extubation,"No difference was detected in time to extubation between the etodolac group (209 +/- 85 min, mean +/- SD) and the vehicle group (207 +/- 98 min).","Oral etodolac, a COX-2 inhibitor, reduces postoperative pain immediately after fast-track cardiac surgery. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14991469/),min,209,108164,DB00921,Buprenorphine
,14991469,time to extubation,"No difference was detected in time to extubation between the etodolac group (209 +/- 85 min, mean +/- SD) and the vehicle group (207 +/- 98 min).","Oral etodolac, a COX-2 inhibitor, reduces postoperative pain immediately after fast-track cardiac surgery. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14991469/),min,207,108165,DB00921,Buprenorphine
,14991469,VASs,"VASs were significantly lower in the etodolac (2.3 +/- 2.1) vs the vehicle group (5.8 +/- 2.0) immediately after extubation ( P = 0.009), but no difference was detected in pain scores at 24 h after surgery, or in the amount of buprenorphine administered in the intensive care unit (ICU), or in the incidence of side effects.","Oral etodolac, a COX-2 inhibitor, reduces postoperative pain immediately after fast-track cardiac surgery. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14991469/),,2.3,108166,DB00921,Buprenorphine
,21438849,C(max),The C(max) of BUP-3G was 8.78???5.23?ng/mL without TPV/r and increased to 12.7???11.7 after steady state of TPV/r was achieved.,Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21438849/),??,8.78,114146,DB00921,Buprenorphine
,21438849,C(max),The C(max) of BUP-3G was 8.78???5.23?ng/mL without TPV/r and increased to 12.7???11.7 after steady state of TPV/r was achieved.,Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21438849/),[?ng] / [ml],5.23,114147,DB00921,Buprenorphine
,21438849,C(max),The C(max) of BUP-3G was 8.78???5.23?ng/mL without TPV/r and increased to 12.7???11.7 after steady state of TPV/r was achieved.,Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21438849/),??,12.7,114148,DB00921,Buprenorphine
,21438849,C(max),The C(max) of BUP-3G was 8.78???5.23?ng/mL without TPV/r and increased to 12.7???11.7 after steady state of TPV/r was achieved.,Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21438849/),??,11.7,114149,DB00921,Buprenorphine
,21438849,AUC,The AUC of BUP-3G was 31.1???19.4?(ng/mL)?,Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21438849/),??,31.1,114150,DB00921,Buprenorphine
,21438849,AUC,The AUC of BUP-3G was 31.1???19.4?(ng/mL)?,Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21438849/),?(,19.4,114151,DB00921,Buprenorphine
,2328175,elimination half-lives,"There were no differences in buprenorphine kinetics between anaesthetized healthy patients and those with renal impairment: mean elimination half-lives 398 and 239 min; clearance 651 and 988 ml min-1; apparent volume of distribution at steady state 313 and 201 litre, respectively.","Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328175/),min,398,115065,DB00921,Buprenorphine
,2328175,elimination half-lives,"There were no differences in buprenorphine kinetics between anaesthetized healthy patients and those with renal impairment: mean elimination half-lives 398 and 239 min; clearance 651 and 988 ml min-1; apparent volume of distribution at steady state 313 and 201 litre, respectively.","Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328175/),min,239,115066,DB00921,Buprenorphine
,2328175,clearance,"There were no differences in buprenorphine kinetics between anaesthetized healthy patients and those with renal impairment: mean elimination half-lives 398 and 239 min; clearance 651 and 988 ml min-1; apparent volume of distribution at steady state 313 and 201 litre, respectively.","Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328175/),[ml] / [min],651,115067,DB00921,Buprenorphine
,2328175,clearance,"There were no differences in buprenorphine kinetics between anaesthetized healthy patients and those with renal impairment: mean elimination half-lives 398 and 239 min; clearance 651 and 988 ml min-1; apparent volume of distribution at steady state 313 and 201 litre, respectively.","Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328175/),[ml] / [min],988,115068,DB00921,Buprenorphine
,2328175,apparent volume of distribution at steady state,"There were no differences in buprenorphine kinetics between anaesthetized healthy patients and those with renal impairment: mean elimination half-lives 398 and 239 min; clearance 651 and 988 ml min-1; apparent volume of distribution at steady state 313 and 201 litre, respectively.","Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328175/),l,313,115069,DB00921,Buprenorphine
,2328175,apparent volume of distribution at steady state,"There were no differences in buprenorphine kinetics between anaesthetized healthy patients and those with renal impairment: mean elimination half-lives 398 and 239 min; clearance 651 and 988 ml min-1; apparent volume of distribution at steady state 313 and 201 litre, respectively.","Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328175/),l,201,115070,DB00921,Buprenorphine
,2328175,infusion rate,"In a second group of 20 patients (eight with renal impairment), buprenorphine was administered by continuous infusion for provision of analgesia and control of ventilation in the ITU (median infusion rate 161 micrograms h-1 (range 36-230 micrograms h-1) for a median duration of 30 h (2-565 h).","Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328175/),[μg] / [h],161,115071,DB00921,Buprenorphine
,2328175,clearance,"Buprenorphine clearance in patients with normal and impaired renal function was similar (934 and 1102 ml min-1, respectively), as were dose-corrected plasma concentrations of buprenorphine.","Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328175/),[ml] / [min],934,115072,DB00921,Buprenorphine
,2328175,clearance,"Buprenorphine clearance in patients with normal and impaired renal function was similar (934 and 1102 ml min-1, respectively), as were dose-corrected plasma concentrations of buprenorphine.","Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328175/),[ml] / [min],1102,115073,DB00921,Buprenorphine
,25061701,bioavailability,"For IM administration, bioavailability was 94.8% and elimination half-life was 92.1 minutes.",Pharmacokinetics of buprenorphine hydrochloride following intramuscular and intravenous administration to American kestrels (Falco sparverius). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25061701/),%,94.8,116790,DB00921,Buprenorphine
,25061701,elimination half-life,"For IM administration, bioavailability was 94.8% and elimination half-life was 92.1 minutes.",Pharmacokinetics of buprenorphine hydrochloride following intramuscular and intravenous administration to American kestrels (Falco sparverius). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25061701/),min,92.1,116791,DB00921,Buprenorphine
,25061701,steady-state volume of distribution,"For IV administration, steady-state volume of distribution was 4,023.8 mL/kg, plasma clearance was 49.2 mL/min/kg, and elimination half-life was 105.5 minutes.",Pharmacokinetics of buprenorphine hydrochloride following intramuscular and intravenous administration to American kestrels (Falco sparverius). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25061701/),[ml] / [kg],"4,023.8",116792,DB00921,Buprenorphine
,25061701,plasma clearance,"For IV administration, steady-state volume of distribution was 4,023.8 mL/kg, plasma clearance was 49.2 mL/min/kg, and elimination half-life was 105.5 minutes.",Pharmacokinetics of buprenorphine hydrochloride following intramuscular and intravenous administration to American kestrels (Falco sparverius). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25061701/),[ml] / [kg·min],49.2,116793,DB00921,Buprenorphine
,25061701,elimination half-life,"For IV administration, steady-state volume of distribution was 4,023.8 mL/kg, plasma clearance was 49.2 mL/min/kg, and elimination half-life was 105.5 minutes.",Pharmacokinetics of buprenorphine hydrochloride following intramuscular and intravenous administration to American kestrels (Falco sparverius). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25061701/),min,105.5,116794,DB00921,Buprenorphine
,18518651,T(max),"Median (range) values for T(max) and MRT were 2 minutes (2 to 5 minutes) and 264 minutes (199 to 600 minutes), respectively.",Pharmacokinetics of buprenorphine following intravenous administration in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18518651/),min,2,117468,DB00921,Buprenorphine
,18518651,MRT,"Median (range) values for T(max) and MRT were 2 minutes (2 to 5 minutes) and 264 minutes (199 to 600 minutes), respectively.",Pharmacokinetics of buprenorphine following intravenous administration in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18518651/),min,264,117469,DB00921,Buprenorphine
,18518651,t(1/2),"Harmonic mean and pseudo SD for t(1/2) were 270+/-130 minutes; mean +/- SD values for remaining pharmacokinetic variables were as follows: C(max), 14+/-2.6 ng/mL; AUC, 3,082+/-1,047 ng x min/mL; Vd(ss), 1.59+/-0.285 L/kg; Cl, 5.4+/-1.9 mL/min/kg; and, k(el), 0.0026+/-0.0,012.",Pharmacokinetics of buprenorphine following intravenous administration in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18518651/),min,270,117470,DB00921,Buprenorphine
,18518651,C(max),"Harmonic mean and pseudo SD for t(1/2) were 270+/-130 minutes; mean +/- SD values for remaining pharmacokinetic variables were as follows: C(max), 14+/-2.6 ng/mL; AUC, 3,082+/-1,047 ng x min/mL; Vd(ss), 1.59+/-0.285 L/kg; Cl, 5.4+/-1.9 mL/min/kg; and, k(el), 0.0026+/-0.0,012.",Pharmacokinetics of buprenorphine following intravenous administration in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18518651/),[ng] / [ml],14,117471,DB00921,Buprenorphine
,18518651,AUC,"Harmonic mean and pseudo SD for t(1/2) were 270+/-130 minutes; mean +/- SD values for remaining pharmacokinetic variables were as follows: C(max), 14+/-2.6 ng/mL; AUC, 3,082+/-1,047 ng x min/mL; Vd(ss), 1.59+/-0.285 L/kg; Cl, 5.4+/-1.9 mL/min/kg; and, k(el), 0.0026+/-0.0,012.",Pharmacokinetics of buprenorphine following intravenous administration in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18518651/),[min·ng] / [ml],"3,082",117472,DB00921,Buprenorphine
,18518651,Vd(ss),"Harmonic mean and pseudo SD for t(1/2) were 270+/-130 minutes; mean +/- SD values for remaining pharmacokinetic variables were as follows: C(max), 14+/-2.6 ng/mL; AUC, 3,082+/-1,047 ng x min/mL; Vd(ss), 1.59+/-0.285 L/kg; Cl, 5.4+/-1.9 mL/min/kg; and, k(el), 0.0026+/-0.0,012.",Pharmacokinetics of buprenorphine following intravenous administration in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18518651/),[l] / [kg],1.59,117473,DB00921,Buprenorphine
,18518651,Cl,"Harmonic mean and pseudo SD for t(1/2) were 270+/-130 minutes; mean +/- SD values for remaining pharmacokinetic variables were as follows: C(max), 14+/-2.6 ng/mL; AUC, 3,082+/-1,047 ng x min/mL; Vd(ss), 1.59+/-0.285 L/kg; Cl, 5.4+/-1.9 mL/min/kg; and, k(el), 0.0026+/-0.0,012.",Pharmacokinetics of buprenorphine following intravenous administration in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18518651/),[ml] / [kg·min],5.4,117474,DB00921,Buprenorphine
,18518651,k(el),"Harmonic mean and pseudo SD for t(1/2) were 270+/-130 minutes; mean +/- SD values for remaining pharmacokinetic variables were as follows: C(max), 14+/-2.6 ng/mL; AUC, 3,082+/-1,047 ng x min/mL; Vd(ss), 1.59+/-0.285 L/kg; Cl, 5.4+/-1.9 mL/min/kg; and, k(el), 0.0026+/-0.0,012.",Pharmacokinetics of buprenorphine following intravenous administration in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18518651/),,0.0026,117475,DB00921,Buprenorphine
,21392040,clearance,"Following i.v. administration, clearance was 7.97±5.16 mL/kg/min, and half-life (T(1/2)) was 3.58 h (harmonic mean).",Pharmacokinetics of intravenous and intramuscular buprenorphine in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21392040/),[ml] / [kg·min],7.97,120019,DB00921,Buprenorphine
,21392040,half-life (T(1/2)),"Following i.v. administration, clearance was 7.97±5.16 mL/kg/min, and half-life (T(1/2)) was 3.58 h (harmonic mean).",Pharmacokinetics of intravenous and intramuscular buprenorphine in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21392040/),h,3.58,120020,DB00921,Buprenorphine
,21392040,Volume of distribution,Volume of distribution was 3.01±1.69 L/kg.,Pharmacokinetics of intravenous and intramuscular buprenorphine in the horse. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21392040/),[l] / [kg],3.01,120021,DB00921,Buprenorphine
,21392040,maximum concentration (C(max)),"Following i.m. administration, maximum concentration (C(max)) was 1.74±0.09 ng/mL, which was significantly lower than the highest measured concentration (4.34±1.22 ng/mL) after i.v. administration (P<0.001).",Pharmacokinetics of intravenous and intramuscular buprenorphine in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21392040/),[ng] / [ml],1.74,120022,DB00921,Buprenorphine
,21392040,maximum concentration (C(max)),"Following i.m. administration, maximum concentration (C(max)) was 1.74±0.09 ng/mL, which was significantly lower than the highest measured concentration (4.34±1.22 ng/mL) after i.v. administration (P<0.001).",Pharmacokinetics of intravenous and intramuscular buprenorphine in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21392040/),[ng] / [ml],4.34,120023,DB00921,Buprenorphine
,21392040,Time to C(max),Time to C(max) was 0.9±0.69 h and T(1/2) was 4.24 h.,Pharmacokinetics of intravenous and intramuscular buprenorphine in the horse. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21392040/),h,0.9,120024,DB00921,Buprenorphine
,21392040,T(1/2),Time to C(max) was 0.9±0.69 h and T(1/2) was 4.24 h.,Pharmacokinetics of intravenous and intramuscular buprenorphine in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21392040/),h,4.24,120025,DB00921,Buprenorphine
,21392040,Bioavailability,Bioavailability was variable (51-88%).,Pharmacokinetics of intravenous and intramuscular buprenorphine in the horse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21392040/),%,51-88,120026,DB00921,Buprenorphine
,24745064,maximum concentration,"Following buccal administration, maximum concentration [jugular: 6.3 (2.9-9.8), carotid: 3.4 (1.9-4.9), medial saphenous: 2.5 (1.7-4.1) ng/mL], area under the curve [jugular: 395 (335-747), carotid: 278 (214-693), medial saphenous: 255 (188-608) ng·min/mL], and bioavailability [jugular: 47 (34-67), carotid: 32 (20-52), medial saphenous: 23 (16-55)%] were higher in the jugular vein than in the carotid artery and medial saphenous vein.",Impact of the blood sampling site on time-concentration drug profiles following intravenous or buccal drug administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24745064/),[ng] / [ml],6.3,121907,DB00921,Buprenorphine
,24745064,maximum concentration,"Following buccal administration, maximum concentration [jugular: 6.3 (2.9-9.8), carotid: 3.4 (1.9-4.9), medial saphenous: 2.5 (1.7-4.1) ng/mL], area under the curve [jugular: 395 (335-747), carotid: 278 (214-693), medial saphenous: 255 (188-608) ng·min/mL], and bioavailability [jugular: 47 (34-67), carotid: 32 (20-52), medial saphenous: 23 (16-55)%] were higher in the jugular vein than in the carotid artery and medial saphenous vein.",Impact of the blood sampling site on time-concentration drug profiles following intravenous or buccal drug administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24745064/),[ng] / [ml],3.4,121908,DB00921,Buprenorphine
,24745064,maximum concentration,"Following buccal administration, maximum concentration [jugular: 6.3 (2.9-9.8), carotid: 3.4 (1.9-4.9), medial saphenous: 2.5 (1.7-4.1) ng/mL], area under the curve [jugular: 395 (335-747), carotid: 278 (214-693), medial saphenous: 255 (188-608) ng·min/mL], and bioavailability [jugular: 47 (34-67), carotid: 32 (20-52), medial saphenous: 23 (16-55)%] were higher in the jugular vein than in the carotid artery and medial saphenous vein.",Impact of the blood sampling site on time-concentration drug profiles following intravenous or buccal drug administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24745064/),[ng] / [ml],2.5,121909,DB00921,Buprenorphine
,24745064,area under the curve,"Following buccal administration, maximum concentration [jugular: 6.3 (2.9-9.8), carotid: 3.4 (1.9-4.9), medial saphenous: 2.5 (1.7-4.1) ng/mL], area under the curve [jugular: 395 (335-747), carotid: 278 (214-693), medial saphenous: 255 (188-608) ng·min/mL], and bioavailability [jugular: 47 (34-67), carotid: 32 (20-52), medial saphenous: 23 (16-55)%] were higher in the jugular vein than in the carotid artery and medial saphenous vein.",Impact of the blood sampling site on time-concentration drug profiles following intravenous or buccal drug administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24745064/),[min·ng] / [ml],395,121910,DB00921,Buprenorphine
,24745064,area under the curve,"Following buccal administration, maximum concentration [jugular: 6.3 (2.9-9.8), carotid: 3.4 (1.9-4.9), medial saphenous: 2.5 (1.7-4.1) ng/mL], area under the curve [jugular: 395 (335-747), carotid: 278 (214-693), medial saphenous: 255 (188-608) ng·min/mL], and bioavailability [jugular: 47 (34-67), carotid: 32 (20-52), medial saphenous: 23 (16-55)%] were higher in the jugular vein than in the carotid artery and medial saphenous vein.",Impact of the blood sampling site on time-concentration drug profiles following intravenous or buccal drug administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24745064/),[min·ng] / [ml],278,121911,DB00921,Buprenorphine
,24745064,area under the curve,"Following buccal administration, maximum concentration [jugular: 6.3 (2.9-9.8), carotid: 3.4 (1.9-4.9), medial saphenous: 2.5 (1.7-4.1) ng/mL], area under the curve [jugular: 395 (335-747), carotid: 278 (214-693), medial saphenous: 255 (188-608) ng·min/mL], and bioavailability [jugular: 47 (34-67), carotid: 32 (20-52), medial saphenous: 23 (16-55)%] were higher in the jugular vein than in the carotid artery and medial saphenous vein.",Impact of the blood sampling site on time-concentration drug profiles following intravenous or buccal drug administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24745064/),[min·ng] / [ml],255,121912,DB00921,Buprenorphine
,24745064,bioavailability,"Following buccal administration, maximum concentration [jugular: 6.3 (2.9-9.8), carotid: 3.4 (1.9-4.9), medial saphenous: 2.5 (1.7-4.1) ng/mL], area under the curve [jugular: 395 (335-747), carotid: 278 (214-693), medial saphenous: 255 (188-608) ng·min/mL], and bioavailability [jugular: 47 (34-67), carotid: 32 (20-52), medial saphenous: 23 (16-55)%] were higher in the jugular vein than in the carotid artery and medial saphenous vein.",Impact of the blood sampling site on time-concentration drug profiles following intravenous or buccal drug administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24745064/),%,47,121913,DB00921,Buprenorphine
,24745064,bioavailability,"Following buccal administration, maximum concentration [jugular: 6.3 (2.9-9.8), carotid: 3.4 (1.9-4.9), medial saphenous: 2.5 (1.7-4.1) ng/mL], area under the curve [jugular: 395 (335-747), carotid: 278 (214-693), medial saphenous: 255 (188-608) ng·min/mL], and bioavailability [jugular: 47 (34-67), carotid: 32 (20-52), medial saphenous: 23 (16-55)%] were higher in the jugular vein than in the carotid artery and medial saphenous vein.",Impact of the blood sampling site on time-concentration drug profiles following intravenous or buccal drug administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24745064/),%,32,121914,DB00921,Buprenorphine
,24745064,bioavailability,"Following buccal administration, maximum concentration [jugular: 6.3 (2.9-9.8), carotid: 3.4 (1.9-4.9), medial saphenous: 2.5 (1.7-4.1) ng/mL], area under the curve [jugular: 395 (335-747), carotid: 278 (214-693), medial saphenous: 255 (188-608) ng·min/mL], and bioavailability [jugular: 47 (34-67), carotid: 32 (20-52), medial saphenous: 23 (16-55)%] were higher in the jugular vein than in the carotid artery and medial saphenous vein.",Impact of the blood sampling site on time-concentration drug profiles following intravenous or buccal drug administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24745064/),%,23,121915,DB00921,Buprenorphine
,22706617,area under the plasma concentration-time curve at steady state (AUC(tau)),"The area under the plasma concentration-time curve at steady state (AUC(tau)), measured over one dosing interval, was similar for elderly [mean ± standard deviation (SD) 9,940 pg/h/ml (4,827 pg/h/ml] and younger [mean ± SD 11,309 (3,670 pg/h/ml] individuals.",Pharmacokinetics of transdermal buprenorphine patch in the elderly. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22706617/),[pg] / [h·ml],"9,940",123589,DB00921,Buprenorphine
,22706617,area under the plasma concentration-time curve at steady state (AUC(tau)),"The area under the plasma concentration-time curve at steady state (AUC(tau)), measured over one dosing interval, was similar for elderly [mean ± standard deviation (SD) 9,940 pg/h/ml (4,827 pg/h/ml] and younger [mean ± SD 11,309 (3,670 pg/h/ml] individuals.",Pharmacokinetics of transdermal buprenorphine patch in the elderly. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22706617/),[pg] / [h·ml],"4,827",123590,DB00921,Buprenorphine
,22706617,area under the plasma concentration-time curve at steady state (AUC(tau)),"The area under the plasma concentration-time curve at steady state (AUC(tau)), measured over one dosing interval, was similar for elderly [mean ± standard deviation (SD) 9,940 pg/h/ml (4,827 pg/h/ml] and younger [mean ± SD 11,309 (3,670 pg/h/ml] individuals.",Pharmacokinetics of transdermal buprenorphine patch in the elderly. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22706617/),[pg] / [h·ml],"11,309",123591,DB00921,Buprenorphine
,16144748,bioavailability,"To assist the clinician in interpreting the relevant literature in establishing dosing parameters for prescription of tablet buprenorphine, this study was designed to compare the steady state: (1) pharmacokinetics and bioavailability, and (2) physiological, subjective and objective opiate effects of two 8 mg buprenorphine tablets (16 mg) to those of 1 ml (8 mg/ml) buprenorphine solution based upon early reports suggesting that the bioavailability of the tablet was approximately 50% of that of the liquid.","Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144748/),%,50,129202,DB00921,Buprenorphine
,16144748,relative bioavailability,"The relative bioavailability of tablet versus solution is estimated to be 0.71; thus, with respect to dosing parameters for the tablet, clinicians should consider using less than 16 mg to achieve bioequivalence to the 8 mg solution.","Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144748/),,0.71,129203,DB00921,Buprenorphine
,25015174,effective concentration at 50 % of maximum (EC50),A saturable maximum effect (E max) model with 0.67 ng/mL effective concentration at 50 % of maximum (EC50) and 91 % E max best described µORO versus buprenorphine plasma concentrations.,"A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25015174/),[ng] / [ml],0.67,129419,DB00921,Buprenorphine
,25015174,E max,A saturable maximum effect (E max) model with 0.67 ng/mL effective concentration at 50 % of maximum (EC50) and 91 % E max best described µORO versus buprenorphine plasma concentrations.,"A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25015174/),%,91,129420,DB00921,Buprenorphine
,30427272,maximal plasma concentration,"Upon pharmacokinetic non-compartment analysis of high-dose buprenorphine (0.1 mg/kg), average maximal plasma concentration was found to be 1.13 ng/ml, time to maximal plasma concentration was 45 mins and area under the plasma concentration-time curve was 94.19 ng*min/ml, representing low but potential bioavailability.",Pharmacokinetics of low-dose and high-dose buprenorphine in cats after rectal administration of different formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30427272/),[ng] / [ml],1.13,130424,DB00921,Buprenorphine
,30427272,time to maximal plasma concentration,"Upon pharmacokinetic non-compartment analysis of high-dose buprenorphine (0.1 mg/kg), average maximal plasma concentration was found to be 1.13 ng/ml, time to maximal plasma concentration was 45 mins and area under the plasma concentration-time curve was 94.19 ng*min/ml, representing low but potential bioavailability.",Pharmacokinetics of low-dose and high-dose buprenorphine in cats after rectal administration of different formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30427272/),min,45,130425,DB00921,Buprenorphine
,30427272,area under the plasma concentration-time curve,"Upon pharmacokinetic non-compartment analysis of high-dose buprenorphine (0.1 mg/kg), average maximal plasma concentration was found to be 1.13 ng/ml, time to maximal plasma concentration was 45 mins and area under the plasma concentration-time curve was 94.19 ng*min/ml, representing low but potential bioavailability.",Pharmacokinetics of low-dose and high-dose buprenorphine in cats after rectal administration of different formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30427272/),[min·ng] / [ml],94.19,130426,DB00921,Buprenorphine
,30427272,residual time,Mean residual time was 152.2 mins and the half-life was 92.6 mins.,Pharmacokinetics of low-dose and high-dose buprenorphine in cats after rectal administration of different formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30427272/),min,152.2,130427,DB00921,Buprenorphine
,30427272,half-life,Mean residual time was 152.2 mins and the half-life was 92.6 mins.,Pharmacokinetics of low-dose and high-dose buprenorphine in cats after rectal administration of different formulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30427272/),min,92.6,130428,DB00921,Buprenorphine
,30427272,Rectal pH,Rectal pH in all cats was between 7.7 and 8.,Pharmacokinetics of low-dose and high-dose buprenorphine in cats after rectal administration of different formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30427272/),,7.7 and 8,130429,DB00921,Buprenorphine
,11923061,"volume of distribution, V(ss)","BN declined triexponentially with a dose-dependent increase in its volume of distribution, V(ss) (8.37-18.2 l/kg) and clearance CL (2.70-6.10 l/h per kg).",Characterization of the pharmacokinetics of buprenorphine and norbuprenorphine in rats after intravenous bolus administration of buprenorphine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11923061/),[l] / [kg],8.37-18.2,132630,DB00921,Buprenorphine
,11923061,clearance CL,"BN declined triexponentially with a dose-dependent increase in its volume of distribution, V(ss) (8.37-18.2 l/kg) and clearance CL (2.70-6.10 l/h per kg).",Characterization of the pharmacokinetics of buprenorphine and norbuprenorphine in rats after intravenous bolus administration of buprenorphine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11923061/),[l] / [h·kg],2.70-6.10,132631,DB00921,Buprenorphine
,27931318,Plasma concentrations,Plasma concentrations of Bup-SR peaked at 1344 pg/mL at 26 h after administration and declined to 429 pg/mL by 48 h.,Pharmacokinetics and Paw Withdrawal Pressure in Female Guinea Pigs (Cavia porcellus) Treated with Sustained-Release Buprenorphine and Buprenorphine Hydrochloride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27931318/),[pg] / [ml],1344,134003,DB00921,Buprenorphine
,27931318,Plasma concentrations,Plasma concentrations of Bup-SR peaked at 1344 pg/mL at 26 h after administration and declined to 429 pg/mL by 48 h.,Pharmacokinetics and Paw Withdrawal Pressure in Female Guinea Pigs (Cavia porcellus) Treated with Sustained-Release Buprenorphine and Buprenorphine Hydrochloride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27931318/),,42,134004,DB00921,Buprenorphine
,27931318,PWP,The PWP of both treatments was similar from 24 to 72 h and ranged from 348 to 450 g.,Pharmacokinetics and Paw Withdrawal Pressure in Female Guinea Pigs (Cavia porcellus) Treated with Sustained-Release Buprenorphine and Buprenorphine Hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27931318/),h,24 to 72,134005,DB00921,Buprenorphine
,27931318,PWP,The PWP of both treatments was similar from 24 to 72 h and ranged from 348 to 450 g.,Pharmacokinetics and Paw Withdrawal Pressure in Female Guinea Pigs (Cavia porcellus) Treated with Sustained-Release Buprenorphine and Buprenorphine Hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27931318/),g,348 to 450,134006,DB00921,Buprenorphine
,28554599,time to Cmax,"Single doses of CAM2038 q1w indicated dose-proportional buprenorphine pharmacokinetics (Cmax and AUC0-7d), with time to Cmax ~20h and an apparent terminal half-life of 3-5days, supporting once-weekly dosing.",Pharmacokinetics and pharmacodynamics of a buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid use disorder. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28554599/),h,20,134270,DB00921,Buprenorphine
,28554599,apparent terminal half-life,"Single doses of CAM2038 q1w indicated dose-proportional buprenorphine pharmacokinetics (Cmax and AUC0-7d), with time to Cmax ~20h and an apparent terminal half-life of 3-5days, supporting once-weekly dosing.",Pharmacokinetics and pharmacodynamics of a buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid use disorder. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28554599/),d,3-5,134271,DB00921,Buprenorphine
,28554599,time to first use,The median time to first use of rescue buprenorphine was 10days.,Pharmacokinetics and pharmacodynamics of a buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid use disorder. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28554599/),d,10,134272,DB00921,Buprenorphine
,32939690,blood concentration at 50% of maximum effect,The buprenorphine blood concentration at 50% of maximum effect for the inhibition of disease progression was 0.77 ng/mL (95% confidence interval 0.32-1.2).,Physiologic Indirect Response Modeling to Describe Buprenorphine Pharmacodynamics in Newborns Treated for Neonatal Opioid Withdrawal Syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32939690/),[ng] / [ml],0.77,137790,DB00921,Buprenorphine
,28070862,t max,Median buprenorphine t max after CAM2038 q4w was 4-10 h (24 h for CAM2038 q1w); mean terminal half-life was 19-25 days (5 days for CAM2038 q1w).,Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28070862/),h,4-10,138015,DB00921,Buprenorphine
,28070862,t max,Median buprenorphine t max after CAM2038 q4w was 4-10 h (24 h for CAM2038 q1w); mean terminal half-life was 19-25 days (5 days for CAM2038 q1w).,Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28070862/),h,24,138016,DB00921,Buprenorphine
,28070862,terminal half-life,Median buprenorphine t max after CAM2038 q4w was 4-10 h (24 h for CAM2038 q1w); mean terminal half-life was 19-25 days (5 days for CAM2038 q1w).,Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28070862/),d,19-25,138017,DB00921,Buprenorphine
,28070862,terminal half-life,Median buprenorphine t max after CAM2038 q4w was 4-10 h (24 h for CAM2038 q1w); mean terminal half-life was 19-25 days (5 days for CAM2038 q1w).,Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28070862/),d,5,138018,DB00921,Buprenorphine
,19726139,AUC(0-24h),"Prior to starting TPV/r, the geometric mean BUP AUC(0-24h) and C(max) were 43.9 ng h/mL and 5.61 ng/mL, respectively.",Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726139/),[h·ng] / [ml],43.9,139075,DB00921,Buprenorphine
,19726139,C(max),"Prior to starting TPV/r, the geometric mean BUP AUC(0-24h) and C(max) were 43.9 ng h/mL and 5.61 ng/mL, respectively.",Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726139/),[ng] / [ml],5.61,139076,DB00921,Buprenorphine
,19726139,steady-state,"After achieving steady-state with TPV/r (> or = 7 days), these values were similar at 43.7 ng h/mL and 4.84 ng/mL, respectively.",Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726139/),[h·ng] / [ml],43.7,139077,DB00921,Buprenorphine
,19726139,steady-state,"After achieving steady-state with TPV/r (> or = 7 days), these values were similar at 43.7 ng h/mL and 4.84 ng/mL, respectively.",Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726139/),[ng] / [ml],4.84,139078,DB00921,Buprenorphine
,19726139,AUC(0-24h),"Similar analyses for norBUP, the primary metabolite of BUP, demonstrated a reduction in geometric mean for AUC(0-24h) [68.7-14.7 ng h/mL; ratio=0.21 (90% CI 0.19-0.25)] and C(max) [4.75-0.94 ng/mL; ratio=0.20 (90% CI 0.17-0.23)].",Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726139/),[h·ng] / [ml],68.7-14.7,139079,DB00921,Buprenorphine
,29287158,time to maximum plasma buprenorphine concentration,"RESULTS Mean time to maximum plasma buprenorphine concentration was 7.2 minutes and 26.1 minutes after administration of the 0.3-mg/kg and 1.8-mg/kg doses, respectively.",Pharmacokinetics of a concentrated buprenorphine formulation in red-tailed hawks (Buteo jamaicensis). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29287158/),min,7.2,139339,DB00921,Buprenorphine
,29287158,time to maximum plasma buprenorphine concentration,"RESULTS Mean time to maximum plasma buprenorphine concentration was 7.2 minutes and 26.1 minutes after administration of the 0.3-mg/kg and 1.8-mg/kg doses, respectively.",Pharmacokinetics of a concentrated buprenorphine formulation in red-tailed hawks (Buteo jamaicensis). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29287158/),min,26.1,139340,DB00921,Buprenorphine
,29287158,elimination half-life,Mean elimination half-life was 6.23 hours for the low dose and 7.84 hours for the high dose.,Pharmacokinetics of a concentrated buprenorphine formulation in red-tailed hawks (Buteo jamaicensis). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29287158/),h,6.23,139341,DB00921,Buprenorphine
,29287158,elimination half-life,Mean elimination half-life was 6.23 hours for the low dose and 7.84 hours for the high dose.,Pharmacokinetics of a concentrated buprenorphine formulation in red-tailed hawks (Buteo jamaicensis). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29287158/),h,7.84,139342,DB00921,Buprenorphine
,33176781,area under the time concentration curve (AUC0-t),"The area under the time concentration curve (AUC0-t) was lower after SC (398 ± 155 ng/mL/min) than IM (696 ± 168 ng/mL/min, p < 0.001) and IV (789 ± 189 ng/mL/min, p < 0.001) administration.",Bioavailability of subcutaneous and intramuscular administrated buprenorphine in New Zealand White rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176781/),[ng] / [min·ml],398,139343,DB00921,Buprenorphine
,33176781,area under the time concentration curve (AUC0-t),"The area under the time concentration curve (AUC0-t) was lower after SC (398 ± 155 ng/mL/min) than IM (696 ± 168 ng/mL/min, p < 0.001) and IV (789 ± 189 ng/mL/min, p < 0.001) administration.",Bioavailability of subcutaneous and intramuscular administrated buprenorphine in New Zealand White rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176781/),[ng] / [min·ml],696,139344,DB00921,Buprenorphine
,33176781,area under the time concentration curve (AUC0-t),"The area under the time concentration curve (AUC0-t) was lower after SC (398 ± 155 ng/mL/min) than IM (696 ± 168 ng/mL/min, p < 0.001) and IV (789 ± 189 ng/mL/min, p < 0.001) administration.",Bioavailability of subcutaneous and intramuscular administrated buprenorphine in New Zealand White rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176781/),[ng] / [min·ml],789,139345,DB00921,Buprenorphine
,33176781,maximum serum concentration,The maximum serum concentration was lower after SC (2.2 ± 1.4 ng/mL) than after IM (11 ± 3.2 ng/mL) administration (p < 0.001).,Bioavailability of subcutaneous and intramuscular administrated buprenorphine in New Zealand White rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176781/),[ng] / [ml],2.2,139346,DB00921,Buprenorphine
,33176781,maximum serum concentration,The maximum serum concentration was lower after SC (2.2 ± 1.4 ng/mL) than after IM (11 ± 3.2 ng/mL) administration (p < 0.001).,Bioavailability of subcutaneous and intramuscular administrated buprenorphine in New Zealand White rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176781/),[ng] / [ml],11,139347,DB00921,Buprenorphine
,33176781,bioavailability,The bioavailability was lower after SC (50 ± 19%) than after IM (95 ± 21%) administration (p = 0.006).,Bioavailability of subcutaneous and intramuscular administrated buprenorphine in New Zealand White rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176781/),%,50,139348,DB00921,Buprenorphine
,33176781,bioavailability,The bioavailability was lower after SC (50 ± 19%) than after IM (95 ± 21%) administration (p = 0.006).,Bioavailability of subcutaneous and intramuscular administrated buprenorphine in New Zealand White rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176781/),%,95,139349,DB00921,Buprenorphine
,33176781,elimination half-life,"The elimination half-life was longer after SC (260 ± 120 min) than after IM (148 ± 26 min, p = 0.002) as well as IV (139 ± 33 min) injection (p < 0.001).",Bioavailability of subcutaneous and intramuscular administrated buprenorphine in New Zealand White rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176781/),min,260,139350,DB00921,Buprenorphine
,33176781,elimination half-life,"The elimination half-life was longer after SC (260 ± 120 min) than after IM (148 ± 26 min, p = 0.002) as well as IV (139 ± 33 min) injection (p < 0.001).",Bioavailability of subcutaneous and intramuscular administrated buprenorphine in New Zealand White rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176781/),min,148,139351,DB00921,Buprenorphine
,33176781,elimination half-life,"The elimination half-life was longer after SC (260 ± 120 min) than after IM (148 ± 26 min, p = 0.002) as well as IV (139 ± 33 min) injection (p < 0.001).",Bioavailability of subcutaneous and intramuscular administrated buprenorphine in New Zealand White rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176781/),min,139,139352,DB00921,Buprenorphine
,33176781,bioavailability,"The bioavailability did not change in the females (36 ± 14%, p = 0.6), whereas it increased in the males (71 ± 23%, p = 0.008).",Bioavailability of subcutaneous and intramuscular administrated buprenorphine in New Zealand White rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176781/),%,36,139353,DB00921,Buprenorphine
,33176781,bioavailability,"The bioavailability did not change in the females (36 ± 14%, p = 0.6), whereas it increased in the males (71 ± 23%, p = 0.008).",Bioavailability of subcutaneous and intramuscular administrated buprenorphine in New Zealand White rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176781/),%,71,139354,DB00921,Buprenorphine
,18694901,length of treatment,The mean length of treatment for those in the neonatal-opium-solution group was 32 compared with 22 days for the buprenorphine group.,Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18694901/),,32,139468,DB00921,Buprenorphine
,18694901,length of treatment,The mean length of treatment for those in the neonatal-opium-solution group was 32 compared with 22 days for the buprenorphine group.,Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18694901/),,22,139469,DB00921,Buprenorphine
,18694901,length of stay,The mean length of stay for the neonatal-opium-solution group was 38 days compared with 27 days for those in the buprenorphine group.,Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18694901/),d,38,139470,DB00921,Buprenorphine
,18694901,length of stay,The mean length of stay for the neonatal-opium-solution group was 38 days compared with 27 days for those in the buprenorphine group.,Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18694901/),d,27,139471,DB00921,Buprenorphine
,20301952,concentration,The mean concentration of methadone in plasma of patients receiving 40 mg of drug per day was 194 ng/ml but in second group (receiving 90 mg of methadone/day) 263 ng/ml.,Developing of LC/MS method with microwave assisted extraction for determination of methadone and it major metabolite (EDDP) in the blood of patients of methadone maintenance treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20301952/),[ng] / [ml],194,142554,DB00921,Buprenorphine
above,25199095,maximal blood concentrations (Cmax),Bup IR at 0.03 and 0.05 mg/kg and Bup SR Lab at 0.3 mg/kg failed to obtain maximal blood concentrations (Cmax) above 1 ng/mL.,Pharmacokinetic comparison of sustained-release and standard buprenorphine in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25199095/),[ng] / [ml],1,146205,DB00921,Buprenorphine
above,25199095,Cmax,All other doses (0.1 and 2 mg/kg Bup IR and 1.2 mg/kg Bup SR Lab) reached a Cmax above 1 ng/mL within 3 h after injection.,Pharmacokinetic comparison of sustained-release and standard buprenorphine in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25199095/),[ng] / [ml],1,146206,DB00921,Buprenorphine
,4020627,pK'a,"Estimated buprenorphine pK'a values are 8.24 and 10 for the ammonium and phenol groups, respectively.","Pharmacokinetics of morphine and its surrogates VI: Bioanalysis, solvolysis kinetics, solubility, pK'a values, and protein binding of buprenorphine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020627/),,8.24,146721,DB00921,Buprenorphine
,4020627,pK'a,"Estimated buprenorphine pK'a values are 8.24 and 10 for the ammonium and phenol groups, respectively.","Pharmacokinetics of morphine and its surrogates VI: Bioanalysis, solvolysis kinetics, solubility, pK'a values, and protein binding of buprenorphine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020627/),,10,146722,DB00921,Buprenorphine
,4020627,intrinsic aqueous solubility,The intrinsic aqueous solubility of neutral buprenorphine is 12.7 +/- 1.2 micrograms/mL at 23 degrees C.,"Pharmacokinetics of morphine and its surrogates VI: Bioanalysis, solvolysis kinetics, solubility, pK'a values, and protein binding of buprenorphine. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020627/),[μg] / [ml],12.7,146723,DB00921,Buprenorphine
,4020627,red blood cell-plasma water partition coefficients,The red blood cell-plasma water partition coefficients of buprenorphine ranged between 6 and 15.,"Pharmacokinetics of morphine and its surrogates VI: Bioanalysis, solvolysis kinetics, solubility, pK'a values, and protein binding of buprenorphine. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020627/),,6 and 15,146724,DB00921,Buprenorphine
,4020627,plasma protein binding,Ultracentrifugation and the red blood cell partition methods led to an estimated 95-98% plasma protein binding.,"Pharmacokinetics of morphine and its surrogates VI: Bioanalysis, solvolysis kinetics, solubility, pK'a values, and protein binding of buprenorphine. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020627/),%,95-98,146725,DB00921,Buprenorphine
,17468320,peak plasma buprenorphine concentration,The mean (sd) peak plasma buprenorphine concentration was 10 (0.81) ng/ml.,Use of a transdermal matrix patch of buprenorphine in cats: preliminary pharmacokinetic and pharmacodynamic data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17468320/),[ng] / [ml],10,148150,DB00921,Buprenorphine
,24684621,volume of distribution (area),The volume of distribution (area) was larger for fentanyl (7.42 L/kg) compared to buprenorphine (3.54 L/kg).,Comparative pharmacokinetics of intravenous fentanyl and buprenorphine in healthy greyhound dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24684621/),[l] / [kg],7.42,150329,DB00921,Buprenorphine
,24684621,volume of distribution (area),The volume of distribution (area) was larger for fentanyl (7.42 L/kg) compared to buprenorphine (3.54 L/kg).,Comparative pharmacokinetics of intravenous fentanyl and buprenorphine in healthy greyhound dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24684621/),[l] / [kg],3.54,150330,DB00921,Buprenorphine
,24684621,plasma clearance,The plasma clearance of fentanyl (38.6 mL·min/kg) was faster than buprenorphine (10.3 mL·min/kg).,Comparative pharmacokinetics of intravenous fentanyl and buprenorphine in healthy greyhound dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24684621/),[min·ml] / [kg],38.6,150331,DB00921,Buprenorphine
,24684621,plasma clearance,The plasma clearance of fentanyl (38.6 mL·min/kg) was faster than buprenorphine (10.3 mL·min/kg).,Comparative pharmacokinetics of intravenous fentanyl and buprenorphine in healthy greyhound dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24684621/),[min·ml] / [kg],10.3,150332,DB00921,Buprenorphine
,24684621,terminal half-life,The terminal half-life of fentanyl (2.22 h) was shorter than buprenorphine (3.96 h).,Comparative pharmacokinetics of intravenous fentanyl and buprenorphine in healthy greyhound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24684621/),h,2.22,150333,DB00921,Buprenorphine
,24684621,terminal half-life,The terminal half-life of fentanyl (2.22 h) was shorter than buprenorphine (3.96 h).,Comparative pharmacokinetics of intravenous fentanyl and buprenorphine in healthy greyhound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24684621/),h,3.96,150334,DB00921,Buprenorphine
,9114907,steady-state plasma buprenorphine concentration,2. The mean steady-state plasma buprenorphine concentration (+/- s.d.) for an infusion rate of 0.72 micrograms kg-1 h-1 was 4.3 +/- 2.6 ng ml-1.,The pharmacokinetics and physiological effects of buprenorphine infusion in premature neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9114907/),[ng] / [ml],4.3,155689,DB00921,Buprenorphine
,9114907,clearance,"3. Buprenorphine clearance was 0.23 +/- 0.07 l h-1 kg-1, the elimination half-life was 20 +/- 8 h and the volume of distribution was 6.2 +/- 2.11 l kg-1.",The pharmacokinetics and physiological effects of buprenorphine infusion in premature neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9114907/),[l] / [h·kg],0.23,155690,DB00921,Buprenorphine
,9114907,elimination half-life,"3. Buprenorphine clearance was 0.23 +/- 0.07 l h-1 kg-1, the elimination half-life was 20 +/- 8 h and the volume of distribution was 6.2 +/- 2.11 l kg-1.",The pharmacokinetics and physiological effects of buprenorphine infusion in premature neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9114907/),h,20,155691,DB00921,Buprenorphine
,9114907,volume of distribution,"3. Buprenorphine clearance was 0.23 +/- 0.07 l h-1 kg-1, the elimination half-life was 20 +/- 8 h and the volume of distribution was 6.2 +/- 2.11 l kg-1.",The pharmacokinetics and physiological effects of buprenorphine infusion in premature neonates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9114907/),[l] / [kg],6.2,155692,DB00921,Buprenorphine
,18598301,half-life,The values for half-life of biophase equilibration were consistent between the neuropsychological tests in the range of 66.6-84.9 min.,Pharmacokinetic-pharmacodynamic relationships of cognitive and psychomotor effects of intravenous buprenorphine infusion in human volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18598301/),min,66.6-84.9,158604,DB00921,Buprenorphine
,16632824,durations of action,"The same dose of buprenorphine base, propionate, enanthate, and decanoate (in oil) also produced a significant antinociceptive effect with longer durations of action of 26, 28, 52, and 70 h, respectively.",Novel depots of buprenorphine prodrugs have a long-acting antinociceptive effect. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16632824/),h,26,160744,DB00921,Buprenorphine
,16632824,durations of action,"The same dose of buprenorphine base, propionate, enanthate, and decanoate (in oil) also produced a significant antinociceptive effect with longer durations of action of 26, 28, 52, and 70 h, respectively.",Novel depots of buprenorphine prodrugs have a long-acting antinociceptive effect. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16632824/),h,28,160745,DB00921,Buprenorphine
,16632824,durations of action,"The same dose of buprenorphine base, propionate, enanthate, and decanoate (in oil) also produced a significant antinociceptive effect with longer durations of action of 26, 28, 52, and 70 h, respectively.",Novel depots of buprenorphine prodrugs have a long-acting antinociceptive effect. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16632824/),h,52,160746,DB00921,Buprenorphine
,16632824,durations of action,"The same dose of buprenorphine base, propionate, enanthate, and decanoate (in oil) also produced a significant antinociceptive effect with longer durations of action of 26, 28, 52, and 70 h, respectively.",Novel depots of buprenorphine prodrugs have a long-acting antinociceptive effect. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16632824/),h,70,160747,DB00921,Buprenorphine
,4024663,t1/2,"After the i.v. injection, the tri-exponential decay of drug from brain occurred with t1/2 values of 0.6, 2.3 and 7.2 h, respectively (plasma t1/2 0.5, 1.4 h, third phase not estimated due to sustained concn.)",Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024663/),h,0.6,166114,DB00921,Buprenorphine
,4024663,t1/2,"After the i.v. injection, the tri-exponential decay of drug from brain occurred with t1/2 values of 0.6, 2.3 and 7.2 h, respectively (plasma t1/2 0.5, 1.4 h, third phase not estimated due to sustained concn.)",Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024663/),h,2.3,166115,DB00921,Buprenorphine
,4024663,t1/2,"After the i.v. injection, the tri-exponential decay of drug from brain occurred with t1/2 values of 0.6, 2.3 and 7.2 h, respectively (plasma t1/2 0.5, 1.4 h, third phase not estimated due to sustained concn.)",Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024663/),h,7.2,166116,DB00921,Buprenorphine
,4024663,plasma t1/2,"After the i.v. injection, the tri-exponential decay of drug from brain occurred with t1/2 values of 0.6, 2.3 and 7.2 h, respectively (plasma t1/2 0.5, 1.4 h, third phase not estimated due to sustained concn.)",Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024663/),h,0.5,166117,DB00921,Buprenorphine
,4024663,plasma t1/2,"After the i.v. injection, the tri-exponential decay of drug from brain occurred with t1/2 values of 0.6, 2.3 and 7.2 h, respectively (plasma t1/2 0.5, 1.4 h, third phase not estimated due to sustained concn.)",Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024663/),h,1.4,166118,DB00921,Buprenorphine
,4024663,t1/2,"Decay of drug from another high-affinity binding site in brain occurred with t1/2 values of 1.1 and 68.7 h, respectively.",Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024663/),h,1.1,166119,DB00921,Buprenorphine
,4024663,t1/2,"Decay of drug from another high-affinity binding site in brain occurred with t1/2 values of 1.1 and 68.7 h, respectively.",Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024663/),h,68.7,166120,DB00921,Buprenorphine
,4024663,apparent dissociation half-lives,"Peak plasma concn. of buprenorphine occurred four weeks after s.c. implantation of a long-acting 10 mg 3H-buprenorphine pellet, and apparent dissociation half-lives of drug from low- and high-affinity binding sites in brain were 4.6 and 6.8 weeks, respectively.",Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024663/),weeks,4.6,166121,DB00921,Buprenorphine
,4024663,apparent dissociation half-lives,"Peak plasma concn. of buprenorphine occurred four weeks after s.c. implantation of a long-acting 10 mg 3H-buprenorphine pellet, and apparent dissociation half-lives of drug from low- and high-affinity binding sites in brain were 4.6 and 6.8 weeks, respectively.",Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024663/),weeks,6.8,166122,DB00921,Buprenorphine
,7082534,time to peak plasma drug concentration,The mean time to peak plasma drug concentration was about 200 min in both the 0.4 mg and 0.8 mg groups (range 90-360 min).,Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7082534/),min,200,166147,DB00921,Buprenorphine
,7082534,absolute systemic availability,The absolute systemic availability was estimated at about 55% for both groups.,Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7082534/),%,55,166148,DB00921,Buprenorphine
,17455115,half-life,BUP cerebral kinetics were best described by a membrane-limited model with a large equilibration delay (half-life of 20 min) between brain and blood due to intermediate permeability (47 ml min(-1)) and a large cerebral distribution volume (595 ml).,Comparison of cerebral pharmacokinetics of buprenorphine and norbuprenorphine in an in vivo sheep model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17455115/),min,20,166660,DB00921,Buprenorphine
,17455115,permeability,BUP cerebral kinetics were best described by a membrane-limited model with a large equilibration delay (half-life of 20 min) between brain and blood due to intermediate permeability (47 ml min(-1)) and a large cerebral distribution volume (595 ml).,Comparison of cerebral pharmacokinetics of buprenorphine and norbuprenorphine in an in vivo sheep model. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17455115/),[ml] / [min],47,166661,DB00921,Buprenorphine
,17455115,cerebral distribution volume,BUP cerebral kinetics were best described by a membrane-limited model with a large equilibration delay (half-life of 20 min) between brain and blood due to intermediate permeability (47 ml min(-1)) and a large cerebral distribution volume (595 ml).,Comparison of cerebral pharmacokinetics of buprenorphine and norbuprenorphine in an in vivo sheep model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17455115/),ml,595,166662,DB00921,Buprenorphine
,17455115,permeability,Significant limitation in permeability (6 ml min(-1)) characterized the cerebral kinetics of norBUP with a cerebral distribution volume (157 ml) giving a blood-brain equilibration half-life (21 min) similar to that for BUP.,Comparison of cerebral pharmacokinetics of buprenorphine and norbuprenorphine in an in vivo sheep model. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17455115/),[ml] / [min],6,166663,DB00921,Buprenorphine
,17455115,cerebral distribution volume,Significant limitation in permeability (6 ml min(-1)) characterized the cerebral kinetics of norBUP with a cerebral distribution volume (157 ml) giving a blood-brain equilibration half-life (21 min) similar to that for BUP.,Comparison of cerebral pharmacokinetics of buprenorphine and norbuprenorphine in an in vivo sheep model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17455115/),ml,157,166664,DB00921,Buprenorphine
,17455115,half-life,Significant limitation in permeability (6 ml min(-1)) characterized the cerebral kinetics of norBUP with a cerebral distribution volume (157 ml) giving a blood-brain equilibration half-life (21 min) similar to that for BUP.,Comparison of cerebral pharmacokinetics of buprenorphine and norbuprenorphine in an in vivo sheep model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17455115/),min,21,166665,DB00921,Buprenorphine
,17455115,logD,"The logD of BUP and norBUP were 3.93 +/- 0.08 and 1.18 +/- 0.04 (mean +/- SD), respectively.",Comparison of cerebral pharmacokinetics of buprenorphine and norbuprenorphine in an in vivo sheep model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17455115/),,3.93,166666,DB00921,Buprenorphine
,17455115,logD,"The logD of BUP and norBUP were 3.93 +/- 0.08 and 1.18 +/- 0.04 (mean +/- SD), respectively.",Comparison of cerebral pharmacokinetics of buprenorphine and norbuprenorphine in an in vivo sheep model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17455115/),,1.18,166667,DB00921,Buprenorphine
,18597246,Bioavailability,Bioavailability was 38% plus or minus 12% for the 20 microg/kg dose and 47%+/-16% for the 120 microg/kg dose.,Pharmacokinetics of buprenorphine following intravenous and oral transmucosal administration in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18597246/),%,38,167428,DB00921,Buprenorphine
,18597246,Bioavailability,Bioavailability was 38% plus or minus 12% for the 20 microg/kg dose and 47%+/-16% for the 120 microg/kg dose.,Pharmacokinetics of buprenorphine following intravenous and oral transmucosal administration in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18597246/),%,47,167429,DB00921,Buprenorphine
>,32486995,bioavailability,For drugs with a high bioavailability (> 70 %) only the impaired hepatic clearance has to be considered.,[Opioid therapy in patients with liver cirrhosis]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32486995/),%,70,167613,DB00921,Buprenorphine
>,32486995,bioavailability,"Buprenorphine, fentanyl, hydromorphone, morphine, naloxone und tapentadol are drugs with a high first-pass effect, while the bioavailability of methadone, oxycodone and tramadol is > 70 %.",[Opioid therapy in patients with liver cirrhosis]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32486995/),%,70,167614,DB00921,Buprenorphine
,31929398,AUC ratios,"The AUC ratios of norbuprenorphine and norbuprenorphine glucuronide to buprenorphine, a measure of CYP3A mediated N-demethylation, were 1.89, 1.84, and 1.33 during the first and second, third trimesters, and postpartum, respectively.",Pregnancy Alters CYP- and UGT-Mediated Metabolism of Buprenorphine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31929398/),,1.89,169279,DB00921,Buprenorphine
,31929398,AUC ratios,"The AUC ratios of norbuprenorphine and norbuprenorphine glucuronide to buprenorphine, a measure of CYP3A mediated N-demethylation, were 1.89, 1.84, and 1.33 during the first and second, third trimesters, and postpartum, respectively.",Pregnancy Alters CYP- and UGT-Mediated Metabolism of Buprenorphine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31929398/),,1.84,169280,DB00921,Buprenorphine
,31929398,AUC ratios,"The AUC ratios of norbuprenorphine and norbuprenorphine glucuronide to buprenorphine, a measure of CYP3A mediated N-demethylation, were 1.89, 1.84, and 1.33 during the first and second, third trimesters, and postpartum, respectively.",Pregnancy Alters CYP- and UGT-Mediated Metabolism of Buprenorphine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31929398/),,1.33,169281,DB00921,Buprenorphine
,31929398,AUC ratios,"The AUC ratios of buprenorphine glucuronide to BUP, indicative of UGT activity, were 0.71, 2.07, and 0.3 at first/second trimesters, third trimester, and postpartum, respectively.",Pregnancy Alters CYP- and UGT-Mediated Metabolism of Buprenorphine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31929398/),,0.71,169282,DB00921,Buprenorphine
,31929398,AUC ratios,"The AUC ratios of buprenorphine glucuronide to BUP, indicative of UGT activity, were 0.71, 2.07, and 0.3 at first/second trimesters, third trimester, and postpartum, respectively.",Pregnancy Alters CYP- and UGT-Mediated Metabolism of Buprenorphine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31929398/),,2.07,169283,DB00921,Buprenorphine
,31929398,AUC ratios,"The AUC ratios of buprenorphine glucuronide to BUP, indicative of UGT activity, were 0.71, 2.07, and 0.3 at first/second trimesters, third trimester, and postpartum, respectively.",Pregnancy Alters CYP- and UGT-Mediated Metabolism of Buprenorphine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31929398/),,0.3,169284,DB00921,Buprenorphine
,2576057,tmax,"For the intranasal administration mean tmax and mean Cmax were 30.6 min and 1.77 ng mL-1, respectively.",The systemic availability of buprenorphine administered by nasal spray. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576057/),min,30.6,169953,DB00921,Buprenorphine
,2576057,Cmax,"For the intranasal administration mean tmax and mean Cmax were 30.6 min and 1.77 ng mL-1, respectively.",The systemic availability of buprenorphine administered by nasal spray. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576057/),[ng] / [ml],1.77,169954,DB00921,Buprenorphine
,2576057,bioavailability,Mean intranasal bioavailability was 48.2 +/- 8.35% (mean +/- s.e.m.) of the intravenous value.,The systemic availability of buprenorphine administered by nasal spray. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576057/),%,48.2,169955,DB00921,Buprenorphine
,33950785,"maximum concentrations (Cmax,)","Mean (SD) maximum concentrations (Cmax,) of morphine in plasma were 6.8 (4.56), 9.56 (8.29), 9.30 (3.35) and 18.99 (9.41) ng/mL for the groups Dex + Mor, Dex + Maro + Mor, Maro + Mor and Mor respectively.","Evaluation of analgesic interaction between morphine, maropitant and dexmedetomidine in dogs undergoing ovariohysterectomy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33950785/),[ng] / [ml],6.8,171104,DB00921,Buprenorphine
,33950785,"maximum concentrations (Cmax,)","Mean (SD) maximum concentrations (Cmax,) of morphine in plasma were 6.8 (4.56), 9.56 (8.29), 9.30 (3.35) and 18.99 (9.41) ng/mL for the groups Dex + Mor, Dex + Maro + Mor, Maro + Mor and Mor respectively.","Evaluation of analgesic interaction between morphine, maropitant and dexmedetomidine in dogs undergoing ovariohysterectomy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33950785/),[ng] / [ml],9.56,171105,DB00921,Buprenorphine
,33950785,"maximum concentrations (Cmax,)","Mean (SD) maximum concentrations (Cmax,) of morphine in plasma were 6.8 (4.56), 9.56 (8.29), 9.30 (3.35) and 18.99 (9.41) ng/mL for the groups Dex + Mor, Dex + Maro + Mor, Maro + Mor and Mor respectively.","Evaluation of analgesic interaction between morphine, maropitant and dexmedetomidine in dogs undergoing ovariohysterectomy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33950785/),[ng] / [ml],9.30,171106,DB00921,Buprenorphine
,33950785,"maximum concentrations (Cmax,)","Mean (SD) maximum concentrations (Cmax,) of morphine in plasma were 6.8 (4.56), 9.56 (8.29), 9.30 (3.35) and 18.99 (9.41) ng/mL for the groups Dex + Mor, Dex + Maro + Mor, Maro + Mor and Mor respectively.","Evaluation of analgesic interaction between morphine, maropitant and dexmedetomidine in dogs undergoing ovariohysterectomy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33950785/),[ng] / [ml],18.99,171107,DB00921,Buprenorphine
,24666428,Mean residence time,"Mean residence time in the i.v. study as compared to the i.m. study was 177 (159-189) vs. 185 (174-214) min, respectively [median (range)].",Pharmacokinetics of buprenorphine following intravenous and intramuscular administration in male rhesus macaques (Macaca mulatta). ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666428/),min,177,173755,DB00921,Buprenorphine
,24666428,Mean residence time,"Mean residence time in the i.v. study as compared to the i.m. study was 177 (159-189) vs. 185 (174-214) min, respectively [median (range)].",Pharmacokinetics of buprenorphine following intravenous and intramuscular administration in male rhesus macaques (Macaca mulatta). ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666428/),min,185,173756,DB00921,Buprenorphine
,24666428,concentration back-extrapolated to time zero,"In the i.v. study, concentration back-extrapolated to time zero was found to be 33.0 (16.8-57.0) ng/mL [median (range)].",Pharmacokinetics of buprenorphine following intravenous and intramuscular administration in male rhesus macaques (Macaca mulatta). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666428/),[ng] / [ml],33.0,173757,DB00921,Buprenorphine
,24666428,maximum serum concentration,"On the other hand, the maximum serum concentration found in the i.m. study was 11.8 (6.30-14.8) ng/mL [median (range)].",Pharmacokinetics of buprenorphine following intravenous and intramuscular administration in male rhesus macaques (Macaca mulatta). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666428/),[ng] / [ml],11.8,173758,DB00921,Buprenorphine
,24666428,Bioavailability,Bioavailability was found to be 68.1 (59.3-71.2)% [median (range)].,Pharmacokinetics of buprenorphine following intravenous and intramuscular administration in male rhesus macaques (Macaca mulatta). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666428/),%,68.1,173759,DB00921,Buprenorphine
,28877414,plasma FEN,"Mean plasma FEN concentration (± SD) 2 hours following patch application was 1.06 ± 0.85 ng/mL, and remained above 0.5 ng/mL for 40 hours.",Evaluation of the analgesic and pharmacokinetic properties of transdermally administered fentanyl in goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28877414/),[ng] / [ml],1.06,175015,DB00921,Buprenorphine
,28877414,concentration,"Mean plasma FEN concentration (± SD) 2 hours following patch application was 1.06 ± 0.85 ng/mL, and remained above 0.5 ng/mL for 40 hours.",Evaluation of the analgesic and pharmacokinetic properties of transdermally administered fentanyl in goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28877414/),[ng] / [ml],1.06,175016,DB00921,Buprenorphine
,28877414,concentration,"Mean plasma FEN concentration (± SD) 2 hours following patch application was 1.06 ± 0.85 ng/mL, and remained above 0.5 ng/mL for 40 hours.",Evaluation of the analgesic and pharmacokinetic properties of transdermally administered fentanyl in goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28877414/),[ng] / [ml],0,175017,DB00921,Buprenorphine
,28877414,Maximum mean plasma FEN concentration (Cmax ),Maximum mean plasma FEN concentration (Cmax ) was 1.84 (ranging from 0.81 to 3.35) ng/mL with average time to maximum concentration (Tmax ) of 12 hours after patch application.,Evaluation of the analgesic and pharmacokinetic properties of transdermally administered fentanyl in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28877414/),[ng] / [ml],1.84,175018,DB00921,Buprenorphine
,28877414,time to maximum concentration (Tmax ),Maximum mean plasma FEN concentration (Cmax ) was 1.84 (ranging from 0.81 to 3.35) ng/mL with average time to maximum concentration (Tmax ) of 12 hours after patch application.,Evaluation of the analgesic and pharmacokinetic properties of transdermally administered fentanyl in goats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28877414/),h,12,175019,DB00921,Buprenorphine
,34273481,fetal/maternal plasma concentration ratio,The median fetal/maternal plasma concentration ratio was 13 - 27 % throughout the exposure period at baseline.,MATERNAL AND FETAL BUPRENORPHINE PHARMACOKINETICS IN PREGNANT SHEEP DURING TRANSDERMAL PATCH DOSING: Buprenorphine pharmacokinetics in pregnant sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34273481/),%,13 - 27,177680,DB00921,Buprenorphine
,28315645,mean plasma concentration,The highest mean plasma concentration for buprenorphine SR occurred at the 24-h time point (0.0098 μg/mL) in the low-dose group and at the 8-h time point (0.015 μg/mL) for the high-dose group.,Pharmacokinetic Profiles of Meloxicam and Sustained-release Buprenorphine in Prairie Dogs (Cynomys ludovicianus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28315645/),,0,181415,DB00921,Buprenorphine
,16855177,dissociation (k(off)),"The values of the parameter estimates of the rate constants for biophase distribution (k(eo)), receptor association (k(on)), and dissociation (k(off)) were 0.0348 min(-1) [95% confidence interval (CI), 0.0193-0.0503 min(-1)], 0.57 ml/ng/min (95% CI, 0.38-0.76 ml/ng/min), and 0.0903 min(-1) (95% CI, 0.035-0.196 min(-1)), respectively.",Mechanism-based pharmacokinetic-pharmacodynamic modeling of the respiratory-depressant effect of buprenorphine and fentanyl in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16855177/),1/[min],0.0903,184681,DB00921,Buprenorphine
,16855177,equilibrium dissociation constant,"The values of the equilibrium dissociation constant and intrinsic activity were 0.16 ng/ml and 0.48 (95% CI, 0.45-0.51), respectively.",Mechanism-based pharmacokinetic-pharmacodynamic modeling of the respiratory-depressant effect of buprenorphine and fentanyl in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16855177/),[ng] / [ml],0.16,184682,DB00921,Buprenorphine
,16855177,intrinsic activity,"The values of the equilibrium dissociation constant and intrinsic activity were 0.16 ng/ml and 0.48 (95% CI, 0.45-0.51), respectively.",Mechanism-based pharmacokinetic-pharmacodynamic modeling of the respiratory-depressant effect of buprenorphine and fentanyl in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16855177/),,0.48,184683,DB00921,Buprenorphine
,25650977,AUC(0-Tlast),"Administration of 0.18 mg/kg SC SRB and 30 μ g/h TDB achieved AUC(0-Tlast) of 221.6 ± 26.8 and 25.2 ± 3.9 ng × h/mL, respectively, compared with 9.7 ± 1.4 ng*h/mL for 0.02 mg/kg IV buprenorphine.",Pharmacokinetics of sustained-release and transdermal buprenorphine in Göttingen minipigs (Sus scrofa domestica). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25650977/),[h·ng] / [ml],221.6,184839,DB00921,Buprenorphine
,25650977,AUC(0-Tlast),"Administration of 0.18 mg/kg SC SRB and 30 μ g/h TDB achieved AUC(0-Tlast) of 221.6 ± 26.8 and 25.2 ± 3.9 ng × h/mL, respectively, compared with 9.7 ± 1.4 ng*h/mL for 0.02 mg/kg IV buprenorphine.",Pharmacokinetics of sustained-release and transdermal buprenorphine in Göttingen minipigs (Sus scrofa domestica). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25650977/),[h·ng] / [ml],25.2,184840,DB00921,Buprenorphine
,25650977,AUC(0-Tlast),"Administration of 0.18 mg/kg SC SRB and 30 μ g/h TDB achieved AUC(0-Tlast) of 221.6 ± 26.8 and 25.2 ± 3.9 ng × h/mL, respectively, compared with 9.7 ± 1.4 ng*h/mL for 0.02 mg/kg IV buprenorphine.",Pharmacokinetics of sustained-release and transdermal buprenorphine in Göttingen minipigs (Sus scrofa domestica). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25650977/),[h·ng] / [ml],9.7,184841,DB00921,Buprenorphine
,9190324,half-life,"From a pharmacokinetic standpoint, tramadol offers high bioavailability, with similar patterns after oral or parenteral administration (half-life 5 to 7 hours, time to peak plasma concentration 3.1 hours, and approximately 20% plasma protein binding).",[Effectiveness and tolerance of tramadol in cancer pain. A comparative study with respect to buprenorphine]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9190324/),h,5 to 7,190044,DB00921,Buprenorphine
,9190324,time to peak plasma concentration,"From a pharmacokinetic standpoint, tramadol offers high bioavailability, with similar patterns after oral or parenteral administration (half-life 5 to 7 hours, time to peak plasma concentration 3.1 hours, and approximately 20% plasma protein binding).",[Effectiveness and tolerance of tramadol in cancer pain. A comparative study with respect to buprenorphine]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9190324/),h,3.1,190045,DB00921,Buprenorphine
,9190324,plasma protein binding,"From a pharmacokinetic standpoint, tramadol offers high bioavailability, with similar patterns after oral or parenteral administration (half-life 5 to 7 hours, time to peak plasma concentration 3.1 hours, and approximately 20% plasma protein binding).",[Effectiveness and tolerance of tramadol in cancer pain. A comparative study with respect to buprenorphine]. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9190324/),%,20,190046,DB00921,Buprenorphine
,27390058,extraction recoveries,The extraction recoveries for all the analytes ranged from 55 to 86.9%.,"Quantitative determination of buprenorphine, naloxone and their metabolites in rat plasma using hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390058/),%,55 to 86.9,190897,DB00921,Buprenorphine
,19601871,f(u),"Scaling of buprenorphine clearance with, or without, correction for the nonspecific microsomal protein binding of buprenorphine (f(u) = 0.42) suggested glucuronidation was a significant route for hepatic clearance of buprenorphine.",Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19601871/),,0.42,192373,DB00921,Buprenorphine
,17185999,half-time,"The half-time values of biophase equilibration (t(1/2, k(eo))) were 16.4 and 75.3 min for fentanyl and buprenorphine, respectively.",Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17185999/),min,16.4,196163,DB00921,Buprenorphine
,17185999,half-time,"The half-time values of biophase equilibration (t(1/2, k(eo))) were 16.4 and 75.3 min for fentanyl and buprenorphine, respectively.",Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17185999/),min,75.3,196164,DB00921,Buprenorphine
,17185999,"t(1/2, k(eo))","The half-time values of biophase equilibration (t(1/2, k(eo))) were 16.4 and 75.3 min for fentanyl and buprenorphine, respectively.",Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17185999/),min,16.4,196165,DB00921,Buprenorphine
,17185999,"t(1/2, k(eo))","The half-time values of biophase equilibration (t(1/2, k(eo))) were 16.4 and 75.3 min for fentanyl and buprenorphine, respectively.",Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17185999/),min,75.3,196166,DB00921,Buprenorphine
,17185999,k(on),"In addition, for buprenorphine, the value of k(on) was 0.246 ml/ng/min and the value of k(off) was 0.0102 min(-1).",Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17185999/),[ml] / [min·ng],0.246,196167,DB00921,Buprenorphine
,17185999,k(off),"In addition, for buprenorphine, the value of k(on) was 0.246 ml/ng/min and the value of k(off) was 0.0102 min(-1).",Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17185999/),1/[min],0.0102,196168,DB00921,Buprenorphine
,17185999,intrinsic activity alpha,"The concentration-effect relationship of buprenorphine was characterized by a ceiling effect at higher concentrations (intrinsic activity alpha=0.56, 95% confidence interval (CI): 0.50-0.62), whereas fentanyl displayed full respiratory depressant effect (alpha=0.91, 95% CI: 0.19-1.62).",Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17185999/),,0.56,196169,DB00921,Buprenorphine
,34281629,maximal observed plasma concentration of buprenorphine (Cmax),The maximal observed plasma concentration of buprenorphine (Cmax) administered IM (2.57 ± 0.95 ng/mL) was significantly higher than administered SQ (1.47 ± 0.61 ng/mL).,Pharmacokinetics of Single-Dose Intramuscular and Subcutaneous Injections of Buprenorphine in Common Marmosets (Callithrix jacchus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281629/),[ng] / [ml],2.57,200260,DB00921,Buprenorphine
,34281629,maximal observed plasma concentration of buprenorphine (Cmax),The maximal observed plasma concentration of buprenorphine (Cmax) administered IM (2.57 ± 0.95 ng/mL) was significantly higher than administered SQ (1.47 ± 0.61 ng/mL).,Pharmacokinetics of Single-Dose Intramuscular and Subcutaneous Injections of Buprenorphine in Common Marmosets (Callithrix jacchus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281629/),[ng] / [ml],1.47,200261,DB00921,Buprenorphine
,34281629,time to Cmax (Tmax),"However, the time to Cmax (Tmax) was not statistically different between routes (17.4 ± 6 min for IM and 19.8 ±7.8 min for SQ).",Pharmacokinetics of Single-Dose Intramuscular and Subcutaneous Injections of Buprenorphine in Common Marmosets (Callithrix jacchus). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281629/),min,17.4,200262,DB00921,Buprenorphine
,34281629,time to Cmax (Tmax),"However, the time to Cmax (Tmax) was not statistically different between routes (17.4 ± 6 min for IM and 19.8 ±7.8 min for SQ).",Pharmacokinetics of Single-Dose Intramuscular and Subcutaneous Injections of Buprenorphine in Common Marmosets (Callithrix jacchus). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281629/),min,19.8,200263,DB00921,Buprenorphine
,34281629,time of the last quantifiable concentration,"The time of the last quantifiable concentration of buprenorphine was 5 ± 1.67 h for IM compared with 6.33 ± 1.51 h for SQ, which was not statistically different.",Pharmacokinetics of Single-Dose Intramuscular and Subcutaneous Injections of Buprenorphine in Common Marmosets (Callithrix jacchus). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281629/),h,5,200264,DB00921,Buprenorphine
,34281629,time of the last quantifiable concentration,"The time of the last quantifiable concentration of buprenorphine was 5 ± 1.67 h for IM compared with 6.33 ± 1.51 h for SQ, which was not statistically different.",Pharmacokinetics of Single-Dose Intramuscular and Subcutaneous Injections of Buprenorphine in Common Marmosets (Callithrix jacchus). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281629/),h,6.33,200265,DB00921,Buprenorphine
,32448336,clearance,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[l] / [h·kg],1.29,200615,DB00921,Buprenorphine
,32448336,clearance,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[l] / [h·kg],1.65,200616,DB00921,Buprenorphine
,32448336,clearance,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[l] / [h·kg],1.40,200617,DB00921,Buprenorphine
,32448336,volume of distribution,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[l] / [kg],6.8,200618,DB00921,Buprenorphine
,32448336,volume of distribution,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[l] / [kg],14.2,200619,DB00921,Buprenorphine
,32448336,volume of distribution,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[l] / [kg],40.1,200620,DB00921,Buprenorphine
,32448336,elimination half-life,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),h,3.7,200621,DB00921,Buprenorphine
,32448336,elimination half-life,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),h,5.7,200622,DB00921,Buprenorphine
,32448336,elimination half-life,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),h,22,200623,DB00921,Buprenorphine
,32448336,area under the plasma concentration-time curved extrapolated to infinity,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[ng] / [h·ml],15.7,200624,DB00921,Buprenorphine
,32448336,area under the plasma concentration-time curved extrapolated to infinity,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[ng] / [h·ml],12.4,200625,DB00921,Buprenorphine
,32448336,area under the plasma concentration-time curved extrapolated to infinity,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[ng] / [h·ml],16.4,200626,DB00921,Buprenorphine
,32448336,Bioavailability,"Bioavailability for IM and SC was 62.6 and 40%, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),%,62.6,200627,DB00921,Buprenorphine
,32448336,Bioavailability,"Bioavailability for IM and SC was 62.6 and 40%, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),%,40,200628,DB00921,Buprenorphine
,32448336,Maximum plasma concentrations,"Maximum plasma concentrations of buprenorphine were 6.2 and 1.3 ng/mL at 0.14 and 0.33 h after IM and SC administration, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[ng] / [ml],6.2,200629,DB00921,Buprenorphine
,32448336,Maximum plasma concentrations,"Maximum plasma concentrations of buprenorphine were 6.2 and 1.3 ng/mL at 0.14 and 0.33 h after IM and SC administration, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[ng] / [ml],1.3,200630,DB00921,Buprenorphine
,17465641,second-order rate constant of receptor association (k(on)),"For the respiratory depressant effect, the values of the second-order rate constant of receptor association (k(on)) and the first-order rate constant of receptor dissociation (k(off)) were 0.23 mL/ng/min (RSE = 15.8%) and 0.014 min(-1) (RSE = 27.7%), respectively, and the value of the equilibrium dissociation constant (K(diss)) was 0.13 nmol/L.",Animal-to-human extrapolation of the pharmacokinetic and pharmacodynamic properties of buprenorphine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17465641/),[ml] / [min·ng],0.23,203046,DB00921,Buprenorphine
,17465641,first-order rate constant of receptor dissociation (k(off)),"For the respiratory depressant effect, the values of the second-order rate constant of receptor association (k(on)) and the first-order rate constant of receptor dissociation (k(off)) were 0.23 mL/ng/min (RSE = 15.8%) and 0.014 min(-1) (RSE = 27.7%), respectively, and the value of the equilibrium dissociation constant (K(diss)) was 0.13 nmol/L.",Animal-to-human extrapolation of the pharmacokinetic and pharmacodynamic properties of buprenorphine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17465641/),1/[min],0.014,203047,DB00921,Buprenorphine
,17465641,equilibrium dissociation constant (K(diss)),"For the respiratory depressant effect, the values of the second-order rate constant of receptor association (k(on)) and the first-order rate constant of receptor dissociation (k(off)) were 0.23 mL/ng/min (RSE = 15.8%) and 0.014 min(-1) (RSE = 27.7%), respectively, and the value of the equilibrium dissociation constant (K(diss)) was 0.13 nmol/L.",Animal-to-human extrapolation of the pharmacokinetic and pharmacodynamic properties of buprenorphine. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17465641/),[nM] / [l],0.13,203048,DB00921,Buprenorphine
,17465641,intrinsic activity alpha,The value of the intrinsic activity alpha was 0.52 (RSE = 3.4%).,Animal-to-human extrapolation of the pharmacokinetic and pharmacodynamic properties of buprenorphine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17465641/),,0.52,203049,DB00921,Buprenorphine
,17465641,k(on),"For the antinociceptive effect, the values of the k(on) and k(off) were 0.015 mL/ng/min (RSE = 18.3%) and 0.053 min(-1) (RSE = 23.1%), respectively.",Animal-to-human extrapolation of the pharmacokinetic and pharmacodynamic properties of buprenorphine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17465641/),[ml] / [min·ng],0.015,203050,DB00921,Buprenorphine
,17465641,k(off),"For the antinociceptive effect, the values of the k(on) and k(off) were 0.015 mL/ng/min (RSE = 18.3%) and 0.053 min(-1) (RSE = 23.1%), respectively.",Animal-to-human extrapolation of the pharmacokinetic and pharmacodynamic properties of buprenorphine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17465641/),1/[min],0.053,203051,DB00921,Buprenorphine
,17465641,K(diss),The value of the K(diss) was 7.5 nmol/L.,Animal-to-human extrapolation of the pharmacokinetic and pharmacodynamic properties of buprenorphine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17465641/),[nM] / [l],7.5,203052,DB00921,Buprenorphine
,17465641,k(e0),The value of the allometric coefficient for the k(e0) was 0.0303 min(-1) (RSE = 11.3%) and the value of the exponent was -0.28 (RSE = 9.6%).,Animal-to-human extrapolation of the pharmacokinetic and pharmacodynamic properties of buprenorphine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17465641/),1/[min],0,203053,DB00921,Buprenorphine
,28416162,Maximum concentration,"Maximum concentration was 23.92 ± 8.64 ng mL-1 at 1 minute (maximum time); elimination half-life was 41.87 ± 17.35 minutes; area under the curve was 486.68 ± 125.66 minutes ng-1 mL-1; clearance was 33.61 ± 13.01 mL minute-1 kg-1, and volume of distribution at steady state was 1.77 ± 0.50 L kg-1.",Pharmacokinetics of buprenorphine following constant rate infusion for postoperative analgesia in dogs undergoing ovariectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28416162/),[ng] / [ml],23.92,204605,DB00921,Buprenorphine
,28416162,elimination half-life,"Maximum concentration was 23.92 ± 8.64 ng mL-1 at 1 minute (maximum time); elimination half-life was 41.87 ± 17.35 minutes; area under the curve was 486.68 ± 125.66 minutes ng-1 mL-1; clearance was 33.61 ± 13.01 mL minute-1 kg-1, and volume of distribution at steady state was 1.77 ± 0.50 L kg-1.",Pharmacokinetics of buprenorphine following constant rate infusion for postoperative analgesia in dogs undergoing ovariectomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28416162/),min,41.87,204606,DB00921,Buprenorphine
,28416162,area under the curve,"Maximum concentration was 23.92 ± 8.64 ng mL-1 at 1 minute (maximum time); elimination half-life was 41.87 ± 17.35 minutes; area under the curve was 486.68 ± 125.66 minutes ng-1 mL-1; clearance was 33.61 ± 13.01 mL minute-1 kg-1, and volume of distribution at steady state was 1.77 ± 0.50 L kg-1.",Pharmacokinetics of buprenorphine following constant rate infusion for postoperative analgesia in dogs undergoing ovariectomy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28416162/),[min] / [ml·ng],486.68,204607,DB00921,Buprenorphine
,28416162,clearance,"Maximum concentration was 23.92 ± 8.64 ng mL-1 at 1 minute (maximum time); elimination half-life was 41.87 ± 17.35 minutes; area under the curve was 486.68 ± 125.66 minutes ng-1 mL-1; clearance was 33.61 ± 13.01 mL minute-1 kg-1, and volume of distribution at steady state was 1.77 ± 0.50 L kg-1.",Pharmacokinetics of buprenorphine following constant rate infusion for postoperative analgesia in dogs undergoing ovariectomy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28416162/),[ml] / [kg·min],33.61,204608,DB00921,Buprenorphine
,28416162,volume of distribution at steady state,"Maximum concentration was 23.92 ± 8.64 ng mL-1 at 1 minute (maximum time); elimination half-life was 41.87 ± 17.35 minutes; area under the curve was 486.68 ± 125.66 minutes ng-1 mL-1; clearance was 33.61 ± 13.01 mL minute-1 kg-1, and volume of distribution at steady state was 1.77 ± 0.50 L kg-1.",Pharmacokinetics of buprenorphine following constant rate infusion for postoperative analgesia in dogs undergoing ovariectomy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28416162/),[l] / [kg],1.77,204609,DB00921,Buprenorphine
,26572942,serum albumin,The patient's serum albumin concentration was 23g/l (reference range: 35-52 g/l).,Breakthrough Pain Associated with a Reduction in Serum Buprenorphine Concentration during Dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26572942/),,23,204862,DB00921,Buprenorphine
,26572942,free buprenorphine,"Pharmacokinetic sampling revealed a free buprenorphine fraction of 32% (consistent with the hypoalbuminaemia), which was markedly reduced at the end of dialysis (free buprenorphine concentration 2.4 µg/l before vs. <0.1 µg/l after dialysis).",Breakthrough Pain Associated with a Reduction in Serum Buprenorphine Concentration during Dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26572942/),[μg] / [l],2.4,204863,DB00921,Buprenorphine
,26572942,concentration,"Pharmacokinetic sampling revealed a free buprenorphine fraction of 32% (consistent with the hypoalbuminaemia), which was markedly reduced at the end of dialysis (free buprenorphine concentration 2.4 µg/l before vs. <0.1 µg/l after dialysis).",Breakthrough Pain Associated with a Reduction in Serum Buprenorphine Concentration during Dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26572942/),[μg] / [l],2.4,204864,DB00921,Buprenorphine
<,26572942,concentration,"Pharmacokinetic sampling revealed a free buprenorphine fraction of 32% (consistent with the hypoalbuminaemia), which was markedly reduced at the end of dialysis (free buprenorphine concentration 2.4 µg/l before vs. <0.1 µg/l after dialysis).",Breakthrough Pain Associated with a Reduction in Serum Buprenorphine Concentration during Dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26572942/),[μg] / [l],0.1,204865,DB00921,Buprenorphine
,24095872,Overall extraction recoveries,Overall extraction recoveries ranged from 68-100% in both matrices.,"High-sensitivity analysis of buprenorphine, norbuprenorphine, buprenorphine glucuronide, and norbuprenorphine glucuronide in plasma and urine by liquid chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24095872/),%,68-100,204867,DB00921,Buprenorphine
,17922561,rate constants of receptor association (k(on)),"For buprenorphine, the values of the rate constants of receptor association (k(on)) and dissociation (k(off)) were 0.203 mL/ng/min and 0.0172 min(-)(1), respectively.",Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17922561/),[ml] / [min·ng],0.203,210557,DB00921,Buprenorphine
,17922561,dissociation (k(off)),"For buprenorphine, the values of the rate constants of receptor association (k(on)) and dissociation (k(off)) were 0.203 mL/ng/min and 0.0172 min(-)(1), respectively.",Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17922561/),min(-)(1),0.0172,210558,DB00921,Buprenorphine
,17922561,equilibrium dissociation constant (K(D)),The value of the equilibrium dissociation constant (K(D)) was 0.18 nmol/L.,Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17922561/),[nM] / [l],0.18,210559,DB00921,Buprenorphine
,17922561,half-life (t((1/2))),The half-life (t((1/2))) of biophase equilibration was 173 minutes.,Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17922561/),min,173,210560,DB00921,Buprenorphine
,17922561,half-life of biophase distribution,"For naloxone, the half-life of biophase distribution was 6.5 minutes.",Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17922561/),min,6.5,210561,DB00921,Buprenorphine
,28240955,maximum concentration,"RESULTS Mean ± SD maximum concentration after IV and SC administration of buprenorphine were 11.60 ± 4.50 ng/mL and 1.95 ± 0.80 ng/mL, respectively.",Pharmacokinetics and pharmacodynamics of buprenorphine and sustained-release buprenorphine after administration to adult alpacas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28240955/),[ng] / [ml],11.60,212427,DB00921,Buprenorphine
,28240955,maximum concentration,"RESULTS Mean ± SD maximum concentration after IV and SC administration of buprenorphine were 11.60 ± 4.50 ng/mL and 1.95 ± 0.80 ng/mL, respectively.",Pharmacokinetics and pharmacodynamics of buprenorphine and sustained-release buprenorphine after administration to adult alpacas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28240955/),[ng] / [ml],1.95,212428,DB00921,Buprenorphine
,28240955,clearance,"Mean clearance was 3.00 ± 0.33 L/h/kg, and steady-state volume of distribution after IV administration was 3.8 ± l.0 L/kg.",Pharmacokinetics and pharmacodynamics of buprenorphine and sustained-release buprenorphine after administration to adult alpacas. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28240955/),[l] / [h·kg],3.00,212429,DB00921,Buprenorphine
,28240955,steady-state volume of distribution,"Mean clearance was 3.00 ± 0.33 L/h/kg, and steady-state volume of distribution after IV administration was 3.8 ± l.0 L/kg.",Pharmacokinetics and pharmacodynamics of buprenorphine and sustained-release buprenorphine after administration to adult alpacas. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28240955/),[l] / [kg],3.8,212430,DB00921,Buprenorphine
,28240955,Terminal elimination half-life,"Terminal elimination half-life was 1.0 ± 0.2 hours and 2.7 ± 2.8 hours after IV and SC administration, respectively.",Pharmacokinetics and pharmacodynamics of buprenorphine and sustained-release buprenorphine after administration to adult alpacas. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28240955/),h,1.0,212431,DB00921,Buprenorphine
,28240955,Terminal elimination half-life,"Terminal elimination half-life was 1.0 ± 0.2 hours and 2.7 ± 2.8 hours after IV and SC administration, respectively.",Pharmacokinetics and pharmacodynamics of buprenorphine and sustained-release buprenorphine after administration to adult alpacas. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28240955/),h,2.7,212432,DB00921,Buprenorphine
,28240955,Mean residence time,"Mean residence time was 1.3 ± 0.3 hours and 3.6 ± 3.7 hours after IV and SC administration, respectively.",Pharmacokinetics and pharmacodynamics of buprenorphine and sustained-release buprenorphine after administration to adult alpacas. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28240955/),h,1.3,212433,DB00921,Buprenorphine
,28240955,Mean residence time,"Mean residence time was 1.3 ± 0.3 hours and 3.6 ± 3.7 hours after IV and SC administration, respectively.",Pharmacokinetics and pharmacodynamics of buprenorphine and sustained-release buprenorphine after administration to adult alpacas. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28240955/),h,3.6,212434,DB00921,Buprenorphine
,28240955,Bioavailability,Bioavailability was 64 ± 28%.,Pharmacokinetics and pharmacodynamics of buprenorphine and sustained-release buprenorphine after administration to adult alpacas. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28240955/),%,64,212435,DB00921,Buprenorphine
,33352843,tmax,"PK non-compartmental characteristics showed considerable variability in parameters between the subjects over the 8-h sampling time (tmax = 1.5 ± 0.7 h, Co = 1.6 ± 1.4 ng/mL, Cmax= 7.1 ± 6 ng/mL, and AUC0-8h = 26.8 ± 17.8 h·ng/mL).",Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33352843/),h,1.5,217404,DB00921,Buprenorphine
,33352843,Co,"PK non-compartmental characteristics showed considerable variability in parameters between the subjects over the 8-h sampling time (tmax = 1.5 ± 0.7 h, Co = 1.6 ± 1.4 ng/mL, Cmax= 7.1 ± 6 ng/mL, and AUC0-8h = 26.8 ± 17.8 h·ng/mL).",Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33352843/),[ng] / [ml],1.6,217405,DB00921,Buprenorphine
,33352843,Cmax,"PK non-compartmental characteristics showed considerable variability in parameters between the subjects over the 8-h sampling time (tmax = 1.5 ± 0.7 h, Co = 1.6 ± 1.4 ng/mL, Cmax= 7.1 ± 6 ng/mL, and AUC0-8h = 26.8 ± 17.8 h·ng/mL).",Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33352843/),[ng] / [ml],7.1,217406,DB00921,Buprenorphine
,33352843,AUC0-8h,"PK non-compartmental characteristics showed considerable variability in parameters between the subjects over the 8-h sampling time (tmax = 1.5 ± 0.7 h, Co = 1.6 ± 1.4 ng/mL, Cmax= 7.1 ± 6 ng/mL, and AUC0-8h = 26.8 ± 17.8 h·ng/mL).",Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33352843/),[h·ng] / [ml],26.8,217407,DB00921,Buprenorphine
,33352843,AUC0-8h ratios,"Subjects had a significantly higher tendency towards CYP-mediated N-demethylation, with the AUC0-8h ratios of the molar concentrations of [Nor-BUP + Nor-BUP-g] to BUP being (3.4 ± 1.9) significantly higher compared with BUP-g to BUP (0.19 ± 0.2).",Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33352843/),,3.4,217408,DB00921,Buprenorphine
,33352843,AUC0-8h ratios,"Subjects had a significantly higher tendency towards CYP-mediated N-demethylation, with the AUC0-8h ratios of the molar concentrations of [Nor-BUP + Nor-BUP-g] to BUP being (3.4 ± 1.9) significantly higher compared with BUP-g to BUP (0.19 ± 0.2).",Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33352843/),,0.19,217409,DB00921,Buprenorphine
,33352843,ka,"A two-compartment population-PK model with linear absorption (ka = 2.54 h-1), distribution (k12= 2.34 h-1, k14 = 1.29 h-1), metabolism (k24 = 1.28 × 10-1 h-1, k23 = 6.43 × 10-2 h-1, k35 = 1.23 × 10-1 h-1, k45 = 8.73 × 10-1 h-1), and elimination (k30 = 3.81 × 10-3 h-1, k50 = 1.27 × 10-1 h-1) adequately described the time-course of BUP and its metabolites, which has been externally validated using published data.",Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33352843/),1/[h],2.54,217410,DB00921,Buprenorphine
,33352843,k12,"A two-compartment population-PK model with linear absorption (ka = 2.54 h-1), distribution (k12= 2.34 h-1, k14 = 1.29 h-1), metabolism (k24 = 1.28 × 10-1 h-1, k23 = 6.43 × 10-2 h-1, k35 = 1.23 × 10-1 h-1, k45 = 8.73 × 10-1 h-1), and elimination (k30 = 3.81 × 10-3 h-1, k50 = 1.27 × 10-1 h-1) adequately described the time-course of BUP and its metabolites, which has been externally validated using published data.",Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33352843/),1/[h],2.34,217411,DB00921,Buprenorphine
,33352843,k14,"A two-compartment population-PK model with linear absorption (ka = 2.54 h-1), distribution (k12= 2.34 h-1, k14 = 1.29 h-1), metabolism (k24 = 1.28 × 10-1 h-1, k23 = 6.43 × 10-2 h-1, k35 = 1.23 × 10-1 h-1, k45 = 8.73 × 10-1 h-1), and elimination (k30 = 3.81 × 10-3 h-1, k50 = 1.27 × 10-1 h-1) adequately described the time-course of BUP and its metabolites, which has been externally validated using published data.",Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33352843/),1/[h],1.29,217412,DB00921,Buprenorphine
,33352843,k24,"A two-compartment population-PK model with linear absorption (ka = 2.54 h-1), distribution (k12= 2.34 h-1, k14 = 1.29 h-1), metabolism (k24 = 1.28 × 10-1 h-1, k23 = 6.43 × 10-2 h-1, k35 = 1.23 × 10-1 h-1, k45 = 8.73 × 10-1 h-1), and elimination (k30 = 3.81 × 10-3 h-1, k50 = 1.27 × 10-1 h-1) adequately described the time-course of BUP and its metabolites, which has been externally validated using published data.",Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33352843/),1/[h],1.28 × 10-1,217413,DB00921,Buprenorphine
,33352843,k23,"A two-compartment population-PK model with linear absorption (ka = 2.54 h-1), distribution (k12= 2.34 h-1, k14 = 1.29 h-1), metabolism (k24 = 1.28 × 10-1 h-1, k23 = 6.43 × 10-2 h-1, k35 = 1.23 × 10-1 h-1, k45 = 8.73 × 10-1 h-1), and elimination (k30 = 3.81 × 10-3 h-1, k50 = 1.27 × 10-1 h-1) adequately described the time-course of BUP and its metabolites, which has been externally validated using published data.",Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33352843/),1/[h],6.43 × 10-2,217414,DB00921,Buprenorphine
,33352843,k35,"A two-compartment population-PK model with linear absorption (ka = 2.54 h-1), distribution (k12= 2.34 h-1, k14 = 1.29 h-1), metabolism (k24 = 1.28 × 10-1 h-1, k23 = 6.43 × 10-2 h-1, k35 = 1.23 × 10-1 h-1, k45 = 8.73 × 10-1 h-1), and elimination (k30 = 3.81 × 10-3 h-1, k50 = 1.27 × 10-1 h-1) adequately described the time-course of BUP and its metabolites, which has been externally validated using published data.",Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33352843/),1/[h],1.23 × 10-1,217415,DB00921,Buprenorphine
,33352843,k45,"A two-compartment population-PK model with linear absorption (ka = 2.54 h-1), distribution (k12= 2.34 h-1, k14 = 1.29 h-1), metabolism (k24 = 1.28 × 10-1 h-1, k23 = 6.43 × 10-2 h-1, k35 = 1.23 × 10-1 h-1, k45 = 8.73 × 10-1 h-1), and elimination (k30 = 3.81 × 10-3 h-1, k50 = 1.27 × 10-1 h-1) adequately described the time-course of BUP and its metabolites, which has been externally validated using published data.",Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33352843/),1/[h],8.73 × 10-1,217416,DB00921,Buprenorphine
,33352843,k30,"A two-compartment population-PK model with linear absorption (ka = 2.54 h-1), distribution (k12= 2.34 h-1, k14 = 1.29 h-1), metabolism (k24 = 1.28 × 10-1 h-1, k23 = 6.43 × 10-2 h-1, k35 = 1.23 × 10-1 h-1, k45 = 8.73 × 10-1 h-1), and elimination (k30 = 3.81 × 10-3 h-1, k50 = 1.27 × 10-1 h-1) adequately described the time-course of BUP and its metabolites, which has been externally validated using published data.",Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33352843/),1/[h],3.81 × 10-3,217417,DB00921,Buprenorphine
,33352843,k50,"A two-compartment population-PK model with linear absorption (ka = 2.54 h-1), distribution (k12= 2.34 h-1, k14 = 1.29 h-1), metabolism (k24 = 1.28 × 10-1 h-1, k23 = 6.43 × 10-2 h-1, k35 = 1.23 × 10-1 h-1, k45 = 8.73 × 10-1 h-1), and elimination (k30 = 3.81 × 10-3 h-1, k50 = 1.27 × 10-1 h-1) adequately described the time-course of BUP and its metabolites, which has been externally validated using published data.",Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33352843/),1/[h],1.27 × 10-1,217418,DB00921,Buprenorphine
above,15734164,recoveries,The recoveries of buprenorphine and buprenorphine propionate were above 84%.,"Simultaneous determination of buprenorphine and its prodrug, buprenorphine propionate, by high-performance liquid chromatography with fluorescence detection: application to pharmacokinetic studies in rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15734164/),%,84,218115,DB00921,Buprenorphine
,15734164,single-to-noise ratio,"The limits of quantitation of buprenorphine and buprenorphine propionate in human or animal blood were 2.0 and 20 ng/ml, respectively, based on a single-to-noise ratio of 3.","Simultaneous determination of buprenorphine and its prodrug, buprenorphine propionate, by high-performance liquid chromatography with fluorescence detection: application to pharmacokinetic studies in rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15734164/),,3,218116,DB00921,Buprenorphine
>,33603137,Occupancy,Occupancy >90% was achieved in most brain regions with plasma concentrations >7 µg/L.,Pharmacokinetic neuroimaging to study the dose-related brain kinetics and target engagement of buprenorphine in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33603137/),%,90,219631,DB00921,Buprenorphine
,22998333,TT,"TT increased above baseline from 15 to 480 minutes and at 30 and 60 minutes after i.v. and i.m. administration, respectively (p<0.05).","Pharmacokinetic and pharmacodynamic modelling of intravenous, intramuscular and subcutaneous buprenorphine in conscious cats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22998333/),min,15,219637,DB00921,Buprenorphine
,22998333,TT,"TT increased above baseline from 15 to 480 minutes and at 30 and 60 minutes after i.v. and i.m. administration, respectively (p<0.05).","Pharmacokinetic and pharmacodynamic modelling of intravenous, intramuscular and subcutaneous buprenorphine in conscious cats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22998333/),,30,219638,DB00921,Buprenorphine
,22998333,Maximum increase in TT,"Maximum increase in TT (mean±SD) was 9.3±4.9°C at 60 minutes (i.v.), 4.6±2.8°C at 45 minutes (i.m.) and 1.9±1.9°C at 60 minutes (s.c.).","Pharmacokinetic and pharmacodynamic modelling of intravenous, intramuscular and subcutaneous buprenorphine in conscious cats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22998333/),°c,9.3,219639,DB00921,Buprenorphine
,22998333,Maximum increase in TT,"Maximum increase in TT (mean±SD) was 9.3±4.9°C at 60 minutes (i.v.), 4.6±2.8°C at 45 minutes (i.m.) and 1.9±1.9°C at 60 minutes (s.c.).","Pharmacokinetic and pharmacodynamic modelling of intravenous, intramuscular and subcutaneous buprenorphine in conscious cats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22998333/),°c,4.6,219640,DB00921,Buprenorphine
,22998333,Maximum increase in TT,"Maximum increase in TT (mean±SD) was 9.3±4.9°C at 60 minutes (i.v.), 4.6±2.8°C at 45 minutes (i.m.) and 1.9±1.9°C at 60 minutes (s.c.).","Pharmacokinetic and pharmacodynamic modelling of intravenous, intramuscular and subcutaneous buprenorphine in conscious cats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22998333/),°c,1.9,219641,DB00921,Buprenorphine
,22998333,t(1/2) k(e0),The PK-PD model showed an onset delay mainly attributable to slow biophase equilibration (t(1/2) k(e0)=47.4 minutes) and receptor binding (k(on)=0.011 mL ng(-1) minute(-1)).,"Pharmacokinetic and pharmacodynamic modelling of intravenous, intramuscular and subcutaneous buprenorphine in conscious cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22998333/),min,47.4,219642,DB00921,Buprenorphine
,22998333,k(on),The PK-PD model showed an onset delay mainly attributable to slow biophase equilibration (t(1/2) k(e0)=47.4 minutes) and receptor binding (k(on)=0.011 mL ng(-1) minute(-1)).,"Pharmacokinetic and pharmacodynamic modelling of intravenous, intramuscular and subcutaneous buprenorphine in conscious cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22998333/),[ml] / [minute·ng],0.011,219643,DB00921,Buprenorphine
,22998333,t(1/2) k(off),Persistence of thermal antinociception was due to slow receptor dissociation (t(1/2) k(off)=18.2 minutes).,"Pharmacokinetic and pharmacodynamic modelling of intravenous, intramuscular and subcutaneous buprenorphine in conscious cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22998333/),min,18.2,219644,DB00921,Buprenorphine
,29521421,terminal half-life,"Median (range) terminal half-life, time to maximum concentration, and maximum plasma concentration of ER-buprenorphine were 12.74 hr (10.43-18.84 hr), 8 hr (4-36 hr), and 5.00 ng/ml (4.29-10.98 ng/ml), respectively.",The pharmacokinetics and analgesic effects of extended-release buprenorphine administered subcutaneously in healthy dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29521421/),h,12.74,224111,DB00921,Buprenorphine
,29521421,time to maximum concentration,"Median (range) terminal half-life, time to maximum concentration, and maximum plasma concentration of ER-buprenorphine were 12.74 hr (10.43-18.84 hr), 8 hr (4-36 hr), and 5.00 ng/ml (4.29-10.98 ng/ml), respectively.",The pharmacokinetics and analgesic effects of extended-release buprenorphine administered subcutaneously in healthy dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29521421/),h,8,224112,DB00921,Buprenorphine
,29521421,maximum plasma concentration,"Median (range) terminal half-life, time to maximum concentration, and maximum plasma concentration of ER-buprenorphine were 12.74 hr (10.43-18.84 hr), 8 hr (4-36 hr), and 5.00 ng/ml (4.29-10.98 ng/ml), respectively.",The pharmacokinetics and analgesic effects of extended-release buprenorphine administered subcutaneously in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29521421/),[ng] / [ml],5.00,224113,DB00921,Buprenorphine
up,29521421,Thermal threshold latency,"Thermal threshold latency was significantly prolonged compared to baseline up to 12 hr and up to 72 hr in IV-B and ER-B, respectively.",The pharmacokinetics and analgesic effects of extended-release buprenorphine administered subcutaneously in healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29521421/),h,12,224114,DB00921,Buprenorphine
up,29521421,Thermal threshold latency,"Thermal threshold latency was significantly prolonged compared to baseline up to 12 hr and up to 72 hr in IV-B and ER-B, respectively.",The pharmacokinetics and analgesic effects of extended-release buprenorphine administered subcutaneously in healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29521421/),h,72,224115,DB00921,Buprenorphine
,16642964,terminal,"The estimated values for the exponents of the 1st, 2nd, and terminal compartments; volume of distribution at steady state; clearance; and area under the concentration-time curve were 12.8/h, 2.13/h, 0.239/h, 6.5 l/kg, 4.3 l/h/kg, and 559 microg/lxh, respectively.",Pharmacokinetics of buprenorphine after intravenous administration in the mouse. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16642964/),1/[h],12.8,228502,DB00921,Buprenorphine
,16642964,area under the concentration-time curve,"The estimated values for the exponents of the 1st, 2nd, and terminal compartments; volume of distribution at steady state; clearance; and area under the concentration-time curve were 12.8/h, 2.13/h, 0.239/h, 6.5 l/kg, 4.3 l/h/kg, and 559 microg/lxh, respectively.",Pharmacokinetics of buprenorphine after intravenous administration in the mouse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16642964/),[μg] / [h·l],559,228503,DB00921,Buprenorphine
,16628138,0- to 24-hour,"In plasma collected from 5 subjects on maintenance daily sublingual doses of 16 mg BUP and 4 mg naloxone, respective 0- to 24-hour areas under the curve were 32, 88, 26, and 316 ng/mL x h for BUP, NBUP, BUPG, and NBUPG.",The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628138/),[ng] / [h·ml],32,230689,DB00921,Buprenorphine
,16628138,0- to 24-hour,"In plasma collected from 5 subjects on maintenance daily sublingual doses of 16 mg BUP and 4 mg naloxone, respective 0- to 24-hour areas under the curve were 32, 88, 26, and 316 ng/mL x h for BUP, NBUP, BUPG, and NBUPG.",The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628138/),[ng] / [h·ml],88,230690,DB00921,Buprenorphine
,16628138,0- to 24-hour,"In plasma collected from 5 subjects on maintenance daily sublingual doses of 16 mg BUP and 4 mg naloxone, respective 0- to 24-hour areas under the curve were 32, 88, 26, and 316 ng/mL x h for BUP, NBUP, BUPG, and NBUPG.",The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628138/),[ng] / [h·ml],26,230691,DB00921,Buprenorphine
,16628138,areas under the curve,"In plasma collected from 5 subjects on maintenance daily sublingual doses of 16 mg BUP and 4 mg naloxone, respective 0- to 24-hour areas under the curve were 32, 88, 26, and 316 ng/mL x h for BUP, NBUP, BUPG, and NBUPG.",The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628138/),[ng] / [h·ml],32,230692,DB00921,Buprenorphine
,16628138,areas under the curve,"In plasma collected from 5 subjects on maintenance daily sublingual doses of 16 mg BUP and 4 mg naloxone, respective 0- to 24-hour areas under the curve were 32, 88, 26, and 316 ng/mL x h for BUP, NBUP, BUPG, and NBUPG.",The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628138/),[ng] / [h·ml],88,230693,DB00921,Buprenorphine
,16628138,areas under the curve,"In plasma collected from 5 subjects on maintenance daily sublingual doses of 16 mg BUP and 4 mg naloxone, respective 0- to 24-hour areas under the curve were 32, 88, 26, and 316 ng/mL x h for BUP, NBUP, BUPG, and NBUPG.",The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628138/),[ng] / [h·ml],26,230694,DB00921,Buprenorphine
,16628138,areas under the curve,"In plasma collected from 5 subjects on maintenance daily sublingual doses of 16 mg BUP and 4 mg naloxone, respective 0- to 24-hour areas under the curve were 32, 88, 26, and 316 ng/mL x h for BUP, NBUP, BUPG, and NBUPG.",The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628138/),[ng] / [h·ml],316,230695,DB00921,Buprenorphine
,16628138,percent of daily dose excreted,"In urine samples respective percent of daily dose excreted in the 24-hour urine were 0.014%, 1.89%, 1.01%, and 7.76%.",The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628138/),%,0.014,230696,DB00921,Buprenorphine
,16628138,percent of daily dose excreted,"In urine samples respective percent of daily dose excreted in the 24-hour urine were 0.014%, 1.89%, 1.01%, and 7.76%.",The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628138/),%,1.89,230697,DB00921,Buprenorphine
,16628138,percent of daily dose excreted,"In urine samples respective percent of daily dose excreted in the 24-hour urine were 0.014%, 1.89%, 1.01%, and 7.76%.",The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628138/),%,1.01,230698,DB00921,Buprenorphine
,16628138,percent of daily dose excreted,"In urine samples respective percent of daily dose excreted in the 24-hour urine were 0.014%, 1.89%, 1.01%, and 7.76%.",The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628138/),%,7.76,230699,DB00921,Buprenorphine
,29940217,perceived dissolve times,Median perceived dissolve times were significantly shorter for BNX-RDT than BNX at high (8.5 versus 16.2 min) and low (7.6 versus 9.1 min) doses.,Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29940217/),min,8.5,233624,DB00921,Buprenorphine
,29940217,perceived dissolve times,Median perceived dissolve times were significantly shorter for BNX-RDT than BNX at high (8.5 versus 16.2 min) and low (7.6 versus 9.1 min) doses.,Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29940217/),min,16.2,233625,DB00921,Buprenorphine
,29940217,perceived dissolve times,Median perceived dissolve times were significantly shorter for BNX-RDT than BNX at high (8.5 versus 16.2 min) and low (7.6 versus 9.1 min) doses.,Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29940217/),min,7.6,233626,DB00921,Buprenorphine
,29940217,perceived dissolve times,Median perceived dissolve times were significantly shorter for BNX-RDT than BNX at high (8.5 versus 16.2 min) and low (7.6 versus 9.1 min) doses.,Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29940217/),min,9.1,233627,DB00921,Buprenorphine
,23599011,AUCtau,"Compared with baseline values, buprenorphine mean AUCtau (69.0 versus 95.6 hr*ng/mL) and mean Cmax (8.4 versus 9.3 ng/mL) increased significantly in the presence of EVG/COBI.",The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23599011/),[h·ng] / [ml],69.0,234347,DB00921,Buprenorphine
,23599011,AUCtau,"Compared with baseline values, buprenorphine mean AUCtau (69.0 versus 95.6 hr*ng/mL) and mean Cmax (8.4 versus 9.3 ng/mL) increased significantly in the presence of EVG/COBI.",The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23599011/),[h·ng] / [ml],95.6,234348,DB00921,Buprenorphine
,23599011,Cmax,"Compared with baseline values, buprenorphine mean AUCtau (69.0 versus 95.6 hr*ng/mL) and mean Cmax (8.4 versus 9.3 ng/mL) increased significantly in the presence of EVG/COBI.",The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23599011/),[ng] / [ml],8.4,234349,DB00921,Buprenorphine
,23599011,Cmax,"Compared with baseline values, buprenorphine mean AUCtau (69.0 versus 95.6 hr*ng/mL) and mean Cmax (8.4 versus 9.3 ng/mL) increased significantly in the presence of EVG/COBI.",The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23599011/),[ng] / [ml],9.3,234350,DB00921,Buprenorphine
,23599011,AUCtau,"Compared with baseline values, norbuprenorphine mean AUCtau (103.4 versus 163.4 hr*ng/mL) and mean Cmax (6.9 versus 9 ng/mL) also increased significantly after achieving steady state EVG/COBI.",The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23599011/),[h·ng] / [ml],103.4,234351,DB00921,Buprenorphine
,23599011,AUCtau,"Compared with baseline values, norbuprenorphine mean AUCtau (103.4 versus 163.4 hr*ng/mL) and mean Cmax (6.9 versus 9 ng/mL) also increased significantly after achieving steady state EVG/COBI.",The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23599011/),[h·ng] / [ml],163.4,234352,DB00921,Buprenorphine
,23599011,Cmax,"Compared with baseline values, norbuprenorphine mean AUCtau (103.4 versus 163.4 hr*ng/mL) and mean Cmax (6.9 versus 9 ng/mL) also increased significantly after achieving steady state EVG/COBI.",The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23599011/),[ng] / [ml],6.9,234353,DB00921,Buprenorphine
,23599011,Cmax,"Compared with baseline values, norbuprenorphine mean AUCtau (103.4 versus 163.4 hr*ng/mL) and mean Cmax (6.9 versus 9 ng/mL) also increased significantly after achieving steady state EVG/COBI.",The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23599011/),[ng] / [ml],9,234354,DB00921,Buprenorphine
,23599011,AUCtau,Naloxone mean AUCtau (0.57 versus 0.45 hr*ng/mL) and mean Cmax (0.25 versus 0.16 ng/mL) decreased after the addition of EVG/COBI.,The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23599011/),[h·ng] / [ml],0.57,234355,DB00921,Buprenorphine
,23599011,AUCtau,Naloxone mean AUCtau (0.57 versus 0.45 hr*ng/mL) and mean Cmax (0.25 versus 0.16 ng/mL) decreased after the addition of EVG/COBI.,The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23599011/),[h·ng] / [ml],0.45,234356,DB00921,Buprenorphine
,23599011,Cmax,Naloxone mean AUCtau (0.57 versus 0.45 hr*ng/mL) and mean Cmax (0.25 versus 0.16 ng/mL) decreased after the addition of EVG/COBI.,The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23599011/),[ng] / [ml],0.25,234357,DB00921,Buprenorphine
,23599011,Cmax,Naloxone mean AUCtau (0.57 versus 0.45 hr*ng/mL) and mean Cmax (0.25 versus 0.16 ng/mL) decreased after the addition of EVG/COBI.,The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23599011/),[ng] / [ml],0.16,234358,DB00921,Buprenorphine
,7306425,systemic availability,The average systemic availability of the drug by this route was estimated to be 30% by 3 h.,Sublingual buprenorphine used postoperatively: clinical observations and preliminary pharmacokinetic analysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7306425/),%,30,235710,DB00921,Buprenorphine
,26172282,CL,"A typical neonate with NAS (body weight, 2.9 kg; postnatal age; 5.4 days) had a CL of 3.5 L/kg/hour and elimination half-life of 11 hours.",Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26172282/),[l] / [h·kg],3.5,243066,DB00921,Buprenorphine
,26172282,elimination half-life,"A typical neonate with NAS (body weight, 2.9 kg; postnatal age; 5.4 days) had a CL of 3.5 L/kg/hour and elimination half-life of 11 hours.",Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26172282/),h,11,243067,DB00921,Buprenorphine
,24236993,pKa,"It has been argued that absorption of buprenorphine through the buccal mucosa is high, in part due to its pKa of 8.24.","Bioavailability of morphine, methadone, hydromorphone, and oxymorphone following buccal administration in cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24236993/),,8.24,243813,DB00921,Buprenorphine
,24236993,pKa,"Morphine, methadone, hydromorphone, and oxymorphone have a pKa between 8 and 9.","Bioavailability of morphine, methadone, hydromorphone, and oxymorphone following buccal administration in cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24236993/),,8 and 9,243814,DB00921,Buprenorphine
,24236993,bioavailability,"Mean ± SE (range) bioavailability was 36.6 ± 5.2 (12.7-49.5), 44.2 ± 7.9 (18.7-70.5), 22.4 ± 6.9 (6.4-43.4), and 18.8 ± 2.0 (12.9-23.5)% for buccal administration of morphine, methadone, hydromorphone, and oxymorphone, respectively.","Bioavailability of morphine, methadone, hydromorphone, and oxymorphone following buccal administration in cats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24236993/),%,36.6,243815,DB00921,Buprenorphine
,24236993,bioavailability,"Mean ± SE (range) bioavailability was 36.6 ± 5.2 (12.7-49.5), 44.2 ± 7.9 (18.7-70.5), 22.4 ± 6.9 (6.4-43.4), and 18.8 ± 2.0 (12.9-23.5)% for buccal administration of morphine, methadone, hydromorphone, and oxymorphone, respectively.","Bioavailability of morphine, methadone, hydromorphone, and oxymorphone following buccal administration in cats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24236993/),%,44.2,243816,DB00921,Buprenorphine
,24236993,bioavailability,"Mean ± SE (range) bioavailability was 36.6 ± 5.2 (12.7-49.5), 44.2 ± 7.9 (18.7-70.5), 22.4 ± 6.9 (6.4-43.4), and 18.8 ± 2.0 (12.9-23.5)% for buccal administration of morphine, methadone, hydromorphone, and oxymorphone, respectively.","Bioavailability of morphine, methadone, hydromorphone, and oxymorphone following buccal administration in cats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24236993/),%,22.4,243817,DB00921,Buprenorphine
,24236993,bioavailability,"Mean ± SE (range) bioavailability was 36.6 ± 5.2 (12.7-49.5), 44.2 ± 7.9 (18.7-70.5), 22.4 ± 6.9 (6.4-43.4), and 18.8 ± 2.0 (12.9-23.5)% for buccal administration of morphine, methadone, hydromorphone, and oxymorphone, respectively.","Bioavailability of morphine, methadone, hydromorphone, and oxymorphone following buccal administration in cats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24236993/),%,18.8,243818,DB00921,Buprenorphine
,10354966,bioavailability,The bioavailability from the tablet was approximately 50% that from the liquid and was not affected by saliva pH.,Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10354966/),%,50,244791,DB00921,Buprenorphine
,8562715,terminal half-life (t1/2c),The most important finding of this study is that the mean terminal half-life (t1/2c) of buprenorphine is 23 hours.,[Pharmacokinetics of buprenorphine in subcutaneous administration]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8562715/),h,23,245059,DB00921,Buprenorphine
,8562715,t1/2c,"This can be explained by the use of insufficiently sensitive analytical procedures and by too short periods of observation of 3 and 13 hours respectively, leading to values of t1/2c of 2 and 5 hours.",[Pharmacokinetics of buprenorphine in subcutaneous administration]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8562715/),h,2,245060,DB00921,Buprenorphine
,8562715,t1/2c,"This can be explained by the use of insufficiently sensitive analytical procedures and by too short periods of observation of 3 and 13 hours respectively, leading to values of t1/2c of 2 and 5 hours.",[Pharmacokinetics of buprenorphine in subcutaneous administration]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8562715/),h,5,245061,DB00921,Buprenorphine
,16732095,rate constant,"The rate constant describing biophase equilibration (k(eo)) was 0.00447 min(-1) (95% confidence interval, 0.00299-0.00595 min(-1)).",Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16732095/),1/[min],0.00447,245348,DB00921,Buprenorphine
,16732095,receptor,"The receptor dissociation rate constant (k(off)) was 0.0785 min(-1) (95% confidence interval, 0.0352-0.122 min(-1)), and k(on) was 0.0631 ml . ng(-1) . min(-1) (95% confidence interval, 0.0390-0.0872 ml . ng(-1) . min(-1)).",Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16732095/),1/[min],0.0785,245349,DB00921,Buprenorphine
,16732095,dissociation rate constant (k(off)),"The receptor dissociation rate constant (k(off)) was 0.0785 min(-1) (95% confidence interval, 0.0352-0.122 min(-1)), and k(on) was 0.0631 ml . ng(-1) . min(-1) (95% confidence interval, 0.0390-0.0872 ml . ng(-1) . min(-1)).",Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16732095/),1/[min],0.0785,245350,DB00921,Buprenorphine
,16732095,k(on),"The receptor dissociation rate constant (k(off)) was 0.0785 min(-1) (95% confidence interval, 0.0352-0.122 min(-1)), and k(on) was 0.0631 ml . ng(-1) . min(-1) (95% confidence interval, 0.0390-0.0872 ml . ng(-1) . min(-1)).",Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16732095/),[ml] / [min·ng],0.0631,245351,DB00921,Buprenorphine
,20206560,peak concentration [B],"The peak concentration [B] was 1.54 ng mL(-1) (±1.98) 60 h after TDB application, although three dogs had no measurable [B] after TDB.",Antinociceptive efficacy and plasma concentrations of transdermal buprenorphine in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206560/),[ng] / [ml],1.54,245458,DB00921,Buprenorphine
,20206560,Maximum thermal threshold (TT),Maximum thermal threshold (TT) was 52.6 °C (±0.48) at 1h after IVB administration and 51.63 °C (±1.01) 72 h after TDB application.,Antinociceptive efficacy and plasma concentrations of transdermal buprenorphine in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206560/),°c,52.6,245459,DB00921,Buprenorphine
,20206560,Maximum thermal threshold (TT),Maximum thermal threshold (TT) was 52.6 °C (±0.48) at 1h after IVB administration and 51.63 °C (±1.01) 72 h after TDB application.,Antinociceptive efficacy and plasma concentrations of transdermal buprenorphine in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206560/),°c,51.63,245460,DB00921,Buprenorphine
,30242851,elimination half-life (t1/2β,"Pharmacokinetic analysis following IV administration demonstrated a short elimination half-life (t1/2β 1.95 ± 0.7 hr), large volume of distribution (6.46 ± 1.54 L/kg), and a high total clearance (55.83 ± 23.75 ml/kg/min), which differs from adult horses.",Pharmacokinetics and physiologic/behavioral effects of buprenorphine administered sublingually and intravenously to neonatal foals. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30242851/),h,1.95,251573,DB00921,Buprenorphine
,30242851,volume of distribution,"Pharmacokinetic analysis following IV administration demonstrated a short elimination half-life (t1/2β 1.95 ± 0.7 hr), large volume of distribution (6.46 ± 1.54 L/kg), and a high total clearance (55.83 ± 23.75 ml/kg/min), which differs from adult horses.",Pharmacokinetics and physiologic/behavioral effects of buprenorphine administered sublingually and intravenously to neonatal foals. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30242851/),[l] / [kg],6.46,251574,DB00921,Buprenorphine
,30242851,total clearance,"Pharmacokinetic analysis following IV administration demonstrated a short elimination half-life (t1/2β 1.95 ± 0.7 hr), large volume of distribution (6.46 ± 1.54 L/kg), and a high total clearance (55.83 ± 23.75 ml/kg/min), which differs from adult horses.",Pharmacokinetics and physiologic/behavioral effects of buprenorphine administered sublingually and intravenously to neonatal foals. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30242851/),[ml] / [kg·min],55.83,251575,DB00921,Buprenorphine
,30242851,maximum concentrations,"Following SL administration, maximum concentrations reached were 0.61 ± 0.11 ng/ml and bioavailability was 25.1% ± 10.9%.",Pharmacokinetics and physiologic/behavioral effects of buprenorphine administered sublingually and intravenously to neonatal foals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30242851/),[ng] / [ml],0.61,251576,DB00921,Buprenorphine
,30242851,bioavailability,"Following SL administration, maximum concentrations reached were 0.61 ± 0.11 ng/ml and bioavailability was 25.1% ± 10.9%.",Pharmacokinetics and physiologic/behavioral effects of buprenorphine administered sublingually and intravenously to neonatal foals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30242851/),%,25.1,251577,DB00921,Buprenorphine
,23562033,elimination half-lives,"The low and high doses of buprenorphine had elimination half-lives of 2.6 ± 0.7 and 5.3 ± 2.0 h, respectively, but the low-dose data were constrained by the sensitivity of the analytical method.",Pharmacokinetics of 2 formulations of buprenorphine in macaques (Macaca mulatta and Macaca fascicularis). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23562033/),h,2.6,253438,DB00921,Buprenorphine
,23562033,elimination half-lives,"The low and high doses of buprenorphine had elimination half-lives of 2.6 ± 0.7 and 5.3 ± 2.0 h, respectively, but the low-dose data were constrained by the sensitivity of the analytical method.",Pharmacokinetics of 2 formulations of buprenorphine in macaques (Macaca mulatta and Macaca fascicularis). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23562033/),h,5.3,253439,DB00921,Buprenorphine
,23562033,elimination half-life,Sustained-release buprenorphine had an elimination half-life of 42.6 ± 26.2 h.,Pharmacokinetics of 2 formulations of buprenorphine in macaques (Macaca mulatta and Macaca fascicularis). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23562033/),h,42.6,253440,DB00921,Buprenorphine
,23562033,AUC0-Tlast,"The AUC0-Tlast of buprenorphine were 9.1 ± 4.3 and 39.0 ± 25.1 ng × h/mL for the low and high doses, respectively, and sustained-release buprenorphine had an AUC0-Tlast of 177 ± 74 ng × h/mL.",Pharmacokinetics of 2 formulations of buprenorphine in macaques (Macaca mulatta and Macaca fascicularis). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23562033/),[h·ng] / [ml],9.1,253441,DB00921,Buprenorphine
,23562033,AUC0-Tlast,"The AUC0-Tlast of buprenorphine were 9.1 ± 4.3 and 39.0 ± 25.1 ng × h/mL for the low and high doses, respectively, and sustained-release buprenorphine had an AUC0-Tlast of 177 ± 74 ng × h/mL.",Pharmacokinetics of 2 formulations of buprenorphine in macaques (Macaca mulatta and Macaca fascicularis). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23562033/),[h·ng] / [ml],39.0,253442,DB00921,Buprenorphine
,23562033,AUC0-Tlast,"The AUC0-Tlast of buprenorphine were 9.1 ± 4.3 and 39.0 ± 25.1 ng × h/mL for the low and high doses, respectively, and sustained-release buprenorphine had an AUC0-Tlast of 177 ± 74 ng × h/mL.",Pharmacokinetics of 2 formulations of buprenorphine in macaques (Macaca mulatta and Macaca fascicularis). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23562033/),[h·ng] / [ml],177,253443,DB00921,Buprenorphine
,23562033,plasma concentration,"Assuming a hypothesized therapeutic buprenorphine plasma concentration threshold of 0.1 ng/mL in macaques, these results suggest that buprenorphine doses of 0.01 mg/kg IM should be administered every 6 to 8 h, whereas doses of 0.03 mg/kg IM can be administered every 12 h.",Pharmacokinetics of 2 formulations of buprenorphine in macaques (Macaca mulatta and Macaca fascicularis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23562033/),,0.,253444,DB00921,Buprenorphine
,17919544,reflex threshold,"The mean (SD) RIII reflex threshold and subjective threshold at baseline were 31.6 (9.5) mA and 45.5 (22.3) mA, respectively.","Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17919544/),ma,31.6,257008,DB00921,Buprenorphine
,17919544,subjective threshold,"The mean (SD) RIII reflex threshold and subjective threshold at baseline were 31.6 (9.5) mA and 45.5 (22.3) mA, respectively.","Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17919544/),ma,45.5,257009,DB00921,Buprenorphine
,17919544,latency,"Mean (SEM) latency before withdrawal of the hand was 69 (10) seconds, corresponding to a mean increase of 63.8% (14.4%) from baseline (P = 0.003).","Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17919544/),seconds,69,257010,DB00921,Buprenorphine
,17919544,t(l/2),Buprenorphine t(l/2) was 2.75 hours.,"Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17919544/),h,2.75,257011,DB00921,Buprenorphine
,18467137,distribution,"The two distribution and the elimination half-lives were 2.9+/-1.8min, 16.5+/-3.7min, and 266.6+/-82.0min, respectively; the clearance was 329.6+/-62.2mL/min, and the steady state volume of distribution was 83.7+/-26.5L.",Pharmacokinetics of buprenorphine after intravenous administration of clinical doses to dogs. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467137/),min,2.9,259922,DB00921,Buprenorphine
,18467137,distribution,"The two distribution and the elimination half-lives were 2.9+/-1.8min, 16.5+/-3.7min, and 266.6+/-82.0min, respectively; the clearance was 329.6+/-62.2mL/min, and the steady state volume of distribution was 83.7+/-26.5L.",Pharmacokinetics of buprenorphine after intravenous administration of clinical doses to dogs. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467137/),min,16.5,259923,DB00921,Buprenorphine
,18467137,elimination half-lives,"The two distribution and the elimination half-lives were 2.9+/-1.8min, 16.5+/-3.7min, and 266.6+/-82.0min, respectively; the clearance was 329.6+/-62.2mL/min, and the steady state volume of distribution was 83.7+/-26.5L.",Pharmacokinetics of buprenorphine after intravenous administration of clinical doses to dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467137/),min,266.6,259924,DB00921,Buprenorphine
,18467137,clearance,"The two distribution and the elimination half-lives were 2.9+/-1.8min, 16.5+/-3.7min, and 266.6+/-82.0min, respectively; the clearance was 329.6+/-62.2mL/min, and the steady state volume of distribution was 83.7+/-26.5L.",Pharmacokinetics of buprenorphine after intravenous administration of clinical doses to dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467137/),[ml] / [min],329.6,259925,DB00921,Buprenorphine
,18467137,steady state volume of distribution,"The two distribution and the elimination half-lives were 2.9+/-1.8min, 16.5+/-3.7min, and 266.6+/-82.0min, respectively; the clearance was 329.6+/-62.2mL/min, and the steady state volume of distribution was 83.7+/-26.5L.",Pharmacokinetics of buprenorphine after intravenous administration of clinical doses to dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467137/),l,83.7,259926,DB00921,Buprenorphine
,23421567,AUC(0-24 h),"Compared with baseline values, buprenorphine AUC(0-24 h) (58.2 vs. 56.0 hr*ng/mL) and C(max) (7.37 vs. 6.60 ng/mL) did not differ significantly after achieving steady-state raltegravir.",Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23421567/),[h·ng] / [ml],58.2,261491,DB00921,Buprenorphine
,23421567,AUC(0-24 h),"Compared with baseline values, buprenorphine AUC(0-24 h) (58.2 vs. 56.0 hr*ng/mL) and C(max) (7.37 vs. 6.60 ng/mL) did not differ significantly after achieving steady-state raltegravir.",Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23421567/),[h·ng] / [ml],56.0,261492,DB00921,Buprenorphine
,23421567,C(max),"Compared with baseline values, buprenorphine AUC(0-24 h) (58.2 vs. 56.0 hr*ng/mL) and C(max) (7.37 vs. 6.60 ng/mL) did not differ significantly after achieving steady-state raltegravir.",Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23421567/),[ng] / [ml],7.37,261493,DB00921,Buprenorphine
,23421567,C(max),"Compared with baseline values, buprenorphine AUC(0-24 h) (58.2 vs. 56.0 hr*ng/mL) and C(max) (7.37 vs. 6.60 ng/mL) did not differ significantly after achieving steady-state raltegravir.",Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23421567/),[ng] / [ml],6.60,261494,DB00921,Buprenorphine
,23421567,AUC(0-24 h),"Naloxone concentrations were unchanged for AUC(0-24 h) (.595 vs. .581 hr*ng/mL), C(max) (.251 vs. .243 ng/mL) and T(max) (.75 vs.1.08 h).",Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23421567/),[h·ng] / [ml],.595,261495,DB00921,Buprenorphine
,23421567,AUC(0-24 h),"Naloxone concentrations were unchanged for AUC(0-24 h) (.595 vs. .581 hr*ng/mL), C(max) (.251 vs. .243 ng/mL) and T(max) (.75 vs.1.08 h).",Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23421567/),[h·ng] / [ml],.581,261496,DB00921,Buprenorphine
,23421567,C(max),"Naloxone concentrations were unchanged for AUC(0-24 h) (.595 vs. .581 hr*ng/mL), C(max) (.251 vs. .243 ng/mL) and T(max) (.75 vs.1.08 h).",Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23421567/),[ng] / [ml],.251,261497,DB00921,Buprenorphine
,23421567,C(max),"Naloxone concentrations were unchanged for AUC(0-24 h) (.595 vs. .581 hr*ng/mL), C(max) (.251 vs. .243 ng/mL) and T(max) (.75 vs.1.08 h).",Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23421567/),[ng] / [ml],.243,261498,DB00921,Buprenorphine
,23421567,T(max),"Naloxone concentrations were unchanged for AUC(0-24 h) (.595 vs. .581 hr*ng/mL), C(max) (.251 vs. .243 ng/mL) and T(max) (.75 vs.1.08 h).",Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23421567/),h,.75,261499,DB00921,Buprenorphine
,23421567,T(max),"Naloxone concentrations were unchanged for AUC(0-24 h) (.595 vs. .581 hr*ng/mL), C(max) (.251 vs. .243 ng/mL) and T(max) (.75 vs.1.08 h).",Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23421567/),h,1.08,261500,DB00921,Buprenorphine
,23421567,AUC(0-12 h),"The AUC(0-12 h) and C(max) of raltegravir did not significantly differ from historical controls (5543 vs. 4428 h*ng/mL and 1070 vs. 1266 ng/mL), respectively.",Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23421567/),[h·ng] / [ml],5543,261501,DB00921,Buprenorphine
,23421567,AUC(0-12 h),"The AUC(0-12 h) and C(max) of raltegravir did not significantly differ from historical controls (5543 vs. 4428 h*ng/mL and 1070 vs. 1266 ng/mL), respectively.",Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23421567/),[h·ng] / [ml],4428,261502,DB00921,Buprenorphine
,23421567,C(max),"The AUC(0-12 h) and C(max) of raltegravir did not significantly differ from historical controls (5543 vs. 4428 h*ng/mL and 1070 vs. 1266 ng/mL), respectively.",Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23421567/),[ng] / [ml],1070,261503,DB00921,Buprenorphine
,23421567,C(max),"The AUC(0-12 h) and C(max) of raltegravir did not significantly differ from historical controls (5543 vs. 4428 h*ng/mL and 1070 vs. 1266 ng/mL), respectively.",Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23421567/),[ng] / [ml],1266,261504,DB00921,Buprenorphine
,17763831,T 50% clearance,"Scintigraphic imaging revealed that clearance of the formulation from the oral cavity was rapid, with a mean T 50% clearance of 0.86 +/- 0.46 min, and T 80% clearance of 2.75 +/- 1.52 min.",Evaluation of the clearance of a sublingual buprenorphine spray in the beagle dog using gamma scintigraphy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17763831/),min,0.86,267429,DB00921,Buprenorphine
,17763831,T 80% clearance,"Scintigraphic imaging revealed that clearance of the formulation from the oral cavity was rapid, with a mean T 50% clearance of 0.86 +/- 0.46 min, and T 80% clearance of 2.75 +/- 1.52 min.",Evaluation of the clearance of a sublingual buprenorphine spray in the beagle dog using gamma scintigraphy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17763831/),min,2.75,267430,DB00921,Buprenorphine
,17763831,T max,"In comparison, absorption of buprenorphine was relatively slow, with a T max of 0.56 +/- 0.13 h.",Evaluation of the clearance of a sublingual buprenorphine spray in the beagle dog using gamma scintigraphy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17763831/),h,0.56,267431,DB00921,Buprenorphine
,28526486,Cmax,"Fentanyl: Cmax was observed at different time points: for the first TP application: 30 hours for 50 μg hour-1, 6 hours for 75 μg hour-1 and 100 μg hour-1 patches; and for the second TP application: 30 hours for 50 μg hour-1 and 36 hours for 75 μg hour-1 patches.",Plasma concentrations of transdermal fentanyl and buprenorphine in pigs (Sus scrofa domesticus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28526486/),h,30,268503,DB00921,Buprenorphine
,28526486,Cmax,"Fentanyl: Cmax was observed at different time points: for the first TP application: 30 hours for 50 μg hour-1, 6 hours for 75 μg hour-1 and 100 μg hour-1 patches; and for the second TP application: 30 hours for 50 μg hour-1 and 36 hours for 75 μg hour-1 patches.",Plasma concentrations of transdermal fentanyl and buprenorphine in pigs (Sus scrofa domesticus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28526486/),h,6,268504,DB00921,Buprenorphine
,28526486,Cmax,"Fentanyl: Cmax was observed at different time points: for the first TP application: 30 hours for 50 μg hour-1, 6 hours for 75 μg hour-1 and 100 μg hour-1 patches; and for the second TP application: 30 hours for 50 μg hour-1 and 36 hours for 75 μg hour-1 patches.",Plasma concentrations of transdermal fentanyl and buprenorphine in pigs (Sus scrofa domesticus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28526486/),h,36,268505,DB00921,Buprenorphine
,20305886,plasma concentration,"A pharmacokinetic study provided dexmedetomidine plasma concentration, set to be 3.0 ng*mL(-1).",Hemodynamics and bispectral index (BIS) of dogs anesthetized with midazolam and ketamine associated with medetomidine or dexmedetomidine and submitted to ovariohysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20305886/),[ng] / [ml],3.0,270806,DB00921,Buprenorphine
,11903869,elimination half-life (t1/2el),"Our data for morphine show elimination half-life (t1/2el) 76.3 min intravenous (i.v.) and 93.6 min intramuscular (i.m.); mean residence time (MRT) 105.0 and 120.5 min; clearance (Clp) 24.1 and 13.9 mL/kg/min; and volume of distribution (V(dss)) 2.6 and 1.7 L/kg, respectively.","Morphine, pethidine and buprenorphine disposition in the cat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,76.3,270824,DB00921,Buprenorphine
,11903869,elimination half-life (t1/2el),"Our data for morphine show elimination half-life (t1/2el) 76.3 min intravenous (i.v.) and 93.6 min intramuscular (i.m.); mean residence time (MRT) 105.0 and 120.5 min; clearance (Clp) 24.1 and 13.9 mL/kg/min; and volume of distribution (V(dss)) 2.6 and 1.7 L/kg, respectively.","Morphine, pethidine and buprenorphine disposition in the cat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,93.6,270825,DB00921,Buprenorphine
,11903869,mean residence time (MRT),"Our data for morphine show elimination half-life (t1/2el) 76.3 min intravenous (i.v.) and 93.6 min intramuscular (i.m.); mean residence time (MRT) 105.0 and 120.5 min; clearance (Clp) 24.1 and 13.9 mL/kg/min; and volume of distribution (V(dss)) 2.6 and 1.7 L/kg, respectively.","Morphine, pethidine and buprenorphine disposition in the cat. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,105.0,270826,DB00921,Buprenorphine
,11903869,mean residence time (MRT),"Our data for morphine show elimination half-life (t1/2el) 76.3 min intravenous (i.v.) and 93.6 min intramuscular (i.m.); mean residence time (MRT) 105.0 and 120.5 min; clearance (Clp) 24.1 and 13.9 mL/kg/min; and volume of distribution (V(dss)) 2.6 and 1.7 L/kg, respectively.","Morphine, pethidine and buprenorphine disposition in the cat. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,120.5,270827,DB00921,Buprenorphine
,11903869,clearance (Clp),"Our data for morphine show elimination half-life (t1/2el) 76.3 min intravenous (i.v.) and 93.6 min intramuscular (i.m.); mean residence time (MRT) 105.0 and 120.5 min; clearance (Clp) 24.1 and 13.9 mL/kg/min; and volume of distribution (V(dss)) 2.6 and 1.7 L/kg, respectively.","Morphine, pethidine and buprenorphine disposition in the cat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),[ml] / [kg·min],24.1,270828,DB00921,Buprenorphine
,11903869,clearance (Clp),"Our data for morphine show elimination half-life (t1/2el) 76.3 min intravenous (i.v.) and 93.6 min intramuscular (i.m.); mean residence time (MRT) 105.0 and 120.5 min; clearance (Clp) 24.1 and 13.9 mL/kg/min; and volume of distribution (V(dss)) 2.6 and 1.7 L/kg, respectively.","Morphine, pethidine and buprenorphine disposition in the cat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),[ml] / [kg·min],13.9,270829,DB00921,Buprenorphine
,11903869,volume of distribution (V(dss)),"Our data for morphine show elimination half-life (t1/2el) 76.3 min intravenous (i.v.) and 93.6 min intramuscular (i.m.); mean residence time (MRT) 105.0 and 120.5 min; clearance (Clp) 24.1 and 13.9 mL/kg/min; and volume of distribution (V(dss)) 2.6 and 1.7 L/kg, respectively.","Morphine, pethidine and buprenorphine disposition in the cat. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),[l] / [kg],2.6,270830,DB00921,Buprenorphine
,11903869,volume of distribution (V(dss)),"Our data for morphine show elimination half-life (t1/2el) 76.3 min intravenous (i.v.) and 93.6 min intramuscular (i.m.); mean residence time (MRT) 105.0 and 120.5 min; clearance (Clp) 24.1 and 13.9 mL/kg/min; and volume of distribution (V(dss)) 2.6 and 1.7 L/kg, respectively.","Morphine, pethidine and buprenorphine disposition in the cat. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),[l] / [kg],1.7,270831,DB00921,Buprenorphine
,11903869,t1/2el,Comparable data for buprenorphine are t1/2el 416.8 and 380.2 min; MRT 417.6 and 409.8 min; Clp 16.7 and 23.7 mL/kg/min; and V(dss) 7.1 and 8.9 L/kg.,"Morphine, pethidine and buprenorphine disposition in the cat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,416.8,270832,DB00921,Buprenorphine
,11903869,t1/2el,Comparable data for buprenorphine are t1/2el 416.8 and 380.2 min; MRT 417.6 and 409.8 min; Clp 16.7 and 23.7 mL/kg/min; and V(dss) 7.1 and 8.9 L/kg.,"Morphine, pethidine and buprenorphine disposition in the cat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,380.2,270833,DB00921,Buprenorphine
,11903869,MRT,Comparable data for buprenorphine are t1/2el 416.8 and 380.2 min; MRT 417.6 and 409.8 min; Clp 16.7 and 23.7 mL/kg/min; and V(dss) 7.1 and 8.9 L/kg.,"Morphine, pethidine and buprenorphine disposition in the cat. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,417.6,270834,DB00921,Buprenorphine
,11903869,MRT,Comparable data for buprenorphine are t1/2el 416.8 and 380.2 min; MRT 417.6 and 409.8 min; Clp 16.7 and 23.7 mL/kg/min; and V(dss) 7.1 and 8.9 L/kg.,"Morphine, pethidine and buprenorphine disposition in the cat. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,409.8,270835,DB00921,Buprenorphine
,11903869,Clp,Comparable data for buprenorphine are t1/2el 416.8 and 380.2 min; MRT 417.6 and 409.8 min; Clp 16.7 and 23.7 mL/kg/min; and V(dss) 7.1 and 8.9 L/kg.,"Morphine, pethidine and buprenorphine disposition in the cat. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),[ml] / [kg·min],16.7,270836,DB00921,Buprenorphine
,11903869,Clp,Comparable data for buprenorphine are t1/2el 416.8 and 380.2 min; MRT 417.6 and 409.8 min; Clp 16.7 and 23.7 mL/kg/min; and V(dss) 7.1 and 8.9 L/kg.,"Morphine, pethidine and buprenorphine disposition in the cat. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),[ml] / [kg·min],23.7,270837,DB00921,Buprenorphine
,11903869,V(dss),Comparable data for buprenorphine are t1/2el 416.8 and 380.2 min; MRT 417.6 and 409.8 min; Clp 16.7 and 23.7 mL/kg/min; and V(dss) 7.1 and 8.9 L/kg.,"Morphine, pethidine and buprenorphine disposition in the cat. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),[l] / [kg],7.1,270838,DB00921,Buprenorphine
,11903869,V(dss),Comparable data for buprenorphine are t1/2el 416.8 and 380.2 min; MRT 417.6 and 409.8 min; Clp 16.7 and 23.7 mL/kg/min; and V(dss) 7.1 and 8.9 L/kg.,"Morphine, pethidine and buprenorphine disposition in the cat. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),[l] / [kg],8.9,270839,DB00921,Buprenorphine
,11903869,t1/2el,"For i.m. pethidine, t1/2el 216.4 min; MRT 307.5 min; Clp 20.8 mL/kg/min and V(dss) 5.2 L/kg.","Morphine, pethidine and buprenorphine disposition in the cat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,216.4,270840,DB00921,Buprenorphine
,11903869,MRT,"For i.m. pethidine, t1/2el 216.4 min; MRT 307.5 min; Clp 20.8 mL/kg/min and V(dss) 5.2 L/kg.","Morphine, pethidine and buprenorphine disposition in the cat. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,307.5,270841,DB00921,Buprenorphine
,11903869,Clp,"For i.m. pethidine, t1/2el 216.4 min; MRT 307.5 min; Clp 20.8 mL/kg/min and V(dss) 5.2 L/kg.","Morphine, pethidine and buprenorphine disposition in the cat. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),[ml] / [kg·min],20.8,270842,DB00921,Buprenorphine
,11903869,V(dss),"For i.m. pethidine, t1/2el 216.4 min; MRT 307.5 min; Clp 20.8 mL/kg/min and V(dss) 5.2 L/kg.","Morphine, pethidine and buprenorphine disposition in the cat. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),[l] / [kg],5.2,270843,DB00921,Buprenorphine
,11903869,tmax,"For i.m. dosing, the tmax for morphine, buprenorphine and pethidine were 15, 3 and 10 min, respectively.","Morphine, pethidine and buprenorphine disposition in the cat. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,15,270844,DB00921,Buprenorphine
,11903869,tmax,"For i.m. dosing, the tmax for morphine, buprenorphine and pethidine were 15, 3 and 10 min, respectively.","Morphine, pethidine and buprenorphine disposition in the cat. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,3,270845,DB00921,Buprenorphine
,11903869,tmax,"For i.m. dosing, the tmax for morphine, buprenorphine and pethidine were 15, 3 and 10 min, respectively.","Morphine, pethidine and buprenorphine disposition in the cat. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,10,270846,DB00921,Buprenorphine
>,26730511,recoveries,The recoveries were >63% and matrix effects were tracked by the deuterated internal standards (IS) with the IS-normalized matrix factor ranging from 0.96 to 1.33 for all three analytes.,"Simultaneous determination of buprenorphine, norbuprenorphine and naloxone in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26730511/),%,63,270954,DB00921,Buprenorphine
,26804639,bioavailability,"In the single-dose study, the 2 formulations exhibited comparable bioavailability of 46% to 51% that was independent of dose, with a single buprenorphine peak concentration from each BBUP dose occurring at 2.5 to 3 hours.",Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804639/),%,46,273236,DB00921,Buprenorphine
,26804639,bioavailability,"In the single-dose study, the 2 formulations exhibited comparable bioavailability of 46% to 51% that was independent of dose, with a single buprenorphine peak concentration from each BBUP dose occurring at 2.5 to 3 hours.",Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804639/),%,51,273237,DB00921,Buprenorphine
,26804639,Cmax,The mean buprenorphine Cmax across the doses ranged from 0.17 ng/mL for the 75-µg dose to 1.43 ng/mL for the 1200-µg dose.,Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804639/),[ng] / [ml],0.17,273238,DB00921,Buprenorphine
,26804639,Cmax,The mean buprenorphine Cmax across the doses ranged from 0.17 ng/mL for the 75-µg dose to 1.43 ng/mL for the 1200-µg dose.,Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804639/),[ng] / [ml],1.43,273239,DB00921,Buprenorphine
,26804639,absolute bioavailability,"The absolute bioavailability of BBUP was 46% to 51% across a 16-fold dose range, with dose-proportional increases in systemic exposure.",Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804639/),%,46,273240,DB00921,Buprenorphine
,26804639,absolute bioavailability,"The absolute bioavailability of BBUP was 46% to 51% across a 16-fold dose range, with dose-proportional increases in systemic exposure.",Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804639/),%,51,273241,DB00921,Buprenorphine
,19874646,recoveries,The mean recoveries were 69.2% for naloxone and 32.0% for nornaloxone.,Determination of naloxone and nornaloxone (noroxymorphone) by high-performance liquid chromatography-electrospray ionization- tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874646/),%,69.2,273880,DB00921,Buprenorphine
,19874646,recoveries,The mean recoveries were 69.2% for naloxone and 32.0% for nornaloxone.,Determination of naloxone and nornaloxone (noroxymorphone) by high-performance liquid chromatography-electrospray ionization- tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874646/),%,32.0,273881,DB00921,Buprenorphine
,19874646,AUC(0-24),Mean AUC(0-24) was 0.303 +/- 0.145 ng/mL.h; mean C(max) was 0.139 +/- 0.062 ng/mL; and T(max) was 0.5 h.,Determination of naloxone and nornaloxone (noroxymorphone) by high-performance liquid chromatography-electrospray ionization- tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874646/),[ng] / [h·ml],0.303,273882,DB00921,Buprenorphine
,19874646,C(max),Mean AUC(0-24) was 0.303 +/- 0.145 ng/mL.h; mean C(max) was 0.139 +/- 0.062 ng/mL; and T(max) was 0.5 h.,Determination of naloxone and nornaloxone (noroxymorphone) by high-performance liquid chromatography-electrospray ionization- tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874646/),[ng] / [ml],0.139,273883,DB00921,Buprenorphine
,19874646,T(max),Mean AUC(0-24) was 0.303 +/- 0.145 ng/mL.h; mean C(max) was 0.139 +/- 0.062 ng/mL; and T(max) was 0.5 h.,Determination of naloxone and nornaloxone (noroxymorphone) by high-performance liquid chromatography-electrospray ionization- tandem mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874646/),h,0.5,273884,DB00921,Buprenorphine
